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1 Introduction – Enediyne derived Natural Products 
 
Cyclic nine- and ten-membered enediyne structures containing natural products have attracted 
attention of the synthetic and pharmacologic community over the past three decades.[1] They 
belong to a fascinating family of secondary metabolites, both in terms of molecular structure 
and biological activity. Although only a few examples have been discovered so far,[2] two of 
them (neocarzinostatin[3] 1 and calicheamicin[4] 2) have been already approved for anticancer 
therapy. Another four are subject of ongoing drug development programs (C-1027 3,[5] 
unicialamycin 4,[6] dynemicin 5,[7] and esperamicin 6,[8] figure 1). 
 
Figure 1: Examples of enediyne derived natural products as (*approved) anticancer 
therapeutic agents (enediyne core displayed in red). 
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Albeit the gene clusters responsible for their biosynthesis have been identified in a whole 
number of actinomycetes,[9] the number of enediyne derived structures isolated so far appears 
quite limited. This might be due to their high tendency to undergo BERGMAN-cyclizations or 
MYERS-SAITO rearrangements,[10] for example upon attempts to isolate them (chapter 1.2). 
Consequently, some cyclization-derived natural products have been discovered in the past, 
including the sporolides 7,[11] amycolamycins 8,[12]  cyanosporasides 9,[13] and fijiolides[14], 
which are subject of this thesis (figure 2). 
 
Figure 2: BERGMAN-cyclization derived natural products (former enediyne structure marked 
in red). 
 
1.2 Isolation and Biological Origin of Fijiolides 
 
Fijiolide A (10a) and B (10b) were isolated in 2010 by FENICAL et al. from marine-derived 
actinomycete strain CNS-653,[14a] which was found in sediment samples from Beqa Lagoon, 
Fiji. Their absolute structures could be determined by combination of 2D NMR spectroscopic 
data, circular dichroism and advanced MOSHER`s method (figure 3) and were found only to 
differ in acetylation of an amino acids substructure. 
 
 
 
Figure 3: Structure of fijiolide A and B, elucidated by FENICAL. 
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Structurally, the fijiolides consist of an 8,9-dihydroxylated benzodihydropentalene core 
structure (red), a β-tyrosine moiety (green) forming the ansa-bridge in a para-cyclophane and 
an amino sugar (blue, figure 4). Key characteristics of 10 include an atrop-isomerism with 
restricted rotation regarding orientation of the tyrosine unit during cyclophane formation 
(alternatively leading to atrop-isomer 11). Furthermore, the fijiolides feature a hindered 
tertiary glycosylated alcohol at C9 and a strained cyclopentadienol subunit incorporated in the 
tricylic indene fragment. 
 
Figure 4: The fijiolides A and B and atrop-isomer 11. 
Biologically they seem to result from Bergman-cyclization of related enediyne precursor 
C-1027 chromophore 12, where 3,6-biradical intermediate 13 would have to be formally 
quenched by a chlorine radical at C3 (scheme 1). The high tendency of cyclic enediyne 
structures to undergo BERGMAN-cyclizations was demonstrated by HIRAMA,[15] INOUE[16] and 
others[17] for a variety of substrates, often occurring spontaneously in solution within minutes. 
However, a regioselective mono-chlorination of 13`s aglycon proved to be difficult when 
carried out using Cl-radical sources for several substrates, predominantly leading to 
chlorination at C6 or dichlorination. Only recently, the application of an ionic pathway using 
LiCl in DMSO to mimic the actinomycete`s seawater environment allowed to address the 
desired C3 position.[15a]  
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Scheme 1: BERGMAN-cyclization of 12 to form fijiolides A and B via biradical 13. 
Further evidence for a collective biosynthetic background of the fijiolides and C-1027 
chromophores was provided by OH et al., who isolated cyclized chromophore III (14a) and V 
(14b), together with fijiolides A and B from an arctic marine actinomycete Streptomyces 
strain ART5 (figure 5).[14b] 
 
Figure 5: Structure of C-1027 chromophore III and V isolated by OH and coworkers.[14b] 
 
1.3 Biosynthesis of C-1027 
 
In 2002 SHEN and coworkers characterized the biosynthetic pathway for C-1027 (3),[18] which 
is likely to be quite similar for the fijiolides due to the already mentioned structural 
relationship between 3 and the fijiolides (chapter 1.2). SHEN et al. cloned and characterized 
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the 85-kilobase gene cluster from streptomyces globisporus, which revealed an iterative type I 
polyketide synthase leading to a highly convergent biosynthesis of four building blocks 15-18 
(scheme 2). 
 
Scheme 2: Hypothesized biosynthetic assembly of the building blocks 15-18 towards C-1027 
chromophore 3. 
In correlation with investigations on the gene cluster of neocarzinostatin[19] SHEN et al. 
concluded a group of open reading frames (ORFs, SgcE and SgcE1 to SgcE11) might be 
involved in the synthesis of enediyne structure 15, together with epoxide hydrolase SgcF 
(scheme 3).  
 
Scheme 3: Hypothetical biosynthetic pathway of enediyne fragment 15. 
Based on the set of enzymes found in the gene cluster the authors proposed a biosynthetic 
route towards amino acid 16 starting with hydroxylation of tyrosine 19, followed by stepwise 
activation of the carboxylic acid. Subsequent chlorination of the catechol and migration of the 
amine might furnish amino acid building block 16 (scheme 4). 
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Scheme 4: Proposed biosynthetic pathways of the synthesis of amino acid 16. 
Biosynthesis of amino sugar 17 might start from glucose and rely on phosphorylation at C1 
and reduction at C6. Oxidation at C4, epimerization and methylation at C5, followed by 
reductive amination and methylation of the resulting amine could furnish amino sugar 17 
(scheme 5).   
Scheme 5: Proposed biosynthetic pathways for the synthesis of amino sugar 17. 
For benzoxazolinate 18 double hydroxylation of benzoic acid 20, followed by mono-
etherification was hypothesized to take place. Amide formation, condensation and activation 
of the benzoic acid would then give building block 18 (scheme 6). 
 
Scheme 6: Proposed biosynthetic pathways for synthesis of benzoxazolinate 18. 
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1.4 Biological Activity 
 
The already mentioned tendency of enediyne containing natural products to cyclize is also 
responsible for their biological activity. While acyclic enediynes usually require harsh 
conditions for cyclization, natural occurring enediynes are often incorporated in cyclic 
skeletons and therefore undergo cyclization under much milder conditions.[15,16] As 
exemplified for calicheamicin 2[20] in scheme 7, a nucleophilic attack cleaves the trisulfide`s 
S-S bond of the allylic trigger heterolytically, which induces intramolecular cyclization to 21 
and facilitates subsequent BERGMAN-cyclization to yield biradical 22. This highly reactive 
1,4-biradical abstracts two H atoms from the DNA backbone which finally results in 
apoptosis. Alternatively, photoactivation, thiols, or non-neutral pH-values also induce 
cyclization.[20,21]  
 
Scheme 7: Mechanism of DNA cleavage exemplified for calicheamicin.[20] 
In contrast to other enediyne-containing natural products C-1027-derived cyclization products 
do not lose their biological activity upon rearrangement entirely, which makes them even 
more attractive targets for medicinal application, due to higher stability. In fact, FENICAL et al. 
found the fijiolides A and B to be potent inhibitors of TNF-α-induced NFκB activation.[14a] 
For fijiolide A, they found reduced activation by 70.3% with an IC50 value of 0.57 µM; 
fijiolide B showed dose-independent inhibition of 46.5%. This finding clearly demonstrates 
the importance of the amine`s acetylation. Furthermore, for fijiolide A an induction of 
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quinone reductase-1 (QR1) with a rate of 3.5 (28.4 µM) was observed; with a concentration of 
1.8 µM necessary to double activity. Fijiolide B had no influence on QR1 activity. In contrast 
to the fijiolides, the structurally related cyclized C-1027 chromophores III (14a) and V (14b, 
figure 5, chapter 1.2) were also found to inhibit isocitrate lyase (ICL, IC50 of 25.6 µM for 
chromophore III, 37.9 µM for V), an enzyme playing a pivotal role in Candida albicans 
pathogenicity. In addition, for both chromophores moderate to high anti-proliferative activity 
was found against a variety of carcinoma cell lines.[14b]  
The inhibitory effects against TNF-α-induced NFκB activation of the fijiolides` bioactivity 
are of particular interest for medicinal chemistry. NFκB (nuclear factor-κB) is a transcription 
factor present in almost all cell types.[22] It is responsible for the immune response of over 
400 genes in case of infections or inflammation and other stressful events.[23] While controlled 
by inhibitory proteins in the resting state, upon external stimuli these proteins get rapidly 
phosphorylated, ubiquitinated and degradated which liberates NFκB for regulating gene 
transcription. However, a variety of viruses[24] tend to utilize NFκB for activating their own 
genes for replication. Furthermore, its extraordinative activation in cancerous cells is well 
documented.[25]  
One of the most potent activators of NFκB is tumor necrosis factor α (TNF-α). While TNF-α 
is essential part of the intact immune response, its misregulation can lead to a variety of 
diseases such as inflammatory or viral infections.[26] Therefore a selective inhibition of TNF-α 
does represent an interesting approach for cancer therapy. 
 
1.5 Current State of Research  
 
Due to their potential as lead structures for medicinal chemistry (chapter 1.4), numerous 
approaches towards synthesis of enediyne related natural products and their substructures 
have been published over the years,[3-14] the ones related to C-1027 and the fijiolides will be 
discussed in the following section. 
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1.5.1.1 Synthesis of the Amino Sugar: HIRAMA`s first Generation Synthesis 
 
HIRAMA`s first generation synthesis[27] of amino sugar 23 started with SHARPLESS epoxidation 
of prenol 24 to give epoxide 25. Benzylation of the primary alcohol, epoxide opening, 
silylation of the corresponding secondary alcohol and hydrogenolytic cleavage of the benzyl 
ether resulted in 26 in 41% yield over four steps. Oxidation of the primary alcohol and 
subsequent STILL-GENNARI olefination gave the (Z)-configured α,β-unsaturated ester, which 
was cyclized under acidic conditions to lactone 28. Reduction using DIBAL and methylation 
furnished lactols 29a and 29b (scheme 10) with following dihydroxylation of this mixture 
yielding 1,4-cis-substituted diol 30 while unreacted lactol 29b could be recycled. Diol 30 was 
converted into the biscarbamate, desilylated, triflated and cyclized under basic conditions to 
give 31. Final reduction of cyclized carbamate 31 with LiAlH4 gave methyl glycoside (‒)-23 
(scheme 8) with identical spectroscopic data to those derived from acidic degradation of 
C-1027 (3). Overall this synthesis yielded (–)-23 in 1-2% with 80% ee over 17 steps and 
helped to verify amino sugar 23`s absolute configuration, which proved to be challenging 
using alternative methods. 
 
Scheme 8: HIRAMA`s first generation synthesis[27] of amino sugar 23. 
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1.5.1.2 HIRAMA`s second Generation Synthesis 
 
HIRAMA`s second generation synthesis[28] of 23 started from L-glutamic acid (32), which was 
cyclized to the γ-lactam ethyl ester, followed by addition of methyl lithium, silylation of the 
resulting alcohol and Boc-protection of the amide to give 33 in 54% yield. Addition of 
PhSeCl to the enolate of 33, GRIECO elimination and dihydroxylation resulted in diol 34 as a 
single diastereomer, which gave δ-lactone 35 after saponification and acidic lactonization. 
Boc-deprotection and reductive amination yielded N,N-dimethylamine 36 in 79%. Protection 
of the diol and DIBAL reduction furnished lactol 37 in 50% yield, which represents to this 
date the shortest synthesis with eleven steps and an overall yield of 13% (scheme 9). 
Furthermore, protection of the diol as disiloxanylidene was hypothesized to be beneficial in 
the stereoselective glycosylation of fijiolides aglycon and subsequent desilylation, which was 
later demonstrated by CRAMER (see chapter 1.5.3).[14c] 
Scheme 9: HIRAMA`s second generation synthesis[28] of amino sugar 37. 
 
1.5.1.3 SEMMELHACK`s Synthesis of 23 
In 2001 SEMMELHACK and coworkers published a synthesis[29] of 23 starting from enantiopure 
α-methyl-L-manno-pyranoside (38). Double acetonide formation and selective hydrolysis of 
the C4/C6 acetonide,[30] followed by carbamate formation at C6 gave 39. Triflation of the 
alcohol and intramolecular SN2 displacement of the latter gave oxazinanone 40. Although 
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reduction of the oxazinone in 40 with LiAlH4 gave the amino alcohol in excellent yield, 
subsequent oxidation resulted in competing elimination at C4, therefore the carbamate of 40 
was cleaved under basic conditions followed by Cbz-protection of the amine to give 41 in 
95% yield. A stepwise oxidation of the alcohol to the methyl ester and α-methylation resulted 
in 42 as a mixture of diastereomers, which were reduced to alcohol 43 using LiAlH4. 
Mesylation of the alcohol, reduction of the mesylate and subsequent acetal deprotection gave 
(–)-23 in 14 steps starting from 38 in 10% yield (scheme 10). 
Scheme 10: SEMMELHACK`s synthesis[29] of amino sugar 23. 
 
1.5.2.1 Synthesis of the Amino Acid: HIRAMA`s Synthesis  
 
The group of HIRAMA developed a synthesis[31] for the β-tyrosine moiety of the fijiolides 
starting from benzaldehyde 44 (scheme 11). The catechol of 44 was orthogonal protected as 
benzyl and MOM ethers and following HWE-reaction gave cinnamic ester 46 in 78% yield. 
Asymmetric conjugate addition with DAVIES` lithium amide[32] 47 resulted in amino ester 48 
with a d.r. of 20:1. Hydrogenolytic deprotection of 48 also caused elimination of the amine, 
so a change of the benzylic phenol protection to a TBS ether gave 49. Subsequent amine 
deprotection, Boc-protection and desilylation gave 50 in nine steps and 46% yield starting 
from aldehyde 44. 
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Scheme 11: HIRAMA`s synthesis of the β-tyrosine moiety of C-1027. 
HIRAMA et al. then used amino acid 50 to investigate regioselective epoxide opening on 
C-1027 building block 51 utilizing CsF in DMF at 80 °C for their synthetic studies towards 
the C-1027 chromophore (52, scheme 12).[31]  
Scheme 12: Epoxide opening by amino acid derivative 50 on C-1027 building block 51. 
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1.5.2.2 CRAMER`s Synthesis of the Amino Acid moiety 
 
CRAMER`s first generation synthesis[14d] of the β-tyrosine moiety 53 started with 
5-chlorovanilic acid (54). O-benzylation of the phenol and a decarboxylative CLAISEN 
condensation gave β-keto ester 55, which was subsequently converted into enamine 56. 
A highly enantioselective hydrogenation using a Ru(OAc)2/DM-Segphos combination yielded 
57. Subsequent acetylation of the amine, hydrogenolytic cleavage of the benzyl ether and 
saponification of the ester gave acid 53 in 41% yield over eight steps (scheme 13a). 
Scheme 13: CRAMER`s two generations of amino acid syntheses. 
After their synthetic efforts had revealed that no orthogonal protection of the catechol was 
necessary (chapter 1.5.3), a slight modification of the protecting group strategy furnished 
bis-silylated amino acid 59 in 32% yield from 5-chloroveratric acid (58, scheme 13b).[14d] 
 Current State of Research – Synthesis of the tricyclic Indene Core 
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1.5.3 CRAMER`s Total Synthesis of Fijiolide A 
 
Synthesis of the tricyclic core structure 60 of the fijiolides (figure 6) represents the 
synthetically most challenging part of the synthesis together with the atrop-selective 
cyclophane formation. Trapping biradical intermediate 13 resulting from BERGMAN-
cyclization of the enediyne precursor C-1027 would deliver 10 (scheme 1, chapter 1.2). 
However, synthetic work of INOUE and HIRAMA[5b-e] towards total synthesis of the C-1027 
chromophore 3 revealed the required enediyne precursor required for this transformation to be 
synthetically equally challenging. 
Figure 6: Benzodihydropentalene core of the fijiolides. 
For their synthesis of fijiolide A, CRAMER and coworkers[14c] developed an elegant synthetic 
route towards tricyclic compound 60 via a highly regioselective [2+2+2]-cycloaddition of 
alkynes 61, 62 and 63 (scheme 14), based on synthetic efforts of YAMAMOTO.[33] A 
preformation of boron-tethered triyne 65 gave under Ru(I)-catalysis 66 (scheme 15a), which 
could then react regioselectively with the unprotected alkyne of diyne 63 (scheme 15b) to 
form highly functionalized 64 in 59% yield as single diastereomer.  
Scheme 14: CRAMER`s highly regioselective [2+2+2]-cycloaddition of alkynes 61 - 63 to 
yield 64. 
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Scheme 15: Preformation of 71 explaining the regioselectivity observed. 
With 64 in hand, chlorination, desilylation-induced allene formation and protection of the diol 
side chain gave precursor 67 for an allenic PAUSON-KHAND reaction,[34] which provided 
cyclopentenone 68 in 36% yield over four steps. Dihydroxylation at C8/C9, regioselective 
tosylation of the resulting alcohol at C8 and acidic deprotection of the side chain`s primary 
alcohol furnished diols 69 and 70 (scheme 16). With this impressive reaction sequence the 
cyclopentenone building block of the fijiolides was accessible to investigate atrop-selective 
cyclophane formation (scheme 17).  
 
Scheme 16: Synthesis of diol 69 via PAUSON-KHAND reaction. 
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Esterification of 69 with β-amino acid 59 (chapter 1.5.2.2), followed by LUCHE reduction 
yielded ester 71 in 68%. Deprotection using CsF induced the desired cyclophane formation 
(scheme 17). The authors explained the observed atropselectivity of 75:74 ≥5:1 with a 
Cs-chelate 73 (path b) which assisted the nucleophilic attack of the para-hydroxy group at 
C8 to form 75 (green arrow). With formation of atropisomer 74 no coordination to the 
cyclopentenol would occur (intermediate 72, path a). As a side product, formation of 
meta-cyclophane 76 was observed (red arrow). Studies using partially protected derivatives at 
any alcohol in 71 always led to lower regio- and atropselectivities in the cyclophane 
formation event, supporting the hypothesis of chelate 73. Overall para-cyclophane 75 was 
isolated in 60% yield starting from 71. 
 
Scheme 17: Cs-chelate assisted para-cyclophane formation to yield 75. 
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After successful construction of the cyclophane moiety, substitution of the allylic alcohol by a 
selenide, glycosylation at C9 with SCHMIDT donor 77 (chapter 1.5.1.2) and silylation of the 
phenol gave allyl selenide 78. Final GRIECO elimination and global deprotection gave 
fijiolide A in 18% yield over five steps from 75 (scheme 18). A variety of other protocols 
investigated for dehydration of 75 to introduce the cyclopentadiene mostly resulted in 
decomposition of the starting material or no conversion at all.[14e] 
 
Scheme 18: End-game of the synthesis of fijiolide A (10a). 
 
Although CRAMER`s retrosynthetic approach remains unmatched in terms of elegance and 
efficiency there still exists one drawback. Albeit extensively studied, the dihydroxylation of 
indene 69 at C8/C9 could not be performed in diastereoselective fashion, effectively resulting 
in a significant loss of starting material at this relatively late stage, giving a low yield of 29% 
for the desired cis-diol (8S,9R)-69.  
 Objective of this project 
18 
 
2 Objective of this Project 
 
With CRAMER`s synthesis leaving only small room for improvement the major contribution to 
seem useful is a synthetic strategy offering selective introduction of the trans-configured 
(8S,9R)-diol incorporated in the benzodihydropentalene substructure. Furthermore, a synthetic 
access towards natural occurring analogous structures bearing stereochemistry at ring C might 
be opened by another strategy. In order to develop a stereoselective synthetic route to the diol 
in the fijiolides, benzodihydropentalene 79 should be targeted as test system (figure 7). 
 
Figure 7: Benzodihydropentalene 79 as test system for diastereoselective introduction of the 
diol in fijiolides (substructure highlighted in red). 
In addition, a synthetic access to the amino acid 81 should be developed, relying on cheap 
starting material. Therefore, a synthesis of 81 starting from eugenol (80) was to be 
encountered (scheme 19). 
Scheme 19: Synthesis of amino acid 81 from eugenol (80). 
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3.1 Retrosynthetic Analysis – Benzodihydropentalene 79 
 
The benzodihydropentalene core 79 should be accessible from cyclopentene 82 via substrate 
directed reduction at C8, addition of two leaving groups to the olefin and subsequent double 
elimination. Hydroxyketone 82 can be derived from indanone 83 by intramolecular enolate 
chemistry followed by α-hydroxylation. Indanone 83 should be accessible from indenone 84 
via enantioselective 1,4-addition with subsequent installation of a leaving group. Indenone 84 
can be obtained from aldehyde 85 via HWE-olefination and subsequent FRIEDEL-CRAFTS 
acylation (scheme 20, path a). 
Scheme 20: Retrosynthetic analysis of benzodihydropentalene core 79. 
After attempts to close ring C via intramolecular enolate chemistry at the stage of ketone 83 
proved to be not productive (chapter 4.3), the synthetic strategy was modified towards 
allylated 1,4-addition product 86 and to install the cyclopentene in 82 by ring closing 
metathesis (scheme 20, path b). 
Overall, the retrosynthetic approach minimizes the use of protecting groups and furthermore 
relies only on enantioselective introduction of a stereogenic center in the asymmetric 
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conjugate addition (ACA) step. Given the manifold examples in literature demonstrating 
generality of this enantioselective conjugate additions (see chapter 4.2) it seemed to be a 
reasonable starting point, even if its application to indenones had to be developed. Although 
the stereocenter introduced in the 1,4-addition is not present in the final compound, it still 
allows substrate-controlled introduction of stereoinformation in all other relevant positions. 
 
3.2 Retrosynthetic Analysis of Amino Acid 81 
 
For the synthesis of amino acid 81 starting from eugenol (80), enantioselective introduction of 
the amine in benzylic position is the most challenging task. Based on the work of DU BOIS,[35] 
amino acid 81 might be obtained from oxathiazinane 87 by ring opening, followed by 
oxidation. Oxathiazinane 87 should be accessible from sulfamate 88 by enantioselective 
CH-amination. Sulfamate 88 itself origins from eugenol via chlorination, hydroboration with 
oxidative work-up and sulfamoylation of the resulting alcohol (scheme 21). 
Scheme 21: Retrosynthetic analysis of amino acid 81. 
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4.1 Synthesis of the Benzodihydropentalene core – Access to Indenone 89 
 
In recent years a variety of indenone syntheses have been developed, due to their 
incorporation in a number of bioactive compounds such as neo-lignin[36] (89) or the COX-2 
inhibitor 90 (figure 8).[37] Especially transition-metal catalyzed access from benzylic esters,[38] 
aldehydes,[39] and other derivatives[40] has been extensively studied. Unfortunately, the 
integration of halides in the starting material restricts the number of appropriate methods. 
Therefore, intramolecular FRIEDEL-CRAFTS acylation of cinnamic acid derivatives was chosen 
as strategy for the construction of indenone 84. 
Figure 8: Examples of indenone-derived biological active compounds. 
For the synthesis of the cinnamic acid precursors, literature known aldehyde 85 was selected 
as starting material. Although benzaldehyde 85 is commercially available, an access to 
decagram quantities was established following a procedure of GILES[41] by chlorinating 
meta-hydroxy benzaldehyde 91 with tert-butyl hypochlorite to yield 85 in 55% after 
recrystallization (scheme 22). That way, the costs for starting material could be reduced 
drastically (91 100 g 44.10 € vs. 85 1 g 41.90 €)[42]. Aldehyde 85 was then methylated and 
used for WITTIG-reaction in water with stable ylide 93 to give (E)-configured cinnamic 
ester 94 in 97% yield. Using ylide 95, the corresponding ethyl ester 96 was obtained in 76% 
yield. 
Scheme 22: Synthesis of cinnamic esters 94 and 96. 
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After several failed attempts to isomerize (E)-configured cinnamic acid derivatives in situ to 
close ring B via FRIEDEL-CRAFTS acylation,[43] a (Z)-selective olefination was considered to 
be the most promising option. Therefore, STILL-GENNARI-olefination[44] using KHMDS and 
18-crown-6 at low temperatures in THF was applied to afford (Z)-configured α,β-unsaturated 
ester 97 in 99% yield as the sole product (scheme 23). 
Scheme 23: STILL-GENNARI-olefination of 92 to yield cinnamic acid ester 97. 
Since the use of reagents as costly as phosphono acetate 27 (5 g, 168 €, 15.7 mmol)[45] at such 
an early stage of the synthesis would limit its overall scalability, an expedient route towards 
27 was established, following a procedure of OBERTHÜR.[46] Phosphonate 98 was bis-silylated 
with TMSCl and transformed into the dichloride using oxalyl chloride and catalytic amounts 
of DMF. Subsequent double esterification with trifluoroethanol and DMAP in CH2Cl2 yielded 
27 in 86% overall yield. These operations could be performed on multigram-scale with only 
one final purification step necessary (scheme 24). 
Scheme 24: Cost-efficient synthesis of phosphono acetate 27.[46] 
Even though the costs for generating gram quantities of (Z)-97 could be significantly 
decreased by synthesis of phosphono acetate 27, the 5.00 equiv. of 18-crown-6 required for 
this olefination still remained a limiting factor.[44] Use of 3.00 equiv. crown ether resulted in 
(E/Z)-mixtures of ~1:2 and for conversion of 3.10 g aldehyde 92 about 30.0 g of crown ether 
were needed (18-crown-6: 100 g, 325 €).[47]  
Therefore, another method to isomerize (E)-configured cinnamic ester 94 was investigated 
following a procedure developed by GILMOUR.[48] Detection of crystalline riboflavin in eyes 
of a broad range of vertebrates led to the finding that riboflavin may catalyze light-induced 
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isomerization of double bonds (as exemplified by WALKER and RADDA for 11-cis-retinol, 
scheme 25).[49]  
Scheme 25: 11-cis-retinol isomerization catalyzed by (–)-riboflavin.[48] 
GILMOUR et al. developed a protocol for isomerization of cinnamic esters (99 → ) under 
catalysis of vitamin B2.[48] A biradical species 101 is formed by photo-excitation, which is 
efficiently generated from (E)-configured cinnamic esters but not from the (Z)-configuration 
due to a poor orbital overlap of the olefin with the π-system of the tilted aromatic ring. 
Consequently, this shifts the (E/Z) equilibrium, which leads to enriched formation of 
(Z)-configured esters 100 (scheme 26).  
Scheme 26: Concept of light-induced E → Z isomerization under riboflavin catalysis. 
However, unsubstituted cinnamic methyl ester only gave a (Z/E) ratio of 60:40 after being 
exposed to the reaction conditions (table 1, entry 1). Only cinnamic esters bearing a 
substituent in benzylic position gave satisfactory ratios of isomerization.[48b] Therefore, it was 
very surprising to find a ratio (Z/E) of up to 6.5:1 for 94 → 97 on a 0.1 mmol scale (entry 2 
and 3), most likely due to the chloro substituent in ortho position also favoring a shift of the 
arene moiety out of plane (scheme 27).  
On a 2.0 mmol scale the ratio (Z/E) dropped to 1.6:1 (entry 4), by increasing dilution a ratio 
of 8:1 could be restored on preparative useful scale of up to 11.0 mmol (entry 5 and 6). Use of 
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the corresponding acid 102 resulted in almost no conversion (entry 7). The ethyl ester 96 gave 
a ratio of 10:1 on a 1.3 mmol scale (entry 8).  
Scheme 27: Photo-induced (–)-riboflavin catalyzed isomerization. 
Table 1: Light-induced E → Z isomerization of cinnamic acid derivatives. 
entry ester residue 
CO2R 
scale 
(mmol) 
concentration 
(M) 
comments yield (%), 
(Z/E)-ratio 
1[48b] Me (99) 0.1 0.070 
Unfunctionalized 
ester,                   
400 nm light 
99, 1.5:1 
2 Me (94) 0.1 0.070 435 nm light 87, 3.5:1 
3 Me (94) 0.1 0.070 365 nm UV-light 93, 6.5:1 
4 Me (94) 2.0 0.070 365 nm UV-light 91, 1.6:1 
5 Me (94) 2.0 0.035 365 nm UV-light 96, 7:1 
6 Me (94) 11.0 0.035 365 nm UV-light 98, 8:1 
7 H (102) 0.1 0.070 365 nm UV-light 92, 1:10 
8 Et (96) 1.3 0.044 365 nm UV-light 98, 10:1 
 
Preliminary tests to further scale up the isomerization process via continuous flow 
implementation failed due to riboflavin`s poor solubility in MeCN. However, GILMOUR and 
coworkers recently reported a covalent immobilization strategy for (–)-riboflavin catalysts, 
which might allow an application of flow chemistry to further scale up of this isomerization 
process.[50] In addition, SEEBERGER and GILMORE could demonstrate the application of 
heterogeneous photocatalysis in continuous flow via serial micro-batch reactors.[51]  
Having developed a reliable access to (Z)-configured cinnamic acid ester 97 the 
FRIEDEL-CRAFTS acylation was to be encountered. Saponification of 97 yielded the 
corresponding acid, which was converted without further purification into the acid chloride 
using oxalyl chloride/DMF. Following FRIEDEL-CRAFTS acylation with aluminum(III) 
chloride in CH2Cl2 gave rise to indenone 84 in 93% yield over three steps (scheme 28). 
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Scheme 28: Completion of ring B via FRIEDEL-CRAFTS acylation. 
In order to install the missing C3-fragment of ring C onto the indenone core of 84, rhodium- 
catalyzed asymmetric conjugate addition (ACA) was hypothesized to allow introduction of 
ring fragment C in a highly enantioselective fashion. Furthermore, when performed with an 
indenone already bearing the diol side chain, a possible substrate`s influence on 
diastereoselectivity might be easier to overcontrol than by classical cuprate addition 
chemistry.[52] The theoretical background of rhodium-catalyzed ACA and application in 
natural product synthesis will be discussed in the following chapter. 
 
4.2 Rhodium-Catalyzed Asymmetric Conjugate Additions 
 
Asymmetric conjugate addition has emerged as one of the fundamental technics in organic 
synthesis to introduce stereochemistry onto MICHAEL acceptors. The groundbreaking work of 
ALEXAKIS,[53] FERINGA[54] and HAYASHI[55] in the 1990s paved the way for asymmetric 
copper- and rhodium-catalyzed conjugate additions (scheme 29). This powerful methodology 
has been applied in numerous total syntheses like HELMCHEN`s Baclofen synthesis,[56] 
COREY`s synthesis of platensimycin,[57] FÜRSTNER`s protecting group free synthesis of 
ecklonialactone B,[58] KOERT`s synthesis of phoslactomycin A[59] or INOUE`s hydroxyzinowol 
synthesis[60] (figure 9, bond formed during ACA depicted in red).  
Scheme 29: HAYASHI`s first example of an Rh-catalyzed asymmetric conjugate addition.[55] 
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Figure 9: Selected natural products syntheses using this methodology.[56-60] 
The generally accepted mechanism[61] of these asymmetric conjugate additions relies on 
transmetalation of the nucleophile onto the rhodium catalyst 103 to give 104, which then 
coordinates the Michael acceptor. Insertion of the alkene into the Rh-C bond forms rhodium-
oxa-π-allyl species 105 with the nucleophile enantioselectively connected to the former 
enone. Hydrolysis then liberates the product (106) and regenerates the catalyst (scheme 30 for 
the addition of PhB(OH)2 to cyclohexenone). 
Scheme 30: General mechanism of rhodium-catalyzed conjugate additions. 
Since the first examples of conjugate additions emerged, a broad range of MICHAEL acceptors 
such as acyclic and cyclic enones,[62] α,β-unsaturated esters,[63] lactones,[58] nitroalkenes,[64] 
amides[65] and alkenyl sulfones[66] have been used for conjugate additions. Furthermore, the 
scope of nucleophiles has been significantly increased to all kinds of boronic acid 
derivatives,[67] silanes,[68] alkenyl zirconium reagents[69] and others.[70] In addition to aryl 
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nucleophiles also alkenyl,[71] some alkyl[72] and even alkynyl[73] nucleophiles were found to be 
transferred in conjugate additions. 
As chiral ligands for rhodium-catalyzed asymmetric conjugate additions, there are three 
general types known in the literature: Phosphine derived compounds like BINAP 107 bearing 
axial chirality, chiral diene ligands like HAYASHI`s (R,R)-Ph-bod 108[74] often derived from 
terpene feedstock, and sulfoxide-olefin hybrid ligands, as exemplified by a work of KNOCHEL 
and coworkers (109, figure 10a). Exemplified coordinative modes of the active catalysts are 
depicted in figure 10b for each ligand type. 
Figure 10: Ligand systems known for Rh-catalyzed asymmetric conjugate additions and their 
coordination modes in the enantioselectivity-inducing step (exemplified for indenone 84). 
While phosphine-based ligands are well established ligands for a broad range of transition 
metals and usually commercially available in both enantiomeric forms, they were among the 
first ligands to be tested in asymmetric conjugate additions and give satisfying results for 
simple substrates.[62] However, especially for more challenging substrates like 
cyclopentenones or for the addition of alkenyl nucleophiles, diene ligands often give superior 
results and operate at lower temperatures than phosphine based systems.[62] Since numerous 
diene ligands are derived from natural occurring terpenes like CARREIRA`s diene 110 from 
carvone[75] (scheme 31a), their main limitation is the availability of the respective terpene. 
Consequently, use of diene ligands is often limited to one enantiomer while the other one 
relies on step-intense synthesis. Exceptions like TROST`s divinyl ethylene carbonate derived 
dienes 112[76] (scheme 31b) are obtained by catalytic asymmetric synthesis, chiral 
resolution[77] or separation of the enantiomers via chiral HPLC.[78]  
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Scheme 31: Synthesis of selected diene ligands. 
Examples of chiral sulfoxide olefin hybrid ligands are relatively rare in the literature 
compared to their diene and phosphine derived counterparts. Although both enantiomers can 
be easily obtained, as demonstrated by LIAO et al., by addition of abundant chiral thiosulfinate 
113 to lithiated aromatics to give 114[79] (scheme 32), their application in organic synthesis to 
this date remains limited. Nevertheless, they offer relatively high coordination ability to 
transition metals and allow conjugate additions even at room temperature.[80] 
Scheme 32: LIAO`s synthesis of sulfoxide alkene hybrid ligand 114.[79] 
In this work, BINAP derivatives and HAYASHI`s phellandrene-derived dienes were mainly 
used as ligands for asymmetric conjugate addition to indenone 84, due to their fast 
preparation[81] and proven application at room temperature. The synthesis of the latter was 
accomplished by DIELS-ALDER cycloaddition of (R)-(‒)-α-phellandrene with methyl 
propiolate to give 115. Addition of MeLi to the ester yielded 116 in 98%. Diene 117 was 
synthesized using n-BuLi (scheme 33). Experiments to further increase the steric bulk by 
addition of phenyl lithium or t-BuLi failed to give any product. 
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Scheme 33: Synthesis of HAYASHI`s phellandrene derived ligands 115 - 117.[81] 
 
4.3 Installation of Ring C via intramolecular Enolate Chemistry 
 
As model structure, boronic acid pinacol ester 120 was chosen to test feasibility of this 
strategy. After initial standard hydroboration procedures[82] failed to deliver 120, WANG`s 
protocol gave (E)-120 in 65% yield using 10 mol% of SCHWARTZ-reagent via 
hydrozirconation/transmetalation starting from propargylic alcohol (118) (scheme 34a).[83] 
Subjected to reaction conditions of rhodium-catalyzed asymmetric conjugate additions with 
indenone 84 as substrate using (S)-BINAP, vinylated indanone 121 was isolated in 88% yield, 
however, with only 25% ee. Nevertheless, the applicability of indenone 84 for Rh-catalyzed 
conjugate additions could be demonstrated (scheme 34b). 
Scheme 34: Hydroboration of TBS-protected propargylic alcohol 119 and subsequent 
rhodium-catalyzed 1,4-addition of 120 to indenone 84. 
Since for strategic reasons a (Z)-configured double bond would be more suitable because it 
would facilitate following operations to close ring C, (Z)-configured pinacol ester 122 was 
synthesized via rhodium-catalyzed hydroboration using a [Rh(cod)Cl]2/P(i-Pr)3-combi-
nation[84] in 86% starting from TBS-protected propargylic alcohol 118 (scheme 35a). The 
adjacent 1,4-addition with indenone 84 gave rise to indanone 123 in 72% yield with full 
retention of double bond configuration (scheme 35b). 
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Scheme 35: Synthesis of pinacol ester 122 from propargylic alcohol and its use in rhodium-
catalyzed conjugate addition to indenone 84. 
Initially, it was planned to perform a ring closure towards tricycle 126 in a one-pot 
desilylation-nonaflation-substitution procedure (scheme 36). Examples from literature[85] have 
already demonstrated the direct conversion of silyl enol ethers into nonaflates using 
nonafluorobutane sulfonyl fluoride (NfF). Even one-pot combinations with subsequent cross 
coupling reactions for a variety of substrates have been reported.[86] Herein, application of 
these protocols for silylated alcohol 123 was tested. It was hypothesized, that catalytic 
amounts of fluoride could partially deprotect the alcohol, forming alcoholate 124 with weakly 
coordinating tetra-n-butyl ammonium (or cesium) counter ion. Alcoholate 124 could then get 
sulfonylated by NfF to form 125, liberating stoichiometric amounts of fluoride to deprotect 
the remaining alcohol. Enolate formation on 125 by addition of base might then allow an 
intramolecular SN2-type substitution to afford tricyclic compound 126 (scheme 36). 
Scheme 36: Initial strategy to close the cyclopentene ring. 
After several unsuccessful attempts to achieve desilylation of 123 with TBAF (1 M in THF or 
trihydrate) or CsF, deprotection using 48% HF in MeCN furnished alcohol 127 in 60% yield. 
Subsequent sulfonylation was neither possible using combination of NaH and NfF, nor NaH 
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and TsCl in THF, probably due to formation of hemi acetal 128 via intramolecular attack of 
alcoholate 124 towards the ketone. After aqueous work up, alcohol 127 was reisolated in all 
cases (scheme 37).  
Scheme 37: Failed attempts to sulfonylate alcohol 127. 
Installation of a leaving group in allylic position under non-basic conditions was achieved by 
BF3•OEt2-mediated iodination using KI in 1,4-dioxane, but the corresponding allyl iodide 129 
decomposed upon removal of solvent. An APPEL-reaction with NBS and PPh3 in CH2Cl2 
furnished allyl bromide 130 in 96% yield (scheme 38). 
Scheme 38: Installation of the allyl halide. 
Intramolecular substitution of bromine in 130 proceeded quite smoothly. However, only vinyl 
cyclopropane 131 was isolated in 66% yield, following an SN2`-type ring closure 
(scheme 39). IKEGAMI et al. described a similar observation for their synthesis of 
bicyclo[3.3.0]oct-6-en-2-one.[87] Their solution, a LiI-promoted ring-expansion, only resulted 
in demethylation on the phenol (scheme 39).  
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Scheme 39: Unexpected formation of vinyl cyclopropane 131. 
Even though other examples from literature offer alternative procedures to expand the 
cyclopropane ring, most of them rely on flash vacuum pyrolysis[88] or stoichiometric use of 
expensive transition metal catalysts,[89] both providing no appealing alternative for synthesis 
of tricycle 126 on preparatively useful scale. Therefore, no further experiments were 
conducted to rearrange vinyl cyclopropane 131. 
 
4.4 Installation of Ring C via Ring Closing Metathesis 
 
After results from chapter 4.2 showed that competing SN2`-type ring closure prevents 
cyclopentene formation, an alternative approach towards tricyclic compound 82 was 
developed (see chapter 3.1, retrosynthesis second generation). With access to vinylation of 
indenone 84 already established, α-allylation followed by isomerization at C2 to give a 
cis-arrangement of allyl and vinyl side chain in 133/134 should allow ring closing metathesis 
to form ring C (scheme 40).  
 
Scheme 40: Revised synthetic strategy for construction of cyclopentene 82. 
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Previously established rhodium-catalyzed 1,4-addition conditions with trifluoroborate 135 
gave vinylated indanone 136 in 96% yield (scheme 41). Unfortunately, the decreased 
reactivity of 135 led in some cases to formation of significant amounts of reduced indanone, 
which could not be separated from 136. Alternative boronic acid-derived vinylation agents 
such as the anhydride or the pinacol ester are usually quite expensive and furthermore often 
suffer from low stability. Therefore, trifluoroborate 135 remained the nucleophile of choice. 
Scheme 41: Conjugate addition of 84 with trifluoroborate 135 and alternative vinylation 
agents. 
When 136 was exposed to KOt-Bu and allyl bromide at rt in THF, a mixture of allylated (137) 
and doubly allylated (138) products was obtained, both with the double bond isomerized into 
benzylic position (scheme 42). 
 
Scheme 42: α-Allylation of indanone 136. 
In order to investigate the double bond`s tendency to isomerize under basic conditions, 
indanone 136 was dissolved in THF, deprotonated using KHMDS and quenched after 20 min 
at –20 °C. Complete isomerization towards indanone 139 with an internal double bond was 
observed (scheme 43). 
 
Scheme 43: Stability test of vinylated indanone 136. 
Since the lability of 136`s double bond under basic conditions caused problems in allylation 
and probably in trans→cis isomerization at C2, the necessity for a more rigid double bond 
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was obvious. Therefore 1,4-addition of indenone 84 was performed using styrene boronic 
acid 140 (scheme 44). 
The styrene moiety in addition product 141 might offer three main advantages compared to 
the simple vinyl unit in 136. The increased reactivity of the boronic acid might suppress 
competing side reactions in the addition process. Moreover, addition of an internal olefin 
residue onto indenone 84 might reduce risk of isomerization. Furthermore, addition product 
141`s increased steric demand of the styryl chain in β-position should have a positive impact 
on substrate-controlled isomerization of the allyl moiety in α-position (scheme 49).  
For addition of styrene boronic acid 140 to indenone 84 a screening of ligands and conditions 
revealed diene ligands to be more performant ligands than phosphine-based ligands (table 2, 
entry 1-3 vs. entry 4-8). No influence of the organic solvent was found (1,4-dioxane vs 
toluene, entry 1 and 2). HAYASHI`s phellandrene derived diene ligands (synthesis see chapter 
4.2) were found to form competent catalysts with Rh-precursor B. However, using ligand 115, 
only low conversions and enantiomeric induction were obtained (entry 4). Ligand 116 gave 
141 in excellent yield with 59% ee at rt (entry 5), by decreasing temperature to 0 °C an ee of 
74% was obtained, again with 99% yield (entry 6). Lowering temperature to –20 °C gave no 
conversion to 141, probably due to solidified solvent mixture. Increasing steric bulk at the 
diene ligand from 116 to 117 resulted in decrease of yield and ee (entry 7). The best ee was 
obtained using CARREIRA`s diene 110[90] with 85% yield and 95% ee (entry 8). In order to 
further increase the ee of indanone 141 it was recrystallized from n-pentane/CH2Cl2 to give 
>99% ee, whose structure and absolute configuration were verified by X-ray crystal structure 
(for representative HPLC-chromatograms see chapter 8.2.3, page 108). 
 
Scheme 44: Asymmetric conjugate addition to indenone 84 with ligands 107-117 tested. 
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Table 2: Optimization of reaction conditions for the asymmetric conjugate addition to 84. 
entry precursor  
cat. 
ligand solvent       
(xx/H2O 10:1) 
yield (%)a ee (%) 
1 A 107 1,4-dioxane 65 41 
2 A 107 toluene 66 41 
3 A 142 toluene 56 38b 
4 B 115 toluene 62 44 
5 B 116 toluene 99 59 
6 B 116 toluene 99 74c 
7 B 117 toluene 45 22 
8 B 110 toluene 85 95 
aisolated yields; catalyst precursor A: [Rh(cod)OH]2 (5 mol%), catalyst precursor B: [Rh(C2H4)2Cl]2 (2 mol%); 
b(S)-enantiomer was obtained; reactions were performed at 25 °C except creaction was performed at 0 °C. 
 
Due to better commercial availability of (R,R,R)-116 (scheme 33, chapter 4.2), indanone 
(R)-141 was synthesized and used for establishing synthetic access to dihydro pentalene 79. 
For natural occurring fijiolides the respective (S)-enantiomer (S)-141 would be required, 
which is accessible using enantiomeric ligand (S,S,S)-116 (5 steps from (R)-(–)-carvone).[91] 
To the best of our knowledge these examples display the first reliable application[92] for 
asymmetric conjugate addition to an indenone. 
Allylation of 141 gave again mixtures of mono- and double-allylated indanones 143 and 144 
(scheme 45a). Variation of leaving group (X = Br, I), base (KHMDS, LDA) or temperature 
(ranging from –20 °C to –78 °C) had no influence on the ratio 143/144. Slow addition of 
electrophile to the enolate only resulted in increased formation of doubly allylated product 
144. Since the ratio of 143/144 seemed to be almost unaffected by most parameters variated, 
the problem might be formation of an equilibrium between enolate 145 and 143 leading to 
141 and 146 which causes significant double allylation due to lower pKa value of the product 
than the starting material (scheme 45b). 
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Scheme 45: Allylation of indanone and equilibrium between the enolates of product and 
starting material. 
Furthermore, the stability of enolate 145 could not be increased; also for 141 complete 
isomerization of the double bond was observed at –20 °C after 20 min. In the allylation 
reaction, formation of isomerized products 147 - 149 was observed with the same product 
ratio 148:149:147 as without isomerization. In order to prevent isomerization, the allylation 
reaction had to be quenched 5 min after addition of base (scheme 46).  
 
Scheme 46: Stability test of indanone 141 and isomerization products 147 – 149 in the 
allylation. 
With the aim of increasing the yield of mono-allylated indanone 143 a series of conditions for 
TSUJI-TROST-type allylations (scheme 47, table 3, entries 1-5), or enamine additions (entry 6 
and 7) were tested, all leading to double allylation, isomerization or no conversion. 
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Scheme 47: Attempted TSUJI-TROST-type allylations using indanone 141. 
Table 3: Alternative allylation procedures tested for the sequence 141 → 143. 
entry Pd-catalyst base X (allyl 
compound)  
additive temperature solvent 
1b Pd(dppf)Cl2 Pyrrolidine OEt - rt MeOH 
2b Pd(dppf)Cl2 Pyrrolidine OAc - rt DMSO 
3b Pd(dppf)Cl2 rac. Proline Br - rt DMSO 
4a 
Pd2dba3 + 
dppf 
KHMDS OCO2Me LiCl 0 °C THF 
5a 
Pd2dba3 + 
dppf 
KHMDS OCO2Me - –78 °C THF 
6b - Pyrrolidine Br - rt DMSO 
7b - rac. Proline Br - rt DMSO 
aisomerization observed; bno conversion. 
When indanone 141 was converted into the silyl enol ether only isomerized product 150 was 
observed (scheme 48). For mono-allylation of 141 without double-bond isomerization 
63% brsm of 143 were the best results obtained (scheme 45a), which is in accordance with the 
literature for alkylation/allylation of indanones.[93] 
 
Scheme 48: Synthesis of silyl enol ether 150 with isomerized double bond. 
With mono-allylated indanone 143 in hand the isomerization was performed, following a 
procedure of KRAUSE,[94] using LiHMDS to generate the lithium enolate. The latter was 
subsequently reprotonated by ethyl salicylate (151) from the sterically less hindered side via 
chelate 152. Overall, an trans→cis isomerization of the allyl group at C2 can be achieved that 
way, (scheme 49a). Although this isomerization process is known to give better results for 
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six- or seven-membered rings, also for five-membered rings remarkable cis/trans-ratios of 4:1 
were reported. For 143 a cis/trans-ratio 143:153 of 2:1 was obtained, limited by the fast 
enolate addition necessary to prevent double-bond isomerization (scheme 46a). The 
subsequent ring closing metathesis (rcm) of the cis/trans mixture using GRUBBS II in CH2Cl2 
yielded tricycle 154 in 70% together with unreacted trans-143 as an inseparable mixture 
(scheme 49b). 
 
Scheme 49: trans→cis Isomerization of 143`s allyl residue and subsequent rcm. 
Subjecting this mixture to conditions for α-hydroxylation using modified conditions from 
ADAM[95] did not result in hydroxylated tricyclic compound 155, probably due to poor 
formation of enolate 156. Generation of 156 would require planarization at C9 and therefore it 
seems to be unlikely for this highly strained system (scheme 50). Nevertheless, hydroxylated 
indanone 157 was isolated with full preservation of the double bonds and without epoxidation 
or other side reactions observed. 
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Scheme 50: α-Hydroxylation of mixture 154:143. 
The obtained cis/trans ratio by isomerization was far from satisfactory and allowed no clean 
isolation of tricycle 154, so installation of the cis-arrangement of allyl and styryl residue was 
combined with oxygenation at C2. Therefore, allylated 143 was deprotonated using KHMDS 
in THF at –78 °C and DMDO was added as O-electrophile to give trans-157 exclusively, 
which was then subjected to ring closing metathesis conditions to yield tricycle 155 in 67% 
yield over two steps. The successful construction of 155 was verified by X-ray 
crystallography (scheme 51).  
 
Scheme 51: Synthesis of α-hydroxyketone 155:  
The low stability of DMDO upon storage required the use of freshly prepared reagent and the 
large amount of acetone hindered the extraction process. (TMSO)2 was synthesized following 
a procedure of BABIN[96] and tested as O-electrophile,[97] however, no improvement in 
comparison to DMDO was found. Other O-electrophiles such as VEDEJ`s reagent[98] or 
DAVIS` oxaziridines[99] (figure 11) were considered but their overall lower atom economy, 
price (DAVIS reagent) or toxicity (VEDEJ`s reagent) made them unattractive alternatives. 
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In situ formed TFDO[100] or O2
[101] were believed not to react fast enough with the enolate of 
149 to prevent double bond isomerization or other unproductive side reactions.   
 
Figure 11: Alternative O-electrophiles considered for α-hydroxylation of 143. 
Due to the high lability of the styrilic double bonds in 141 and 143 (scheme 46a), the reaction 
sequence of allylation, oxygenation and metathesis was streamlined with only aqueous work 
up in between to give tricycle 155 from 141 in 25% yield over three steps on 1.55 mmol scale 
(scheme 51).  
 
4.5 Installation of the Cyclopentadiene in Ring C 
 
After successful assembly of the carbon core structure in 79, adjustment of the oxidation 
states had to be carried out, starting with diastereoselective reduction at C8. Initially, a 
directed EVANS-SAKSENA reduction[102] was planned to establish trans-diol 158 (scheme 52a). 
However, subjected to typical reaction conditions no reduction of the ketone was observed 
even at 70 °C for 16 h. Instead, reduction using Red-Al[103] in toluene at –60 °C yielded 
almost exclusively trans-diol 158 (scheme 52b). At higher temperatures or with faster 
addition of Red-Al, a cis/trans mixture of up to 1:2 was observed. Although not productive 
for further synthesis, cis-159 helped to verify the trans-relationship in its diastereomer 
trans-158 by observing a correlation of the benzylic proton at C8 and the allyl proton at C10 
in an NOESY experiment (figure 12).  
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Scheme 52: Directed reduction of 155`s ketone at C8. 
 
Figure 12: NOESY of cis-159 showing a correlation of 8-H and 10-H. 
After several attempts to reproduce exclusive formation of trans-158 and a series of varying 
temperature, time of addition and concentration it was found fundamental to solidify Red-Al 
at –78 °C first. Slow addition of ketone 155 as 0.03M solution at temperatures below –60 °C 
until complete consumption of 155 restored the trans/cis ratio of >15:1 on 1.0 mmol scale.  
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For synthesis of the natural product 10a a cis-selective reduction would be more suitable since 
it allows a cyclophane-formation by substitution of an alcohol derived leaving group at C8 
analogous to CRAMER`s strategy (scheme 17, chapter 1.5.3). A cis-selective reduction of 155 
might be achieved by coordination of alcohol and ketone with LEWIS acids to shield the 
alcohol`s face from an attacking hydride (NARASAKA-PRASAD-type reduction,[104] 
scheme 53a) Alternatively, trans-158 could be selectively tosylated at C8, the addition of base 
might lead to epoxide 160, which could then be opened by an appropriate phenolate to 
achieve an overall double inversion at C8 to yield 161 (scheme 53b). 
 
Scheme 53: NARASAKA-PRASAD reduction for ketone 155 and alternative strategy for 
installing a phenol ether at C8. 
With the trans-relationship in diol 158 successfully installed, formation of the 
cyclopentadiene moiety was addressed next. Etherification of 158 to block both alcohols gave 
twice methylated olefin 162 in reasonable yield. In order to demonstrate a possible 
discrimination between both alcohols in 158, the benzylic position (C8) was selectively 
esterificated to yield 163 using para-nitro benzoyl chloride which unfortunately did not 
crystallize to verify its structure by X-ray crystallography (scheme 54).  
Synthesis of the Benzodihydropentalene core 
 
43 
 
 
Scheme 54: Methylation and regioselective esterification of diol 158. 
With both alcohols protected, conversion of olefin 162 into dihydropentalene 79 was 
investigated. The general strategy for this formal oxidation at C1 and C10 relied on adding 
two leaving groups onto olefin 162 to allow double elimination towards cyclopentadiene 79 
(scheme 55). As potential leaving groups, halides and selenides were identified to be the most 
promising options. 
 
Scheme 55: General strategy for installing the cyclopentadiene moiety. 
Bromination of 162 yielded unstable dibromide 164 which upon treatment with excess of 
KHMDS at low temperatures gave allyl bromide 165 in 30% yield (scheme 56a). A second 
HBr elimination towards 79 was unsuccessful as well as substitution of bromide in 165 by 
seleno phenolate towards 166 for a subsequent GRIECO elimination (scheme 56b). 
Scheme 56: Bromination of cyclopentene 162 and subsequent attempts to obtain 79. 
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The addition of PhSeCl was found to be reversible (scheme 57), upon addition of base olefin 
162 was reisolated. Addition of PhSeBr to 162 did not give any product at all, as well as a 
combination of (PhSe)2/NCS following a procedure of SHARPLESS.
[105] 
Scheme 57: Attempted addition of PhSeCl to olefin 162. 
For their synthesis of the hupehenols[106] ZHAO et al. found a SeO2-mediated oxidation of 
highly substituted cyclopentene 167 to give cyclopentadiene 168 in 90% yield instead of the 
expected RILEY-oxidation product allyl alcohol 169 (scheme 58a). Their explanations for this 
finding was a competing β-H elimination (green path) instead of a [2,3]-sigmatropic shift 
(red path) taking place after the ene-reaction. When olefin 162 was subjected to ZHAO`s 
conditions the expected cyclopentadiene 79 was detected via GCMS, but neither 79 nor 
typical allylic oxidation product 170 were isolated (scheme 58b). 
Scheme 58: Unexpected formation of cyclopentadiene 168 during attempted allylic oxidation 
of 167[106] and SeO2-mediated elimination of cyclopentene 162 to cyclopentadiene 79. 
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With the results from previous investigations suggesting a stepwise installation of leaving 
groups to be necessary, olefin 162 was stereoselectively epoxidized using DMDO in 72% 
yield to give 171. Subsequent base-catalyzed epoxide opening towards allylic alcohol 172 
was not achieved. A regioselective epoxide opening at C11 by seleno phenolate finally gave 
access to α-hydroxy selenide 173, which was subsequently oxidized with H2O2 to give allyl 
alcohol 174 in 71% starting from epoxide 171 (scheme 59). The regioselectivity of the ring 
opening event was in accordance with previously observed trends for opening of the 
bromonium-ion transitioned in the formation of dibromide 164 (scheme 56). 
Scheme 59: Synthesis of allyl alcohol 174 from cyclopentene 162 via epoxidation, epoxide 
opening and GRIECO elimination. 
The tricyclic carbon skeleton was found to be prone to elimination of methanol under slightly 
acidic conditions. In order to minimize the risk of elimination taking place in synthesis of 
allylic alcohol 174, the sequence of reduction of hydroxyketone 155, methylation, epoxidation 
and GRIECO elimination was streamlined with one final purification to give 174 in 32% yield 
over five steps. 
For syn-elimination of the alcohol in compound 174 (scheme 60) a screening of conditions 
began with BURGESS reagent,[107] which gave <10% yield of dihydropentalene 79 (table 4, 
entry 1). Neither with MARTIN sulfurane[108] (entry 2) nor using APPEL conditions (entry 3) 
from chapter 4.3 an elimination to 79 was observed. Finally, elimination of an in situ formed 
triflate[109] using an excess of KHMDS and PhNTf2 as sulfonylating agent gave 
cyclopentadiene 79 in 82% yield. Diene 79 showed a remarkable stability, even after 10 d at rt 
in C6D6, only traces of product degradation were observed by TLC. 
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Scheme 60: Final elimination of the alcohol in 181 to yield cyclopentadiene 84. 
 
Table 4: Conditions screened for elimination of 174 → 79. 
entry conditions yield (%) 
1 BURGESS reagent, C6H6, 80 °C, 2 h <10 
2 MARTIN sulfurane, CH2Cl2, 0 °C to rt, 24 h - 
3 PPh3, NBS, CH2Cl2, rt, 2 d - 
4 KHMDS, PhNTf2, THF, –78 °C, 20 min 82 
 
 
With synthetic access to the fijiolide`s core structure 79 developed, a combination with 
MESCH`s protocol (scheme 61a)[110] for the construction of the diol side chain would be 
necessary for the total synthesis of the fijiolides. This might be realized by introduction of the 
side chain before the indenone is constructed, which would further increase the number of 
linear steps by four and would additionally require use of protecting groups tolerating 
aqueous basic as well as LEWIS-acidic conditions for indenone construction (path a). 
Alternative side-chain installation at the indenone stage would require masking the enone 
(path b). Overall installation after formation of the tricyclic core structure would be desirable 
since formation of ring C represents the reaction sequence bottleneck in synthesis of the 
pentalene core but would require protection of the cyclopentene for dihydroxylation as well 
(path c, scheme 61b). 
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Scheme 61: a) MESCH`s installation of the diol side chain and strategies for the application in 
the total synthesis of the fijiolides. 
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5.1 Synthesis of Amino Acid 81 
 
For the synthesis of the amino acid moiety eugenol (80) was identified to be the optimal 
starting material, due to its good availability (500 g 91.50 €)[111] and the fact, that for 
construction of amino acid 81 no C-C bonds need to be formed.  
The synthesis of amino acid 81 started with oxychlorination of eugenol (80), following a 
procedure of GUSEVSKAYA.[112] Under O2-atmosphere a copper-assisted radical formation in 
ortho/para position to the phenol is believed to take place, which subsequently reacts with 
CuCl2 to afford the chlorinated species (scheme 62a). The para-position of eugenol is blocked 
by the allyl substituent, therefore the ortho chlorinated species is the only product observed. 
Following this protocol, chlorinated eugenol 175 was isolated in 85% yield (scheme 62b). 
Scheme 62: Oxychlorination of eugenol (80). 
In the beginning of the synthesis, an orthogonal protection strategy of both phenolic alcohols 
of amino acid 81 was believed to simplify regioselective cyclophane formation (scheme 17, 
chapter 1.5.3). Therefore, TBS-protection of the phenol of chlorinated eugenol 175 was 
performed to yield 176 in 85% (scheme 63). However, CRAMER`s synthesis[14c] demonstrated 
that no orthogonal protection is necessary. Hence, the synthetic route was later modified to 
methylate phenol 175 (see chapter 5.3). TBS-protection of 175 was followed by 
hydroboration of the allyl chain, which yielded alcohol 177 in 74% after oxidative work up 
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(scheme 63). Subsequent sulfamoylation of 177 using in situ formed sulfamoyl chloride[113] 
gave sulfamate 178 in 80% yield on gram scale as substrate for the rhodium-catalyzed 
enantioselective CH amination. The theoretical background of the amination strategy will be 
discussed in the following chapter. 
Scheme 63: Synthesis of TBS-protected sulfamate 178. 
 
5.2 Rhodium-Catalyzed CH-Amination 
 
Although synthetic utility of CH-amination on a broad scope only emerged in the past two 
decades, the first examples of CH-amination reactions reach back almost one and a half 
centuries to the development of the HOFMANN-LÖFFLER-FREYTAG reaction (scheme 64a).[114] 
While this long known methodology has been refined over the years (scheme 64b 
and c)[115,116] allowing it`s application under much milder conditions, CH-amination as a 
research field has matured to offer several fascinating solutions to this complex synthetic 
challenge. 
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Scheme 64: Examples of the HOFMANN-LÖFFLER-FREYTAG reaction. 
One of the biggest challenges is not only to overcome the CH-bond`s high enthalpic stability 
(representative values see figure 13),[117] but also to selectively address one particular bond in 
the presence of several others in a comparable energy range.  
Figure 13: CH-bond-dissociation energies. 
In order to resolve the selectivity issue of CH-functionalization three general concepts have 
been developed: Substrate-controlled reactions by offering certain privileged CH-bonds as 
exemplified by GAUNT et al.[118] (scheme 65a), via installation of a directing group 
(scheme 65b, demonstrated for oximes by SANFORD and coworkers)[119] or by intramolecular 
cyclization via nitrene-insertion[120] favoring a certain ring-size (scheme 65c). While the first 
two concepts rely on offering CH-bonds in close proximity to the coordinated transition metal 
complex on rigid substrates the nitrene insertions tolerates a broad range of substrates 
irrespective of their rotational degrees of freedom. Therefore, targeting an enantioselective 
CH-amination in benzylic position for the amine`s introduction via rhodium-catalyzed 
nitrene-based cyclization of DU BOIS` sulfamates seems to be predestinated (see scheme 65c). 
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Scheme 65: General concepts to achieve selectivity in CH-functionalization. 
In the early 80s, BRESLOW and GELLMANN reported the first inter- and intramolecular 
transition metal-catalyzed CH-aminations of imino iodinane species in their efforts to mimic 
catalytic activity of cytochrome P-450 (scheme 66a).[121] Mechanistically, the formation of a 
rhodium-nitrenoid was proposed, which subsequently inserts into the benzylic tertiary 
CH-bond (scheme 66b). 
Scheme 66: First examples of transition metal-catalyzed CH-amination by BRESLOW and 
GELLMAN.[121] 
The main limitation to this method was the low stability of the starting material (exemplified 
synthesis in scheme 66a). Therefore, the utility of this transformation was underestimated for 
almost two decades. 
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In 2001, the groups of DU BOIS[120,122] and DAUBAN[123] demonstrated independently that 
sulfamates, carbamates and urea derivatives form imino iodinane species in situ in the 
presence of Iodine(III) containing oxidation agents. These can be directly used to achieve 
CH-amination of secondary, tertiary, and benzylic CH-bonds. Mechanistic investigations[124] 
and DFT-calculations[125] proposed the oxidation of the amine 179 to imino iodinane 180, 
which subsequently forms the rhodium-nitrenoid species 181 that can insert into CH-bonds to 
produce oxathiazinane 182 (scheme 67a, transition state A). A radical-based CH-abstraction 
mechanism was also discussed (scheme 67a, transition state B), however, radical clock 
experiments[126] could exclude the formation of radicals with a lifetime of more than 200 fs. 
Nevertheless, empirical observations concerning reactivity of CH-bonds are in accordance 
with typical ones for radical processes (scheme 67b). 
Scheme 67: Mechanism of the rhodium-catalyzed CH-amination and relative reactivity of 
CH-bonds therein. 
Although a broad range of transition metals are able to catalyze CH-aminations, such as 
Cu-,[127] Ag-,[128] Fe-,[129] Mn-,[130] or Ru-complexes,[131] the use of dimeric Rh-carboxylate 
complexes was boosted by DU BOIS` development of Rh2(esp)2 (183) with tethered 
carboxylate units (figure 14a). Thereby, the catalysts` lability towards oxidation was 
overcome which strongly enhanced its performance and allowed reduction of catalyst loading 
in intramolecular cyclizations to 0.15 mol%.[132] Additionally, the first examples of 
intermolecular CH-amination with acceptable conversion were reported,[133] albeit with 
overall bigger selectivity issues than for intramolecular examples. The utility of this method 
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was demonstrated in a number of total syntheses such as manzacidine A and C,[134] 
saxitoxin,[135] or tetrodotoxin[136] and others[137] (figure 14b). 
Figure 14: Structure of the Rh2(esp)2 catalyst and total syntheses relying on rhodium-
catalyzed CH-aminations (CN-bond formed depicted in red). 
With the major improvements in CH-amination in recent years, there are still some limitations 
remaining. First of all, the iodine(III) oxidant used also tends to oxidize labile substrates and, 
even worse, Rh(II,II)-dimers to catalytical inactive Rh(II,III)-dimers, which can be easily 
observed by change of the reaction color to red. One solution to this problem was proposed by 
BERRY et al. by introduction of the stable, catalytical active Rh(II,III)-dimer Rh2(espn)2Cl (184, 
scheme 68a),[138] which could increase the turnover number (TON) for the examples 
investigated by the factor 2-3 and allowed conversions with only 0.05 mol% catalyst loading. 
Another solution might be the invention of substrates not relying on iodine(III) oxidation 
prior to nitrene formation as exemplified by LEBEL and coworkers[139] or CHIARA[140] et al. 
(scheme 68b and c). The latter might be of particular interest, since most organic azides as 
nitrene precursors failed to react under typical CH-amination conditions.[139] 
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Scheme 68: BERRY`s Rh(II,III)-dimer and examples of substrates not relying on oxidation prior 
to nitrene formation. 
Another drawback of rhodium-catalyzed CH-aminations is enantioselectivity. While for 
tertiary CH-bonds a complete retention of configuration can be observed and 
substrate-directed reactions give high diastereoselectivity, as exemplified by DU BOIS` 
saxitoxin synthesis[135] (see figure 14b), application of chiral rhodium tetracarboxylate 
catalysts only gave poor enantioinduction. In 2008, DU BOIS published a series of rhodium 
carboxamidate dimers, demonstrating that Rh2(S-nap)4 (185)
[35] could overcome this issue, 
mainly due to a hydrogen bridge significantly enhancing the catalyst`s redox potential 
(scheme 69a, comparison with its methylated analogue 186). A solution for intermolecular 
CH-amination was proposed by DAUBAN and coworkers[141] by the use of Rh2(S-nttl)4 in 
combination with chiral sulfonimidamides 189 resulting in a matched/mismatched scenario 
giving benzylic amination products in up to 89% yield with excellent de`s (scheme 69b). 
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Scheme 69: Rh2(S-nap)4 and its methylated analogue, their application in enantioselective 
CH-amination and DAUBAN`s diastereoselective intermolecular amination. 
For synthesis of amino acid 81, application of DU BOIS` Rh2(S-nap)4 catalyst 185 for 
intramolecular CH-amination was believed to offer sufficient enantiocontrol, given the 
comparable examples in literature (187 → 188, scheme 69a) demonstrating high enantiomeric 
induction by this catalyst. Synthesis of Rh2(S-nap)4 was achieved by cyclization of 
(L)-ornithine hydrochloride (190) to the lactam followed by tosylation in a single flask and 
subsequent ligand exchange onto Rh2(OAc)4 in (scheme 70). Further experiments to produce 
ligands with different sulfonylation patterns to vary the electronic and steric demand remained 
unsuccessful.  
Scheme 70: Synthesis of Rh2(S-nap)4 from ornithine hydrochloride 185.
[35] 
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5.3 Synthesis of Oxathiazinane 193 
 
After CH-amination of sulfamate 178 (scheme 71) with Rh2(esp)2 and PhI(OPiv)2 gave 
racemic oxathiazinane 192 in 90% yield (table 5, entry 1), a transfer of the optimized reaction 
conditions towards the chiral Rh2(S-nap)4 gave only unsatisfactory 44% ee in CH2Cl2 and 
53% ee in benzene, although excellent yields were achieved (entry 2-4). Use of Rh2(S-dosp)4 
(figure 15a) resulted in 12% ee in favor of (S)-192 (entry 5). It was reasoned that two in the 
activation of the sulfamate liberated carboxylate moieties (see mechanism, chapter 5.2) of the 
oxidating agent undertook a ligand exchange on the catalyst, causing a loss of 
stereoinformation at the catalyst and consequently a loss of enantioselectivity in the product.  
Scheme 71: CH-Amination of sulfamate 178 to yield oxathiazinane 192. 
Indeed, the use of iodosobenzene as oxidating agent gave 192 with up to 87% ee (for 
representative HPLC-chromatograms see chapter 8.3.1, page 142). On the downside, the yield 
dropped drastically (entries 6 and 7). The general problem using iodosobenzene as oxidating 
reagent is the compounds` low solubility, which requires the addition of large amounts of 
oxidating agent at once, whereby side-reactions such as partial catalyst degradation or other 
unproductive oxidative processes get encouraged. In addition, H2O is liberated in the 
activation of the sulfamate which seems to inhibit the reaction as well. A shortened reaction 
time of 2 h and the use of freshly activated 3 Å molecular sieves yielded 192 in acceptable 
66% yield with 84% ee (entry 8). Nevertheless, the crystal structure of oxathiazinane 192 
(figure 15b) revealed the opposite enantiomer had been formed, due to a wrong prediction of 
enantioselectivity in the original literature.[142]  
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Table 5: Enantioselective CH-amination using different catalyst and oxidation agents.  
entry Rh-catalyst solvent oxidating 
agent 
additive yield 
(%)a 
ee (%) 
1 Rh2(esp)2 CH2Cl2 PhI(OPiv)2 MgO 90 - 
2 Rh2(S-nap)4 CH2Cl2 PhI(OPiv)2 MgO 82 44 
3 Rh2(S-nap)4 CH2Cl2 PhI(OPiv)2 MgO, 4Å MS 98 37 
4 Rh2(S-nap)4 benzene PhI(OPiv)2 MgO, 4Å MS 99 53 
5 Rh2(S-dosp)4 benzene PhIO MgO, 4Å MS 77 12
b 
6 Rh2(S-nap)4 CH2Cl2 PhIO MgO, 4Å MS 37 82 
7 Rh2(S-nap)4 benzene PhIO MgO, 4Å MS 30 87 
8 Rh2(S-nap)4 CH2Cl2 PhIO 
MgO, 3Å MS 
(powdered) 
66 84 
9 Rh2(S-nap)4 benzene PhIO 
MgO, 3Å MS 
(powdered) 
45 79 
aisolated yields; bthe (S)-enantiomer was obtained. 
Figure 15: Rh2(S-dosp)4 and crystal structure of oxathiazinane 192. 
In order to establish synthetic access to amino acid 81 the route was further investigated with 
the (R)-enantiomer. However, by application of Rh2(R-nap)4 the (S)-enantiomer of 192 can be 
obtained. Cbz-protection of the amine was achieved in 92% yield, using KOt-Bu and CbzCl 
in THF (scheme 74). It is literature known, that the enhanced electrophilicity of the protected 
amine allows ring opening under much milder conditions, compared to unprotected 
oxathiazinanes.[122] DU BOIS could demonstrate that even weak nucleophiles such as water are 
able to open the ring towards the corresponding amino alcohol at slightly elevated 
temperatures. Following his procedure, oxathiazinane 193 was supposed to be opened by 
heating to 70 °C in MeCN/H2O and a subsequent modified PINNICK oxidation would give 
raise to amino acid 195 (scheme 72). However, after several attempts, 195 could not be 
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isolated, probably due to the low stability of the TBS-phenol ether under the strong acidic 
reaction conditions. Modification of oxidation conditions for classical PINNICK conditions[143] 
also remained unsuccessful. Furthermore, isolation of the amino alcohol 194 for a separated 
oxidation was unsuccessful as well. 
Scheme 72: Failed attempts to isolate amino alcohol 194. 
 
5.3 Second Generation Synthesis of the Amino Acid 
 
Since the TBS-protecting group proved to be unstable in the oxidation step and in addition 
was hypothesized to be a possible cause for low yields in CH-amination of 187 using 
iodosobenzene, another protection for phenol 175 was investigated. CRAMER had shown that 
no orthogonal protection of the catechol`s alcohols in synthesis of the cyclophane is required 
(scheme 17, chapter 1.5.3), so a second methyl ether was chosen for its greater stability under 
acidic conditions and possible simultaneous deprotection of both alcohols.  
In addition, the oxathiazinane was to be acetylated instead of Cbz-protected, since the final 
product fijiolide A would feature the same substitution pattern. 
With the revised protecting group strategy suggesting an overall greater stability, previously 
established transformations (chapter 5.1) furnished twice methylated sulfamate 197 in 52% 
yield over four steps on gram scale starting from eugenol (scheme 73). 
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Scheme 73: Synthesis of doubly methylated sulfamate 197. 
CH-amination of 197 using Rh2(esp)2 gave oxathiazinane 198 in quantitative yield, however, 
using Rh2(S-nap)4/iodosobenzene again resulted in a significant loss of yield (scheme 74). 
Oxathiazinane 198 was isolated in 60% yield with 88% ee, structurally verified by X-ray 
crystallography (for representative HPLC-chromatograms see chapter 8.3.2, page 152).  
Scheme 74: CH-amination of sulfamate 197 to yield oxathiazinane 198. 
In order to increase the oxidation agent`s solubility an ortho-substituted derivative 200 was 
synthesized in two steps from ortho-iodo phenol (199) following a procedure of NEMYKIN 
and ZHDANKIN[144] (scheme 75). Iodosobenzene 200`s secondary phenolic ether prevents it`s 
oligomerization and increases it`s solubility. Unfortunately, 200 was found to be no potent 
oxidating agent for this kind of transformation, therefore no further experiments were 
performed to increase the oxidation reagent`s solubility. 
Synthesis of the Amino Acid 
60 
 
Scheme 75: Synthesis of ortho-substituted iodosobenzene analogue 200. 
For the purpose of testing the catechol`s stability using DU BOIS` conditions 
oxathiazinane 198 was Cbz-protected in 82% yield and the subsequent ring opening/PINNICK 
oxidation protocol gave Cbz-protected amino acid 203 in 70% yield (scheme 76a). In order to 
avoid a step-intensive Cbz-deprotection/acetylation sequence of amino acid 203, 
oxathiazinane 198 was acetylated with AcCl and KOt-Bu in 84% yield. Employing Ac2O as 
acetylation agent resulted in partial ring opening by the acetate rather than protection of the 
amine. DU BOIS` protocol then furnished acetylated amino acid 206 in 83% yield. However, 
lower temperatures and shorter reaction time in the ring opening were found to be 
fundamental to prevent deacetylation. The enantiomer of CRAMER`s amino acid 
intermediate 59 was then obtained by deprotection of 206 using AlBr3/EtSH and subsequent 
TES-protection in 68% yield (scheme 76b).[145]  
Scheme 76: Protection, ring opening and oxidation of 198 to yield amino acids 203 and 206 
and synthesis of CRAMER`s intermediate 59.  
When comparing the NMR-spectroscopic data of 59 (figure 16 and 17) with that reported by 
CRAMER all signals were in accordance with the literature (see table 6 and 7). As expected, 
the opposite enantiomer was obtained, which led to a reversed optical rotation (see chapter 
8.3.2, page 163). 
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Figure 16: 1H-NMR of amino acid 59. 
Table 6: 1H-NMR-Spectroscopic comparison of 59 with data reported by CRAMER. 
 Amino Acid 59 CRAMER`s Amino Acid 59  
Proton δH [ppm] multi. (J[Hz]) δH [ppm] multi. (J[Hz]) Deviation Δδ [ppm] 
TES 0.72-0.80 m 0.73-0.82 m 0.02 
TES 0.96 td, (6.0, 7.8) 0.97 td, (6.0, 7.8) 0.01 
Ac 2.03 s 2.04 s 0.01 
2-HA 2.80 dd, (5.8, 16.1) 2.82 dd, (5.8, 16.1) 0.02 
2-HB 2.91 dd, (5.8, 16.1) 2.91 dd, (5.8, 16.1) 0.00 
3-H 5.30 dt, (5.8, 8.4) 5.32 dt, (5.8, 8.4) 0.02 
NH 6.48 d, (8.5) 6.47 d, (8.5) 0.01 
Ar 6.67 d, (2.3) 6.68 d, (2.3) 0.01 
Ar 6.86 d, (2.3) 6.87 d, (2.3) 0.01 
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Figure 17: 13C-NMR of amino acid 59. 
Table 7: 13C-NMR-Spectroscopic comparison of 59 with data reported by CRAMER. 
 Amino Acid 59 CRAMER`s Amino Acid 59  
Carbon δC [ppm] δC [ppm] Deviation Δδ [ppm] 
TES 5.2 5.0 0.2 
TES 5.6 5.4 0.2 
TES 6.7 6.6 0.1 
TES 6.8 6.7 0.1 
Me 23.4 23.2 0.2 
C2 39.5 39.5 0.0 
C3 48.8 48.6 0.2 
Ar 116.6 116.4 0.2 
Ar 120.0 119.8 0.2 
Ar 126.8 126.6 0.2 
Ar 133.4 133.3 0.1 
Ar 143.6 143.4 0.2 
Ar 148.4 148.2 0.2 
NAc 170.1 170.1 0.0 
CO2H 174.8 175.0 0.2 
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6 Summary and Outlook 
 
In this thesis, a stereoselective access to the benzodihydropentalene core structure 79 and the 
amino acid fragment 81 of the fijiolides was developed. For benzodihydropentalene 79 the 
synthetic strategy relied on introduction of a styryl moiety onto indenone 84 allowing 
construction of ring C via ring closing metathesis. Essential for this strategy was the early 
introduction of the alcohol at C9, that enabled the cis-arrangement of the previously installed 
allyl and the styryl moiety. Although the fijiolides` core does not contain a stereocenter at C1, 
enantioselective introduction of the styryl residue in this position allowed to build up the 
cyclopentadienol in a stereocontrolled fashion with a high degree of substrate control 
(scheme 77).  
Scheme 77: Enantioselective conjugate addition to indenone 84 and following transformations 
leading to benzodihydropentalene 79. 
For construction of indenone 84, a highly flexible route starting from literature known 
aldehyde 92 was established via FRIEDEL-CRAFTS acylation of an cinnamic acid. The 
corresponding ester 97 could be obtained by STILL-GENNARI-olefination from aldehyde 92. In 
addition, an environmentally friendly alternative to direct (Z)-selective olefination of 92 was 
developed for construction of the FRIEDEL-CRAFTS precursor by riboflavin-catalyzed 
(E→Z)-isomerization of ester 94 under UV-light. Subsequent saponification of ester 97 and 
transformation into the acid chloride enabled aluminum(III) chloride promoted intramolecular 
acylation to yield 84 on gram scale (scheme 78). 
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Scheme 78: Synthesis of Indenone 84 from aldehyde 85. 
Indenone 84 was then used for rhodium-catalyzed asymmetric conjugate addition with 
alkenyl boronic acid derivative 140 to yield indanone derivative 141. With HAYASHI`s 
diene 116, indanone (R)-141 was obtained in 99% yield with 74% ee, which could be further 
increased by recrystallization to >99% ee, structurally secured by X-ray crystallography. The 
use of CARREIRA`s diene ligand 110 gave 141 in 85% with 95% ee (scheme 79). In addition, 
the conjugate addition of three more alkenyl nucleophiles could be achieved in good to 
excellent yield. However, synthesis of the resulting addition products proved to be not 
productive for the construction of benzodihydropentalene 79. 
Scheme 79: Conjugate addition of alkenyl boronic acid derivatives to indenone 84. 
With the first reliable protocol for asymmetric conjugate addition on indenones developed, 
application of this method could be used for synthesis of a variety of biological active 
compounds. Formal syntheses of three different examples are depicted in scheme 80. By this 
method, functionalization of various biological active indenones should be possible. 
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Scheme 80: Proposed application of asymmetric conjugate additions for formal syntheses of 
biological active indanones.[146,147,148] 
With indanone 141 in hand, allylation was performed to yield allylated indanone 143. 
Although extensively studied, neither formation of the double allylated product 144, nor the 
fast isomerization of the double bond could be effectively suppressed. α-Hydroxylation of 143 
and subsequent ring closing metathesis gave α-hydroxy ketone 155. Furthermore, the 
non-oxygenated tricyclic ketone 154 was obtained as inseparable mixture with 143 by 
trans→cis isomerization at C2 of 143 with subsequent ring closing metathesis. However, for 
154, installation of the alcohol at C9 towards ketone 155 remained unsuccessful. Ketone 155 
was reduced to diol 158 in substrate-directed, highly diastereoselective fashion with a 
trans/cis ratio of >15:1. Methylation of 158 gave olefin 162, which was then epoxidized. 
Regioselective epoxide opening with NaSePh at C11, followed by elimination of the selenide 
under oxidative conditions yielded allylic alcohol 174. Cyclopentadiene 79 was then accessed 
via syn-elimination of an in situ formed triflate (scheme 81). Alternative routes for double 
elimination of cyclopentene 162`s additions products towards 79 remained unsuccessful. Due 
to the apparent lability of various substrates en route to 79 the amount of purification steps 
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from indanone 141 to cyclopentadiene 79 was reduced to three column chromatographic 
separations. 
Scheme 81: Synthesis of benzodihydropentalene 79 from ketone 141. 
Overall, the synthetic strategy does not rely on many non-strategic redox reactions or the use 
of various protecting groups. With eight steps of construction reactions and one step of 
strategic redox reactions in overall twelve steps a percent ideality of 75% can be calculated 
following BARAN`s definition[149] of ideal synthesis (equation 1) for construction of 79 
starting from aldehyde 92. 
%𝑖𝑑𝑒𝑎𝑙𝑖𝑡𝑦 =
(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑖𝑜𝑛 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑠)+(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑐 𝑟𝑒𝑑𝑜𝑥−𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛𝑠)
(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑠𝑡𝑒𝑝𝑠)
* 100 
Equation 1: BARAN`s definition of synthetic ideality. 
Due to the tilted geometry of ring C in tricyclic compound 155 and the products resulting 
from it, a high degree of regio- and stereoselectivity could be observed for construction of 
diene 79. This finding could be helpful for synthesis of tricyclic systems of a few similar 
natural products core structures (see figure 2, chapter 1.1). Furthermore, the synthetic strategy 
for construction of the cyclopentadiene from an cyclopentene might be applicable in general. 
 
Synthesis of Amino Acid 59 
 
Synthesis of amino acid 81 started with chlorination of eugenol (80) following a procedure of 
GUSEVSKAYA. Subsequent methylation of the phenol, hydroboration of the olefin with 
oxidative work up and sulfamoylation gave sulfamate 197 in 52% yield over four steps 
starting from 80 as substrate for rhodium-catalyzed CH-amination (scheme 82). The 
TBS protected sulfamate 178 was synthesized by analogous reactions but could not be 
oxidized to the respective amino acid. 
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Scheme 82: Synthesis of sulfamate 197 from eugenol (80). 
Sulfamate 197 was then cyclized under Rh2(S-nap)4-catalysis via enantioselective nitrene 
CH-insertion to give oxathiazinane 198 in 60% yield with 88% ee, structurally secured by 
X-ray crystallography. The choice of the oxidation agent utilized was found to be crucial. 
Although oxathiazinane 198 could be obtained in quantitative yield using PhI(OPiv)2, a 
continuous ligand exchange of the liberated carboxylate moieties with the catalyst was 
hypothesized to be the cause for a significant loss of enantioinduction.  
Acetylation of oxathiazinane 198`s amine, ring opening and PINNICK oxidation then furnished 
amino acid 206. Deprotection of the catechol and TES-protection gave the enantiomer of 
CRAMER`s intermediate 59 in 15% over eight steps with 88% ee. No C-C bonds have to be 
formed starting from cheap material, which should allow to perform the reaction sequence 
towards 59 on gram-scale (scheme 83). 
Scheme 83: Synthesis of CRAMER`s amino acid derivative 59 from sulfamate 198. 
For synthesis of amino acid 59, three steps of construction and two steps of strategic redox-
reactions out of eight total steps give 63% ideality. 
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Figure 18: Summary of the synthetic efforts. 
Overall, a stereoselective access to the benzodihydropentalene structure (red) and the amino 
acid (green) could be developed (figure 18). Furthermore, MESCH could demonstrate in his 
Bachelor thesis how to achieve the installation of the diol side chain (blue) from a methoxy 
group on a test system. Combined with the amino sugar`s literature known synthesis (black, 
chapter 1.5.1) a new synthetic access to fijiolide A would be achieved. 
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7 Zusammenfassung und Ausblick 
 
In der vorliegenden Arbeit wurde ein stereoselektiver Zugang zum Benzodihydropentalen-
kern 79 und der Aminosäure 81 der Fijiolide entwickelt. Die Synthesestrategie für 
Dihydropentalen 79 beruhte auf der Addition eines Styrylrestes an Indenon 84 als Vorläufer 
für den Aufbau von Ring C via Ringschlussmetathese. Als entscheidend stellte sich dabei die 
frühzeitige Einführung des Alkohols an C9 heraus, durch den zuverlässig eine 
cis-Konfiguration des zuvor eingeführten Allyl- und Styrylsubstituenten erreicht werden 
konnte. Auch wenn die Fijiolide kein Stereozentrum an C1 besitzen, ermöglichte die 
enantioselektive Einführung des Styrylrestes den stereoselektiven Aufbau des 
Cyclopentadienols mit einem hohen Maß an Substratkontrolle (Schema 84). 
Schema 84: Enantioselektive 1,4-Addition an Indenon 84 und der darauffolgende Aufbau des 
Benzodihydropentalens 79. 
Der Zugang zu Indenon 84 gelang ausgehend vom literaturbekannten Aldehyd 92, durch 
intramolekulare FRIEDEL-CRAFTS Acylierung von einem Zimtsäurederivat. Der entsprechende 
(Z)-konfigurierte Ester 97 konnte durch STILL-GENNARI Olefinierung erhalten werden. 
Alternativ zur (Z)-selektiven Olefinierung konnte unter UV-Licht eine Riboflavin-katalysierte 
(E→Z)-Isomerisierung durchgeführt werden ausgehend von Ester 94. Die anschließende 
Verseifung von Ester 97 ermöglichte die intramolekulare Acylierung des entsprechenden 
Säurechlorids in Gegenwart von Aluminium(III)chlorid (Schema 85). 
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Schema 85: Synthese des Indenons 84 ausgehend von Aldehyd 92. 
Indenon 84 wurde dann in rhodiumkatalysierten 1,4-Additionen mit verschiedenen 
Alkenylboronsäure-Derivaten eingesetzt. Unter Verwendung von HAYASHI`s Dien 
Ligand 116 konnte Indanon (R)-141 in 99% Ausbeute mit 74% ee erhalten werden. Durch 
Umkristallisation konnte der ee auf >99% erhöht werden, was via Kristallstrukturanalyse 
bestätigt wurde. Unter Verwendung von CARREIRA`s Dien Ligand 110 konnte (R)-141 sogar 
mit 95% ee in 85% Ausbeute isoliert werden (Schema 86). Zusätzlich konnten die 
Additionsprodukte von drei weiteren Alkenylnukleophilen in guten bis sehr guten Ausbeuten 
erhalten werden, deren Addition für die Synthese von 79 jedoch nicht zielführend war. 
Schema 86: Asymmetrische 1,4-Addition von Alkenylboronsäure-Derivaten an Indenon 84. 
Durch die Entwicklung des ersten verlässlichen Protokolls für die asymmetrische 
1,4-Addition an Indenone ist die Übertragung auf andere Indenone für die Darstellung einiger 
biologisch aktiver Substanzen denkbar. Formale Synthesen für drei Beispiele sind Schema 87 
zu entnehmen. Auf diesem Wege sollte die Funktionalisierung von Indenonen als Bausteine 
einer Reihe von biologisch aktiver Verbindungen gelingen. 
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Schema 87: Vorschläge für die Anwendung der enantioselektiven 1,4-Addition in der 
formalen Synthese biologisch aktiver Indanone.[146-148] 
Indanon 141 wurde anschließend α-allyliert, wodurch Indanon 143 erhalten wurde. Auch nach 
umfassenden Untersuchungen konnte dabei weder die doppelte Allylierung zu Indanon 144, 
noch die Anfälligkeit der styrylischen Doppelbindung für Isomerisierungen unterbunden 
werden. Eine darauffolgende α-Hydroxylierung von 143 und Ringschlussmetathese lieferte 
α-Hydroxyketon 155. Zudem konnte das nicht hydroxylierte tricyclische Keton 154 aus 
Indanon 143 durch trans→cis Isomerisierung an C2 und Ringschlussmetathese als 
untrennbares Gemisch mit 143 erhalten werden. Das Einführen des Alkohols an C9 hin zu 
155 verblieb für Keton 154 jedoch erfolglos. Die anschließende substratkontrollierte 
Reduktion von 155 an C8 lieferte trans-Diol 158 mit einer Diastereoselektivität von 
d.r. >15:1. Durch Methylierung des Diols wurde das Cyclopenten 162 erhalten, das dann 
epoxidiert werden konnte. Die regioselektive Epoxidöffnung mit NaSePh an C11, gefolgt von 
einer oxidativen Eliminierung ergab Allylalkohol 174. Dieser konnte anschließend durch 
syn-Eliminierung eines in situ erzeugten Triflats in das Cyclopentadien 79 überführt werden 
(Schema 88). Alternative Routen zur doppelten Eliminierung an Additionsprodukten von 
Cyclopenten 162 hin zu Dien 79 blieben erfolglos. Aufgrund der beobachteten Instabilität 
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diverser Intermediate in der Synthese von Cyclopentadien 79 wurde die Anzahl der 
chromatografischen Reinigungen ausgehend von Indanon 141 auf drei über neun Stufen 
reduziert. 
Schema 88: Synthese des Benzodihydropentalens 79 ausgehend von Keton 147. 
Insgesamt konnte in der Synthese von Cyclopentadien 79 die Verwendung von 
Schutzgruppen oder nicht zielführenden Redox-Operationen minimiert werden. BARANs 
Definition der idealen Synthese entsprechend (Gleichung 2) konnte bei acht strategischen 
Bindungsknüpfungen und einer Reduktion bei zwölf gesamten Stufen 75% Idealität für den 
Aufbau von Cyclopentadien 79 ausgehend von Aldehyd 92 erreicht werden. 
% 𝐼𝑑𝑒𝑎𝑙𝑖𝑡ä𝑡 =
(𝐴𝑛𝑧𝑎ℎ𝑙 𝑑𝑒𝑟 𝐵𝑖𝑛𝑑𝑢𝑛𝑔𝑘𝑛ü𝑝𝑓𝑢𝑛𝑔𝑒𝑛)+(𝐴𝑛𝑧𝑎ℎ𝑙 𝑠𝑡𝑟𝑎𝑡𝑒𝑔𝑖𝑠𝑐ℎ𝑒𝑟 𝑅𝑒𝑑𝑜𝑥−𝑅𝑒𝑎𝑘𝑡𝑖𝑜𝑛𝑒𝑛)
(𝐴𝑛𝑧𝑎ℎ𝑙 𝑑𝑒𝑟 𝑔𝑒𝑠𝑎𝑚𝑡𝑒𝑛 𝑆𝑡𝑢𝑓𝑒𝑛)
* 100 
Gleichung 2: BARANs Definition der idealen Synthese. 
Durch die gewinkelte Geometrie von Ring C des tricyclischen Ketons 155 und seiner 
Folgeverbindungen konnte zudem ein hohes Maß an Regio- und Diastereoselektivität bei den 
Operationen zum Aufbau des Diens 79 beobachtet werden. Dies könnte sich vor allem für den 
Aufbau der tricyclischen Systeme einer Reihe von ähnlich strukturierten Naturstoffgerüsten 
als nützlich erweisen. Die Strategie zum Aufbau des Cyclopentdiens ausgehend von 
Cyclopentenen sollte zudem auch auf andere Systeme übertragbar sein. 
 
Synthese der Aminosäure 59 
 
Die Synthese der Aminosäure 81 begann mit der Oxychlorierung von Eugenol (80) nach einer 
Vorschrift von GUSEVSKAYA. Durch anschließende Schützung des Phenols, Hydroborierung 
des Olefins mit oxidativer Aufarbeitung und Sulfamoylierung des resultierenden Alkohols 
konnte Sulfamat 197 in 52% über vier Stufen als Substrat für die Rhodium-katalysierte 
CH-Aminierung dargestellt werden (Schema 89). Über eine analoge Sequenz wurde zudem 
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das TBS-geschützte Sulfamat 178 erhalten, welches allerdings nicht zur entsprechenden 
Aminosäure oxidiert werden konnte. 
Schema 89: Synthese des Sulfamats 197 ausgehend von Eugenol (80). 
Sulfamat 197 konnte anschließend unter Rh2(S-nap)4-Katalyse via Nitreninsertion nach 
DU BOIS in 60% Ausbeute mit 88% ee in das Oxathiazinan 198 überführt werden, dessen 
Struktur durch Kristallstrukturanalyse bestätigt werden konnte. Die Wahl des 
Oxidationsmittels war dabei von entscheidender Bedeutung. Obwohl unter Verwendung von 
PhI(OPiv)2 Oxazinan 198 in quantitativer Ausbeute erhalten werden konnte, führte vermutlich 
ein kontinuierlicher Ligandenaustausch der Carboxylatreste mit dem Katalysator zu stark 
verminderten Enantiomerenüberschüssen.  
Durch Acetylierung von 198, gefolgt von der Öffnung des Oxathiazinan-Rings durch Wasser 
und anschließender PINNICK-Oxidation des resultierenden Aminoalkohols, wurde Aminosäure 
206 erhalten. Diese wurde durch Entschützen des Catechols und nachgelagerte 
TES-Schützung in CRAMER`s Aminosäure-Intermediat 59 überführt. So gelang die Synthese 
von Aminosäure 59 ausgehend von Eugenol in 15% Ausbeute über acht Stufen mit 88% ee. 
Dafür mussten ausgehend von ausgesprochen billigem Startmaterial keine C-C Bindungen 
geknüpft werden, was eine Synthese von 59 im Gramm-Maßstab ermöglichen sollte 
(Schema 90). 
Schema 90: Synthese von CRAMERs Aminosäure Derivat 59 ausgehend von Sulfamat 197. 
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Für die Synthese der Aminosäure 59 wurde mit drei Konstruktionsreaktionen und zwei 
essentiellen Redox-Reaktionen bei acht Stufen insgesamt eine prozentuale Idealität von 63% 
errechnet. 
 
 
Abbildung 19: Zusammenfassung der synthetisierten Bausteine. 
Zusammengefasst konnte ein neuer stereoselektiver Zugang zur Benzodihydropentalen 
Struktur (rot) und der Aminosäure (grün) entwickelt werden (Abbildung 19). Zudem gelang 
es MESCH in seiner Bachelorarbeit, ausgehend von einem Methylether, die Diol-Seitenkette 
an einem Testsystem aufzubauen (blau). In Kombination mit der literaturbekannten Synthese 
des Aminozuckers (schwarz, Kapitel 1.5.1) sollte so ein neuer Zugang zu Fijiolid A gelingen. 
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8.1 Experimental Part – General Methods and Materials 
 
All commercially available reagents and reactants were used without purification unless 
otherwise noted. The following reagents were prepared/dried as stated: 
Phosphate puffer pH 7: 135.5 g KH2PO4 and 162.0 g Na2HPO4∙2 H2O were 
dissolved in 1 L distilled H2O. 
NEt3, i-Pr2NH: Refluxing in the presence of CaH2 with subsequent distillation under 
Ar-atmosphere.  
All solvents were distilled by rotary evaporation. Solvents for non-aqueous reactions were 
dried as follows prior to use: 
1,4-dioxane 99.5%, Extra Dry, stored over molecular sieves, purchased from Acros 
Organics, used without further purification. 
CH2Cl2 was refluxed and distilled from CaH2 under Ar-atmosphere.  
Cyclohexane 99.8%, Extra Dry, stored over molecular sieves, purchased from Acros 
Organics, used without further purification. 
DMF HPLC-grade, purchased from Acros Organics, used without further purification. 
MeCN HPLC-grade, purchased from Acros Organics, used without further 
purification. 
MeOH was dried by refluxing with Mg-turnings (5g/L) and subsequent distillation 
under Ar-atmosphere. 
THF was dried with KOH and subsequently distilled from sodium/benzophenone. 
respectively from Solvona® under Ar-atmosphere.  
Toluene was refluxed in the presence of Na with subsequent distillation under Ar-
atmosphere. 
All non-aqueous reactions were carried out using flame-dried glassware under argon 
atmosphere.  
Reactions were monitored by thin layer chromatography (TLC) using Merck Silica Gel 60 
F254-plates and visualized by fluorescence quenching under UV-light. In addition, TLC-plates 
were stained using a CeSO4/phosphomolybdic acid stain. Chromatographic purification of 
products was performed on Merck Silica Gel 60 (230-400 mesh) unless otherwise noted using 
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a forced flow of eluents. Concentration under reduced pressure was performed by rotary 
evaporation at 40 °C and appropriate pressure and by exposing to high vacuum at room 
temperature if necessary. 
NMR spectra were recorded on a Bruker AV II 300 MHz, AV III 500 MHz and AV III HD 
500 MHz spectrometer at room temperature. Chemical shifts are reported in ppm with the 
solvent resonance as internal standard. Data are reported as follows: s = singlet, d = doublet, 
t = triplet, q = quartet, quint = quintet, m = multiplet. 
Mass spectra were recorded by the mass service department of the Philipps-University 
Marburg. HR-ESI mass spectra were acquired with a LTQ-FT mass spectrometer (Thermo 
Fischer Scientific). The resolution was set to 100.000.  
IR spectra were recorded on a Bruker IFS 200 spectrometer. The absorption bands are given 
in wave numbers (cm‒1), intensities are reported as follows: s = strong, m = medium, w = 
weak, br = broad band.  
Melting points were determined on a Mettler Toledo MP70 using one end closed capillary 
tubes. 
Optical rotations were determined at 25 °C for the Na-D wavelength (589 nm) with a Krüss 
P8000-T polarimeter. 
Light induced isomerizations were performed using High Power single chip LED H2A1-
H365-r4 and H2A1-H435 from Roithner Lasertechnik GmbH. 
HPLC measurements were performed using a 1200 combination from Agilent Technologies 
(G1312B Quat-pump, G1329B ALS-sampler, G1316A thermostat, G4212B Diodenarray-
detector). 
X-ray crystallographic analysis were performed by the X-ray crystallographic department of 
the Philipps-University Marburg on a Bruker D8 QUEST or STOE STADIVARI. Structures 
were solved by direct methods; all atoms were refined anisotropically (except H). 
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8.2 Synthetic Procedures for Preparation of the Benzodihydropentalene 
core 
 
 tert-Butyl hypochlorite 
 
t-Butanol [M 74.12; ρ 0.78] 1.00 equiv. 558 mmol 52.4 mL 
NaOCl [M 74.44; 12wt%]  1.00 equiv. 558 mmol 285 mL 
AcOH [M 60.05; ρ 1.05] 1.10 equiv. 614 mmol 35.1 mL 
 
At 0 °C t-BuOH (52.4 mL, 558 mmol, 1.00 equiv.) and AcOH (35.1 mL, 614 mmol, 
1.10 equiv.) were added to aq. NaOCl (285 mL, 558 mmol, 12wt%, 1.00 equiv.) and the 
mixture was stirred for 3 min. The layers were separated, the org. layer was washed with H2O 
(2x50 mL) and 10% aq. Na2CO3 (2x50 mL) and filtrated over CaCl2 to yield t-BuOCl (41.1 g, 
379 mmol, 68%) as yellow liquid. 
 
1H-NMR:  300 MHz, CDCl3; δ = 1.33 (s, 9 H, t-Bu) ppm. 
 
The spectroscopic data obtained matched that reported in the literature.[150] 
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 2-Chloro-3-hydroxybenzaldehyde 85 
 
Aldehyde 91 [M 122.12] 1.00 equiv. 358 mmol 43.7 g 
t-BuOCl [M 108.57; ρ 0.96]  1.02 equiv. 370 mmol 40.6 g 
Aldehyde 91 (43.7 g, 358 mmol, 1.00 equiv.) was dissolved in aq. AcOH (100 mL, 90%) at rt. 
t-BuOCl (40.6 g, 370 mmol, 1.02 equiv.) was added dropwise and the mixture was stirred at rt 
for 2 h. After filtration the precipitate was recrystallized from 50% aq. AcOH to yield 
aldehyde 85 (30.8 g, 197 mmol, 55%) as colorless crystals. 
 
1H-NMR:  300 MHz, CDCl3; δ = 5.86 (sbr, 1 H, OH), 7.22-7.31 (m, 2 H, Ar), 7.48 (dd, 
J = 2.2, 7.1 Hz, 1 H, Ar), 10.35 (s, 1 H, CHO) ppm. 
 
The spectroscopic data of 85 matched that reported in the literature.[41] 
 
 2-Chloro-3-methoxybenzaldehyde 92 
 
Phenol 85 [M 122.12] 1.00 equiv. 31.9 mmol 5.00 g 
NaH [60wt%, mineral oil; M 24.00] 1.20 equiv. 38.3 mmol 1.53 g 
MeI [M 141.94; ρ 2.28] 2.00 equiv. 63.9 mmol 3.98 mL 
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Under Ar-atmosphere phenol 85 (5.00 g, 31.9 mmol, 1.00 equiv.) was dissolved in DMF 
(400 mL). At 0 °C NaH (1.53 g, 38.3 mmol, 60wt% in mineral oil, 1.20 equiv.) was added. 
After 15 min MeI (3.98 mL, 63.9 mmol, 2.00 equiv.) was added and the mixture was stirred at 
rt for 12 h. The reaction was quenched by the addition H2O (200 mL), extracted with 
cyclohexane (3x100 mL), washed with brine (150 mL), dried over Na2SO4, filtrated and 
concentrated in vacuo. After column chromatography (n-pentane/EtOAc 8:1) methylated 
phenol 92 (5.44 g, 31.9 mmol, 99%) was obtained as colorless solid. 
 
TLC:   Rf = 0.28 (n-pentane/EtOAc 8:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.96 (s, 3 H, OMe), 7.16 (dd, J = 1.4, 8.0 Hz, 1 H, Ar), 
7.34 (t, J = 8.0 Hz, 1 H, Ar), 7.54 (dd, J = 1.4 Hz, 8.0 Hz, 1 H, Ar), 10.53 
(s, 1 H, CHO) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 56.7 (OMe), 117.2 (Ar), 120.9 (Ar), 126.9 (Ar), 
127.7 (Ar), 133.8 (Ar), 155.7 (Ar), 190.2 (CHO) ppm.  
 
HR-MS: (ESI+); m/z calc. for C8H7ClO2Na [M-Na]
+ 193.0027, found 193.0027.  
 
FT-IR: (neat); ῦ = 2923 (m), 2853 (w), 1729 (w), 1696 (m), 1574 (m), 1470 (m), 1452 
(w), 1434 (m), 1384 (w), 1359 (w), 1304 (w), 1272 (s), 1241 (w), 1193 (w), 
1154 (w), 1113 (w), 1051 (m), 990 (w), 934 (w), 904 (w), 776 (m), 714 (w), 
616 (w) cm-1.  
 
m.p.:   38 °C (EtOAc). 
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 Methyl 2-(bis((trimethylsilyl)oxy)phosphoryl)acetate 207 
 
Phosphono acetate 98 [M 182.11] 1.00 equiv. 60.0 mmol 9.60 mL 
TMSCl [M 108.64; ρ 0.85] 5.00 equiv. 300 mmol 38.1 mL 
 
Under Ar-atmosphere phosphono acetate 98 (9.60 mL, 60.0 mmol, 1.00 equiv.) and freshly 
distilled TMSCl (38.1 mL, 300 mmol, 5.00 equiv.) were stirred at 80 °C for 4 d. All volatile 
compounds were removed under reduced pressure and the crude silylated phosphono acetate 
207 was directly used for the next step without further purification.  
 
1H-NMR:  300 MHz, CDCl3; δ = 0.30 (s, 18 H, TMS), 2.89 (d, J = 22.5 Hz, 2 H, CH2), 
3.71 (s, 3 H, OMe) ppm. 
 
The spectrum of 207 matched that reported in the literature.[46] 
 
 Methyl 2-(dichlorophosphoryl)acetate 208 
 
Silylated phosphono acetate 207 [M 298.42] 1.00 equiv. 60.0 mmol 17.9 g 
Oxalyl chloride [M 126.93; ρ 1.48] 2.50 equiv. 150 mmol 13.1 mL 
DMF [M 73.10, ρ 0.95] 0.01 equiv.   
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Under Ar-atmosphere crude silylated phosphono acetate 207 (17.9 g, 60.0 mmol, 1.00 equiv.) 
was dissolved in CH2Cl2 (120 mL). At 0 °C oxalyl chloride (13.1 mL, 150 mmol, 2.50 equiv.) 
and catalytic amounts of DMF (1 drop) were added slowly. The mixture was stirred at rt for 
1 h, before all volatile compounds were removed in vacuo. The crude dichloride 208 was used 
for the next step without further purification.  
 
1H-NMR:  300 MHz, CDCl3; δ = 3.75 (d, J = 19.1 Hz, 2 H, CH2), 3.84 (s, 3 H, OMe) 
ppm. 
 
The spectrum of 208 matched that reported in the literature.[46] 
 
 Methyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate 27 
 
Dichloride 208 [M 190.94] 1.00 equiv. 60.0 mmol 11.5 g 
NEt3 [M 101.19; ρ 0.73] 6.00 equiv. 360 mmol 50.4 mL 
Trifluoroethanol [M 100.04; ρ 1.38] 4.00 equiv. 240 mmol 17.4 mL 
DMAP [M 122.17] 0.05 equiv. 1.20 mmol 144 mg 
 
Under Ar-atmosphere crude dichloride 208 (11.5 g, 60.0 mmol, 1.00 equiv.) was dissolved in 
CH2Cl2 (60 mL). At 0 °C NEt3 (50.4 mL, 360 mmol, 6.00 equiv.) and 2,2,2-trifluoroethanol 
(17.4 mL, 240 mmol, 4.00 equiv.) in CH2Cl2 (60 mL) were added slowly. Catalytic amounts 
of DMAP (144 mg, 1.20 mmol, 0.05 equiv.) were added and the mixture was stirred at rt for 
16 h. The mixture was diluted with CH2Cl2 (1.00 L), washed with brine (450 mL), dried over 
Na2SO4, filtrated and all volatile compounds were removed in vacuo. After column 
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chromatography (n-pentane/EtOAc 2:1) phosphono acetate 27 (16.3 g, 51.2 mmol, 86%) was 
obtained as colorless oil. 
 
TLC:   Rf = 0.27 (n-pentane/EtOAc 2:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.16 (d, J = 21.2 Hz, 2 H, CH2), 3.96 (s, 3 H, OMe), 4.46 
(m, 4 H, CH2OP) ppm.  
 
The spectroscopic data of 27 matched that reported in the literature.[46] 
 
 (Z)-2-Chloro-3-methoxy cinnamic acid methyl ester 97 
 
Aldehyde 92 [M 170.59] 1.00 equiv. 18.2 mmol 3.10 g 
Phosphono acetate 27 [M 318.19; ρ 1.50] 1.20 equiv. 22.7 mmol 4.80 mL 
KHMDS [0.5 M, toluene; M 199.48] 1.20 equiv. 22.7 mmol 45.4 mL 
18-crown-6 [M 264.32] 5.00 equiv. 114 mmol 30.0 g 
 
Under Ar-atmosphere phosphono acetate 27 (4.80 mL, 22.7 mmol, 1.20 equiv.) and 
18-crown-6 (30.0 g, 114 mmol, 5.00 equiv.) were dissolved in THF (250 mL). At –78 °C 
KHMDS (45.4 mL, 22.7 mmol, 0.5 M in toluene, 1.20 equiv.) and aldehyde 92 (3.10 g, 
18.2 mmol, 1.00 equiv.) were added and the mixture was stirred for 30 min. Sat. aq. NH4Cl 
(100 mL) was added to the reaction mixture, it was slowly warmed to rt, extracted with Et2O 
(3x100 mL), the combined org. layers were dried over Na2SO4, filtrated and all volatile 
compounds were removed in vacuo. After column chromatography (n-pentane/EtOAc 8:1) 
α,β-unsaturated ester 97 (4.10 g, 18.1 mmol, 99%) was obtained as colorless oil. 
Experimental Procedures 
83 
 
TLC:   Rf = 0.23 (n-pentane/EtOAc 8:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.65 (s, 3 H, OMe), 3.96 (s, 3 H, OMe), 6.09 
(d, J = 12.2 Hz, 1 H, 2-H), 6.91 (d, J = 8.0 Hz, 1 H, Ar), 7.06 (d, J = 8.0 Hz, 
1 H, Ar), 7.15 (d, J = 12.2 Hz, 1 H, 3-H), 7.20 (t, J = 8.0 Hz, 1 H, Ar) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 51.4 (OMe), 56.7 (OMe), 112.0 (Ar), 121.7 (C2), 121.8 
(Ar), 122.6 (Ar), 126.6 (Ar), 135.7 (Ar), 140.9 (C3), 155.2 (Ar), 166.2 (C1) 
ppm. 
 
HR-MS:  (ESI+); m/z calc. for C11H11ClO3Na [M-Na]
+ 249.0289, found 249.0285. 
 
FT-IR:  (neat); ῦ = 3214 (w), 2918 (w), 2853 (w), 1729 (m), 1640 (w), 1572 (w), 1471 
(w), 1453 (w), 1433 (m), 1352 (w), 1267 (m), 1215 (w), 1164 (m), 1090 (w), 
1066 (s), 960 (m), 903 (w), 832 (m), 777 (w), 721 (w), 654 (w), 614 (w), 554 
(w), 527 (w), 470 (w), 445 (w) cm-1. 
 
 (E)-2-Chloro-3-methoxy cinnamic acid methyl ester 94 
 
Aldehyde 92 [M 170.59] 1.00 equiv. 10.0 mmol 1.70 g 
Ylide 93 [M 334.35] 1.20 equiv. 12.0 mmol 3.99 g 
Ylide 93 (3.99 g, 12.0 mmol, 1.20 equiv.) was dissolved in H2O (80 mL), aldehyde 92 
(1.70 g, 10.0 mmol, 1.00 equiv.) was added and the mixture was heated to 90 °C for 1.5 h. 
The reaction mixture was diluted with CH2Cl2 (50 mL) and the layers were separated. The aq. 
layer was extracted with CH2Cl2 (2x20 mL), the combined org. layers were dried over 
MgSO4, filtrated and all volatile compounds were removed under reduced pressure. After 
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column chromatography (n-pentane/EtOAc 8:1) α,β-unsaturated ester 94 (2.20 g, 9.71 mmol, 
97%, E/Z 4:1) was obtained as colorless solid. 
 
TLC:   Rf = 0.23 (n-pentane/EtOAc 8:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.82 (s, 3 H, OMe), 3.91 (s, 3 H, OMe), 6.42 
(d, J = 16.0 Hz, 1 H, 2-H), 6.94-6.97 (m, 1 H, Ar), 7.23-7.25 (m, 2 H, Ar), 8.14 
(d, J = 16.0 Hz, 1 H, 3-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 52.0 (OMe), 56.5 (OMe), 113.1 (Ar), 119.5 (C2), 121.1 
(Ar), 126.6 (Ar), 127.4 (Ar), 134.4 (Ar), 141.0 (C3), 155.8 (Ar), 167.0 (C1) 
ppm. 
 
HR-MS:  (ESI+); m/z calc. for C11H11ClO3 Na [M-Na]
+ 249.0289, found 249.0285. 
 
FT-IR: (neat); ῦ = 2923 (m), 2949 (w), 2842 (w), 1716 (s), 1637 (w), 1571 (m), 1471 
(w), 1430 (m), 1268 (s), 1170 (m), 1111 (w), 1070 (m), 1046 (w), 1015 (w), 
981 (w), 941 (w), 864 (w), 826 (w), 783 (m), 735 (w), 702 (w), 652 (w) cm-1. 
 
m.p.:  74.6 °C (EtOAc). 
 
 Isomerization of (E)-2-chloro-3-methoxy cinnamic acid methyl ester 94 
 
Cinnamic ester 94 [M 226.66] 1.00 equiv. 11.0 mmol 2.50 g 
(–)-riboflavin [M 376.37] 0.05 equiv. 0.55 mmol 207 mg 
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Under Ar-atmosphere ester 94 (2.50 g, 11.0 mmol, 1.00 equiv.) and (–)-riboflavin (207 mg, 
0.55 mmol, 0.05 equiv.) were dissolved in MeCN (300 mL) and stirred under irradiation with 
UV-light (365 nm) at rt for 24 h. The reaction mixture was filtrated through a plug of silica 
and concentrated in vacuo to yield cinnamic acid ester 97 (2.45 g, 11.0 mmol, 98%, Z/E 8:1) 
as colorless oil. 
 
The Z/E ratio was determined by comparing the integrals of the olefinic protons at C2. 
The spectroscopic data matched that of 8.2.7. 
 
 (E)-2-Chloro-3-methoxy cinnamic acid ethyl ester 96 
 
Aldehyde 92 [M 170.59] 1.00 equiv. 1.91 mmol 325 mg 
Ylide 95 [M 334.35] 1.20 equiv. 2.29 mmol 796 mg 
 
Ylide 95 (796 mg, 2.29 mmol, 1.20 equiv.) was dissolved in H2O (15 mL), aldehyde 92 
(325 mg, 1.91 mmol, 1.00 equiv.) was added and the mixture was stirred at rt for 16 h. The 
reaction mixture was diluted with CH2Cl2 (5 mL) and the layers were separated. The aq. layer 
was extracted with CH2Cl2 (2x2 mL), the combined org. layers were dried over MgSO4, 
filtrated and all volatile compounds were removed under reduced pressure. After column 
chromatography (n-pentane/EtOAc 8:1) α,β-unsaturated ester 96 (336 mg, 1.39 mmol, 74%, 
E/Z 4:1) was obtained as colorless oil. 
 
TLC:   Rf = 0.38 (n-pentane/EtOAc 8:1). 
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1H-NMR:  300 MHz, CDCl3; δ = 1.35 (t, J = 7.1 Hz, 3 H, Me), 3.92 (s, 3 H, OMe), 4.28 
(q, J = 7.1 Hz, 2 H, OCH2), 6.42 (d, J = 16.0 Hz, 1 H, 2-H), 6.95-6.97 (m, 1 H, 
Ar), 7.23-7.25 (m, 2 H, Ar), 8.13 (d, J = 16.0 Hz, 1 H, 3-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 14.5 (Me), 56.5 (OMe), 60.8 (OCH2), 113.0 (Ar), 119.5 
(C2), 121.5 (Ar), 123.6 (Ar), 127.3 (Ar), 134.4 (Ar), 140.7 (C3), 155.7 (Ar), 
166.6 (C1) ppm. 
 
HR-MS:  (ESI+); m/z calc. for C12H13ClO3 Na [M-Na]
+ 249.0445, found 263.0439. 
 
FT-IR: (neat); ῦ = 3056 (w), 2981 (w), 1717 (m), 1638 (w), 1591 (w), 1570 (w), 1472 
(w), 1436 (m), 1403 (w), 1270 (m), 1194 (s), 1118 (m), 1069 (w), 1031 (w), 
997 (w), 832 (w), 785 (w), 751 (w), 721 (s), 696 (m), 644 (w), 541 (s), 506 (w), 
438 (w) cm-1. 
 
 Isomerization of (E)-2-chloro-3-methoxy cinnamic acid ethyl ester 209 
 
Cinnamic ester 96 [M 240.68] 1.00 equiv. 1.33 mmol 321 mg 
(-)-riboflavin [M 376.37] 0.05 equiv. 66.7 µmol 25.1 mg 
 
Under Ar-atmosphere ester 96 (321 mg, 1.33 mmol, 1.00 equiv.) and (–)-riboflavin (25.1 mg, 
66.7 µmol, 0.05 equiv.) were dissolved in MeCN (30 mL) and stirred under irradiation with 
UV-light (365 nm) at rt for 24 h. The reaction mixture was filtrated through a plug of silica 
and concentrated in vacuo to yield cinnamic acid ester 209 (316 mg, 1.31 mmol, 98%, 
Z/E 10:1) as colorless oil. 
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The Z/E ratio was determined by comparing the integrals of the olefinic protons at C2. 
 
TLC:   Rf = 0.38 (n-pentane/EtOAc 8:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 1.17 (t, J = 7.1 Hz, 3 H, Me), 3.91 (s, 3 H, OMe), 4.11 
(q, J = 7.1 Hz, 2 H, OCH2), 6.08 (d, J = 12.2 Hz, 1 H, 2-H), 6.91 (dd, J = 1.4, 
8.0 Hz, 1 H, Ar), 7.06 (dd, J = 1.4, 8.0 Hz, 1 H, Ar), 7.13 (d, J = 12.2 Hz, 1 H, 
3-H), 7.19 (dd, J = 8.0, 8.0 Hz, 1 H, Ar) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 14.1 (Me), 56.4 (OMe), 60.4 (OCH2), 111.9 (Ar), 121.7 
(C2), 122.3 (Ar), 122.6 (Ar), 126.5 (Ar), 135.8 (Ar), 140.4 (C3), 155.1 (Ar), 
165.8 (C1) ppm. 
 
HR-MS:  (ESI+); m/z calc. for C12H13ClO3 Na [M-Na]
+ 249.0445, found 263.0442. 
FT-IR: (neat); ῦ = 2980 (m), 2938 (w), 2841 (w), 1721 (s), 1638 (w), 1592 (w), 1570 
(m), 1472 (s), 1432 (m), 1404 (w), 1386 (w), 1293 (w), 1269 (s), 1208 (w), 
1181 (s), 1109 (w), 1069 (s), 1048 (w), 1031 (w), 982 (w), 955 (w), 899 (w), 
831 (w), 783 (m), 723 (w), 639 (w) cm-1. 
 
 (Z)-2-Chloro-3-methoxy cinnamic acid 210 
 
 
Cinnamic ester 97 [M 226.66] 1.00 equiv. 15.4 mmol 3.50 g 
LiOH [2.0 M, aq.; M 23.95] 8.00 equiv. 123 mmol 61.8 mL 
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Ester 97 (3.50 g, 15.4 mmol, 1.00 equiv.) was dissolved in THF (40 mL), aq. LiOH (61.8 mL, 
123 mmol, 2.0 M, 8.00 equiv.) was added and the mixture was stirred at rt for 12 h. The 
reaction mixture was acidified with aq. HCl (1.0 M) to reach pH = 1, it was diluted with 
CH2Cl2 (50 mL) and the layers were separated. The aq. layer was extracted with CH2Cl2 
(2x25 mL), the combined org. layers were dried over Na2SO4, filtrated and all volatile 
compounds were removed in vacuo to yield acid 210 (3.28 g, 15.4 mmol, 99%) as 
pale-yellow solid. The crude product was directly used for the next step without further 
purification.  
 
TLC:   Rf = 0.25 (CH2Cl2/MeOH 15:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.91 (s, 3 H, OMe), 6.07 (d, J = 12.2 Hz, 1 H, 2-H), 6.91 
(dd, J = 1.5, 8.0 Hz, 1 H, Ar), 7.06 (d, J = 8.0 Hz, 1 H, Ar), 7.17 (d, J = 8.0 Hz, 
1 H, Ar), 7.23 (d, J = 12.0 Hz, 1 H, 3-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 56.4 (OMe), 112.2 (Ar), 121.0 (C2), 121.7 (Ar), 122.7 
(Ar), 126.8 (Ar), 135.3 (Ar), 143.0 (C3), 155.1 (Ar), 170.1 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C10H9ClO3Na [M-Na]
+ 235.0132, found 235.0128. 
 
FT-IR: (neat); ῦ = 2968 (m), 2844 (w), 2740 (w), 2561 (w), 1709 (m), 1636 (m), 1571 
(m), 1474 (m), 1456 (w), 1437 (w), 1420 (w), 1291 (w), 1270 (m), 1240 (s), 
1211 (w), 1074 (m), 1048 (w), 913 (w), 826 (w), 802 (w), 763 (w), 720 (w), 
643 (w), 614 (w) cm-1. 
 
m.p.:   163 °C (CH2Cl2). 
 
When ethyl ester 209 (310 mg, 1.29 mmol) was saponificated under analogous conditions 
270 mg (1.27 mmol, 99%) of cinnamic acid 210 were obtained. 
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 4-Chloro-5-methoxyinden-1-one 84 
 
Acid 210 [M 212.63] 1.00 equiv. 6.58 mmol 1.40 g 
Oxalyl chloride [M 126.93; ρ 1.48] 2.50 equiv. 16.5 mmol 1.41 mL 
DMF [M 73.10, ρ 0.95] 0.01 equiv.   
AlCl3 [M 133.34] 2.40 equiv. 15.8 mmol 2.11 g 
 
Under Ar-atmosphere crude acid 210 (1.40 g, 6.58 mmol, 1.00 equiv.) was dissolved in 
CH2Cl2 (20 mL). At 0 °C oxalyl chloride (1.41 mL, 16.5 mmol, 2.00 equiv.) and DMF 
(1 drop) were added and the mixture was stirred at rt for 2 h. The reaction mixture was diluted 
with CH2Cl2 (20 mL), AlCl3 (2.11 g, 15.8 mmol, 2.40 equiv.) was added at 0 °C and it was 
further stirred at rt for 1 h. The mixture was diluted with sat. aq. ROCHELLE salt (150 mL), the 
layers were separated, the aq. layer was extracted with CH2Cl2 (3x30 mL) and the org. layer 
was washed with aq. NaOH (50 mL, 0.1 M) and brine (75 mL). The org. layer was dried over 
MgSO4, filtrated and was concentrated in vacuo. After filtration over a short pad of neutral 
aluminum oxide (activity I) indenone 84 (1.20 g, 6.17 mmol, 94%) was obtained as yellow 
solid.  
 
TLC:   Rf = 0.25 (n-pentane/EtOAc 8:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.94 (s, 3 H, OMe), 5.99 (d, J = 6.0 Hz, 1 H, 2-H), 6.66 
(d, J = 8.0 Hz, 1 H, 6-H), 7.33 (dd, J = 0.9, 8.0 Hz, 1 H, 7-H), 7.69 (dd, J = 0.9, 
6.0 Hz, 1 H, 3-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 56.8 (OMe), 109.8 (C6), 118.0 (Ar), 122.5 (C2), 124.2 
(7-H), 129.4 (Ar), 144.6 (Ar), 145.6 (C3), 160.0 (Ar), 196.4 (C1) ppm. 
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HR-MS:  (ESI+); m/z calc. for C10H8ClO2H [M-H]
+ 195.0207, found 195.0206. 
 
FT-IR: (neat); ῦ = 2941 (w), 2846 (w), 1711 (s), 1594 (s), 1571 (w), 1477 (m), 1437 
(w), 1329 (m), 1284 (s), 1187 (w), 1166 (w), 1131 (w), 1061 (m), 970 (w), 921 
(w), 882 (w), 824 (w), 794 (w), 763 (w), 733 (w), 645 (w), 610 (w), 509 (w) 
cm-1. 
 
m.p.:  240 °C decomposition (CH2Cl2). 
 
8.2.2 tert-Butyl dimethyl(prop-2-yn-1-yloxy)silane 119 
 
Propargyl alcohol 118 [M 56.06; ρ 0.97] 1.00 equiv. 89.1 mmol 5.15 mL 
Imidazole [68.08] 2.00 equiv. 178 mmol 12.1 g 
TBSCl [M 150.72] 1.10 equiv. 99.0 mmol 14.9 g 
Under Ar-atmosphere propargylic alcohol 118 (5.15 mL, 89.1 mmol, 1.00 equiv.) was 
dissolved in CH2Cl2 (80 mL). At 0 °C imidazole (12.1 g, 178 mmol, 2.00 equiv.) and TBSCl 
(14.9 g, 99.0 mmol, 1.10 equiv.) were added and the mixture was stirred at rt for 1 h. The 
reaction mixture was washed with H2O (100 mL), dried over Na2SO4 and the solvent was 
removed under reduced pressure. After column chromatography (n-pentane/EtOAc 40:1) 
TBS-protected propargylic alcohol 119 (13.6 g, 79.8 mmol, 90%) was isolated as colorless 
liquid.  
 
TLC:   Rf = 0.37 (n-pentane/EtOAc 20:1). 
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1H-NMR:  300 MHz, CDCl3; δ = 0.13 (s, 6 H, TBS), 0.91 (s, 9 H, TBS), 2.38 
(t, J = 2.4 Hz, 1 H, CH), 4.31 (d, J = 2.4 Hz, 2 H, CH2) ppm. 
 
The spectroscopic data of 119 matched that reported in the literature.[151] 
 
 (E)-tert-Butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)allyl)-
oxy)silane 126 
 
Propargyl alcohol 119 [M 170.32; ρ 0.84] 1.00 equiv. 14.7 mmol 2.50 mL 
SCHWARTZ reagent [M 257.87] 0.10 equiv. 1.47 mmol 378 mg 
NEt3 [M 101.19; ρ 0.73] 0.10 equiv. 1.47 mmol 0.20 mL 
Pinacolborane [M 127.98] 1.10 equiv. 15.4 mmol 1.97 mL 
Under Ar-atmosphere TBS-protected propargylic alcohol 119 (2.50 mL, 14.7 mmol, 
1.00 equiv.), SCHWARTZ reagent (378 mg, 1.47 mmol, 0.10 equiv.), NEt3 (0.20 mL, 
1.47 mmol, 0.10 equiv.) and pinacol borane (1.97 mL, 15.4 mmol, 1.10 equiv.) were stirred at 
60 °C for 16 h. The reaction mixture was filtrated through a pad of silica to yield 
(E)-configured boronic pinacol ester 120 (3.40 g, 12.2 mmol, 83%) as yellow oil. 
 
TLC:   Rf = 0.50 (n-pentane/EtOAc 20:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.06 (s, 6 H, TBS), 0.91 (s, 9 H, TBS), 1.27 (s, 12 H, 
Me), 4.25 (dd, J = 2.1, 3.6 Hz, 2 H, 1-H), 5.75 (dt, J = 2.1, 17.9 Hz, 1 H, 3-H), 
6.68 (dt, J = 3.6, 17.9 Hz, 1 H, 2-H) ppm. 
 
The spectroscopic data of 120 matched that reported in the literature.[83] 
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 (Z)-tert-Butyldimethyl((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) allyl)o-
xy)silane 122 
 
Propargyl alcohol 119 [M 170.32; ρ 0.84] 1.20 equiv. 1.28 mmol 0.26 mL 
[Rh(cod)Cl]2 [M 493.08] 0.02 equiv. 16.0 µmol 7.90 mg 
Pi-Pr3 [M 160.24; ρ 0.84] 0.06 equiv. 64.0 µmol 12.0 µL 
NEt3 [M 101.19; ρ 0.73] 5.00 equiv. 5.34 mmol 0.74 mL 
Pinacolborane [M 127.98] 1.00 equiv. 1.07 mmol 0.16 mL 
Under Ar-atmosphere [Rh(cod)Cl]2 (7.90 mg, 16.0 µmol, 0.02 equiv.) was dissolved in 
cyclohexane (3 mL). Pi-Pr3 (12.0 µL, 6.40 µmol, 0.06 equiv.), NEt3 (0.74 mL, 5.34 mmol, 
5.00 equiv.) and pinacolborane (0.16 mL, 1.07 mmol 1.00 equiv.) were added and the mixture 
was stirred at rt for 30 min. TBS-protected propargylic alcohol 119 (0.26 mL, 1.29 mmol, 
1.20 equiv.) was added and the reaction mixture was stirred at rt for 2 h. The reaction mixture 
was concentrated in vacuo. After column chromatography (n-pentane/EtOAc 20:1) 
(Z)-configured boronic pinacol ester 122 (242 mg, 0.87 mmol, 81%) was isolated as yellow-
brown oil. 
 
TLC:   Rf = 0.50 (n-pentane/EtOAc 20:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.07 (s, 6 H, TBS), 0.91 (s, 9 H, TBS), 1.26 (s, 12 H, 
Me), 4.50 (dd, J = 1.7, 6.1 Hz, 2 H, 1-H), 5.39 (dt, J = 1.7, 13.4 Hz, 1 H, 3-H), 
6.51 (dt, J = 6.1, 13.4 Hz, 1 H, 2-H) ppm. 
 
The spectroscopic data of 122 matched that reported in the literature.[84] 
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 (S,E)-3-(3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-4-chloro-5-methoxy-2,3-
dihydroinden-1-one 121 
 
Indenone 84 [M 194.61] 1.00 equiv. 436 µmol 85.0 mg 
[Rh(cod)OH]2 [M 388.93] 0.02 equiv. 13.4 µmol 6.10 mg 
(S)-BINAP 107 [M 622.67] 0.10 equiv. 67.0 µmol 41.7 mg 
Boronic acid ester 120 [M 298.31] 1.80 equiv. 1.68 mmol 500 mg 
LiOH∙H2O [M 31.96] 0.50 equiv. 335 µmol 14.1 mg 
 
Under Ar-atmosphere [Rh(cod)OH]2 (6.1 mg, 13.4 µmol, 0.02 equiv.), boronic acid ester 120 
(500 mg, 1.68 mmol, 1.80 equiv.) and (S)-BINAP 107 (41.7 mg, 67.0 µmol, 0.10 equiv.) were 
stirred in degassed 1,4-dioxane/H2O (2.2 mL, 10:1) at rt for 30 min. Indenone 84 (85.0 mg, 
436 µmol, 1.00 equiv.) and LiOH∙H2O (14.1 mg, 335 µmol, 0.50 equiv.) were added and the 
reaction mixture was stirred at this temperature for 5 h. It was diluted with H2O (5 mL), 
extracted with Et2O (3x5 mL), dried over Na2SO4 and all volatile compounds were removed 
in vacuo. After column chromatography (n-pentane/EtOAc 4:1) vinylated indanone 121 
(142 mg, 387 µmol, 88%, 25% ee) was obtained as pale-yellow oil. 
 
TLC:   Rf = 0.15 (n-pentane/EtOAc 8:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.03 (s, 6 H, TBS), 0.88 (s, 6 H, TBS), 2.55 (dd, J = 2.1, 
19.0 Hz, 1 H, 2-HA), 2.99 (dd, J = 8.1, 19.0 Hz, 1 H, 2-HB), 3.99 (s, 3 H, OMe), 
4.09-4.17 (m, 3 H, 3-H, 3`-H), 5.68-5.64 (m, 2 H, 2`-H, 3`-H), 7.00 (d, 
J = 8.4 Hz, 1 H, 6-H), 7.67 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
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13C-NMR:  75 MHz, CDCl3; δ = –5.1 (TBS), 18.6 (TBS), 26.1 (TBS), 40.4 (C3), 44.6 
(C2), 56.9 (OMe), 63.4 (C3`), 112.1 (C6), 120.8 (Ar), 123.5 (C7), 129.2 (C1`), 
131.2 (C2`), 131.5 (Ar), 155.4 (Ar), 160.7 (Ar), 203.6 (CO) ppm. 
 
HR-MS: (ESI+); m/z calc. for C19H27ClO3SiH [M-H]
+ 367.1491, found 367.1502. 
 
FT-IR: (neat); ῦ = 2930 (m), 2854 (w), 1704 (s), 1597 (s), 1571 (w), 1478 (m), 1438 
(w), 1329 (m), 1283 (s), 1251 (m), 1188 (w), 1166 (w), 1130 (w), 1067 (s), 
1044 (w), 969 (w), 912 (w), 890 (w), 867 (w), 836 (w), 812 (m), 794 (w), 726 
(w), 698 (w), 597 (w) cm-1. 
 
HPLC: (Chiralpac IC, n-hexane/EtOAc 9/1, 0.7 mL/min, 254 nm) tR(major) = 
12.1 min, tR(minor) = 13.2 min. 
 
 (Z)-3-(3-((tert-Butyldimethylsilyl)oxy)prop-1-en-1-yl)-4-chloro-5-methoxy-2,3-
dihydroinden-1-one 123 
 
Indenone 84 [M 194.61] 1.00 equiv. 272 µmol 53.0 mg 
[Rh(cod)OH]2 [M 456.19] 0.03 equiv. 13.4 µmol 5.70 mg 
rac.-BINAP 107 [M 622.67] 0.10 equiv. 42.0 µmol 26.1 mg 
Boronic acid ester 122 [M 298.31] 2.00 equiv. 838 µmol 250 mg 
LiOH∙H2O [M 31.96] 0.50 equiv. 210 µmol 8.81 mg 
Under Ar-atmosphere [Rh(cod)OH]2 (5.70 mg, 13.4 µmol, 0.03 equiv.), boronic acid ester 122 
(250 mg, 838 µmol, 2.00 equiv.) and rac. BINAP 107 (26.1 mg, 42.0 µmol, 0.10 equiv.) were 
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stirred in degassed 1,4-dioxane/H2O (2.2 mL, 10:1) at rt for 30 min. Indenone 84 (53.0 mg, 
272 µmol, 1.00 equiv.) and LiOH∙H2O (8.81 mg, 210 µmol, 0.50 equiv.) were added and the 
reaction mixture was stirred at this temperature for 5 h. It was diluted with H2O (3 mL), 
extracted with Et2O (3x3 mL), dried over Na2SO4, filtrated and all volatile compounds were 
removed in vacuo. After column chromatography (n-pentane/EtOAc 4:1) vinylated 
indanone 123 (72.0 mg, 196 µmol, 72%) was obtained as pale-yellow oil. 
 
TLC:   Rf = 0.15 (n-pentane/EtOAc 4:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 0.11 (s, 6 H, TBS), 0.93 (s, 9 H, TBS), 2.46 (dd, J = 1.9, 
18.0 Hz, 1 H, 2-HA), 3.01 (dt, J = 8.6, 18.0 Hz, 1 H, 2-HB), 3.99 (s, 3 H, OMe), 
4.34-4.41 (m, 2 H, 3`-H), 4.47 (ddd, J = 1.7, 5.8, 7.1 Hz, 1 H, 3-H), 5.21 
(tt, J = 1.7, 10.7 Hz, 1 H, 1`-H), 5.67 (dt, J = 5.8, 10.7 Hz, 1 H, 2`-H), 7.01 
(d, J = 8.4 Hz, 1 H, 6-H), 7.68 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR: 75 MHz, CDCl3; δ = –5.1 (TBS), 18.6 (TBS), 26.1 (TBS), 40.4 (C3), 44.6 
(C2), 56.9 (OMe), 63.4 (C3`), 112.1 (C6), 120.8 (Ar), 123.5 (C7), 129.2 (Ar), 
131.2 (C1`), 131.5 (C2`), 155.4 (Ar), 160.7 (Ar), 203.6 (CO) ppm. 
 
HR-MS: (ESI+); m/z calc. for C19H27ClO3SiH [M-H]
+ 367.1491, found 367.1502. 
 
FT-IR: (neat); ῦ = 3246 (s), 2943 (s), 2836 (m), 1601 (m), 1576 (s), 1496 (s), 1461 (s), 
1423 (m), 1362 (m), 1305 (m), 1286 (s), 1241 (s), 1187 (m), 1147 (s), 1053 (s), 
1023 (s), 993 (s), 922 (s), 871 (s), 785 (s), 618 (w), 573 (w), 549 (w), 522 (w) 
cm-1. 
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 (Z)-4-Chloro-3-(3-hydroxypropenyl)-5-methoxyindanone 127 
 
Indanone 123 [M 366.96] 1.00 equiv. 382 µmol 140 mg 
HF [48wt%, aq.; M 20.00] 50.00 equiv. 19.0 mmol 0.70 mL 
The TBS-protected allyl silyl ether 123 (140 mg, 382 µmol, 1.00 equiv.) was dissolved in 
MeCN (1 mL). Aq. HF (0.70 mL, 19.0 mmol, 48%, 50.00 equiv.) was added and the mixture 
was stirred at rt for 2 h. Sat. aq. NaHCO3 (15 mL) was added to quench the reaction and the 
mixture was extracted with CH2Cl2 (3x5 mL). The combined org. layers were dried over 
MgSO4, filtrated and all volatile compounds were removed in vacuo. After column 
chromatography (n-pentane/EtOAc 4:1 to 1:1) allylic alcohol 127 (58.0 mg, 0.23 mmol, 60%) 
was isolated as yellow oil.  
 
TLC:   Rf = 0.61 (EtOAc). 
 
1H-NMR:  300 MHz, CDCl3; δ = 1.76 (sbr, 1 H, OH), 2.44 (dd, J = 2.2, 19.2 Hz, 1 H, 
2-HA), 3.03 (dd, J = 8.8, 19.2 Hz, 1 H, 2-HB), 3.98 (s, 3 H, OMe), 4.39 
(t, J = 8.8 Hz, 1 H, 3-H), 4.45 (ddd, J = 1.4, 2.2, 6.6 Hz, 2 H, 3`-H), 5.28 
(t, J = 10.5 Hz, 1 H, 2`-H), 5.74 (dt, J = 6.6, 10.5 Hz, 1 H, 1`-H), 7.01 
(d, J = 8.4 Hz, 1 H, Ar), 7.68 (d, J = 8.4 Hz, 1 H, Ar) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 36.4 (C2), 44.7 (C3), 56.9 (OMe), 59.2 (C3`), 112.3 (C6), 
120.5 (Ar), 123.7 (C7), 130.0 (C1`), 131.1 (Ar), 131.7 (C2`), 155.3 (Ar), 160.8 
(Ar), 203.4 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C13H13ClO3H [M-H]
+ 253.0626, found 253.0633. 
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FT-IR: (neat); ῦ = 3246 (s), 2943 (s), 2836 (s), 1601 (m), 1576 (m), 1496 (s), 1461 (s), 
1423 (s), 1362 (m), 1305 (m), 1286 (m), 1241 (s), 1187 (s), 1147 (s), 1053 (m), 
1023 (m), 993 (m), 922 (s), 871 (m), 785 (s), 618 (s), 573 (s), 549 (w), 522 (w) 
cm-1. 
 
 (Z)-3-(3-Bromopropenyl)-4-chloro-5-methoxyindanone 130 
 
Allyl alcohol 127 [M 252.69] 1.00 equiv. 135 µmol 34.0 mg 
PPh3 [M 262.28] 1.20 equiv. 161 µmol 42.0 mg 
NBS [M 177.99] 1.20 equiv. 161 µmol 29.0 mg 
Under Ar-atmosphere allyl alcohol 127 (34.0 mg, 135 µmol, 1.00 equiv.) was dissolved in 
CH2Cl2 (2 mL). In a separate flask PPh3 (42.0 mg, 161 µmol, 1.20 equiv.) and NBS (29.0 mg, 
161 µmol, 1.20 equiv.) were dissolved in CH2Cl2 (2 mL) and stirred under Ar-atmosphere at 
rt for 5 min. This mixture was then added to the allyl alcohol and stirred at rt for 12 h. All 
volatile compounds were removed under reduced pressure and after column chromatography 
(n-pentane/EtOAc 4:1) allyl bromide 130 (49.0 mg, 156 µmol, 96%) was isolated as colorless 
oil.  
 
TLC:   Rf = 0.12 (n-pentane/EtOAc 8:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 2.47 (dd, J = 2.4, 19.2 Hz, 1 H, 2-HA), 3.10 (dd, J = 8.6, 
19.2 Hz, 1 H, 2-HB), 3.99 (s, 3 H, OMe), 4.11 (dd, J = 7.6, 10.5 Hz, 1 H, 
3`-HA), 4.31 (t, J = 9.7 Hz, 1 H, 3-H), 4.42 (ddd, J = 2.5, 8.2, 10.5 Hz, 1 H, 
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3`-HB), 5.36 (t, J = 10.3 Hz, 1 H, 2`-H), 5.87 (ddd, J = 7.6, 8.2, 10.3 Hz, 1 H, 
1`-H), 7.03 (d, J = 8.4 Hz, 1 H, 6-H), 7.70 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
13C-NMR:  75 MHz, CDCl3; δ = 26.8 (CH2Br), 35.9 (C2), 44.2 (C3), 57.0 (OMe), 112.5 
(C6), 120.7 (Ar), 123.7 (C7), 126.7 (Ar), 131.1 (C1`), 134.3 (C2`), 154.8 (Ar), 
160.8 (Ar), 202.9 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C13H12BrClO2Na [M-Na]
+ 338.9580, found 338.9580. 
 
FT-IR: (neat); ῦ = 3246 (s), 2943 (s), 2836 (s), 1601 (m), 1576 (m), 1496 (s), 1461 (s), 
1423 (s), 1362 (m), 1305 (m), 1286 (m), 1241 (s), 1187 (s), 1147 (s), 1053 (m), 
1023 (s), 993 (s), 922 (s), 871 (s), 785 (s), 618 (s), 573 (s), 549 (w), 522 (w) 
cm-1. 
 
 4-Chloro-5-methoxy-1-vinyl-2,3-dihydrocyclopropainden-1-one 131 
 
Allyl bromide 130 [M 315.59] 1.00 equiv. 111 µmol 35.0 mg 
KOt-Bu [M 112.21] 1.10 equiv. 122 µmol 13.7 mg 
Under Ar-atmosphere allyl bromide 130 (35.0 mg, 111 µmol, 1.00 equiv.) was dissolved in 
THF (1 mL). KOt-Bu (13.7 mg, 122 µmol, 1.10 equiv.) was added and the reaction mixture 
was stirred at rt for 1 h. It was diluted with H2O (2 mL), extracted with CH2Cl2 (3x2 mL), 
dried over Na2SO4, filtrated and all volatile compounds were removed under reduced 
pressure. After column chromatography (n-pentane/EtOAc 4:1) vinyl cyclopropane 131 
(17.0 mg, 72.4 µmol, 66%) was isolated as colorless oil. 
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TLC:   Rf = 0.20 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.18 (dt, J = 3.1, 8.5 Hz, 1 H, 1`-H), 2.55 (dd, J = 3.1, 
4.9 Hz, 1 H, 3-H), 3.09 (dd, J = 3.0, 4.9 Hz, 1 H, 2-H), 3.97 (s, 3 H, OMe), 
5.09 (dd, J = 1.0, 10.3 Hz, 1 H, 3`-HA), 5.21 (dd, J = 1.0, 17.0 Hz, 1 H, 3`-HB), 
5.55 (ddd, J = 8.5, 10.3, 17.0 Hz, 1 H, 2`-H), 6.86 (d, J = 8.4 Hz, 1 H, 6-H), 
7.55 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 27.6 (C3), 35.6 (C2), 48.7 (C1`), 56.9 (OMe), 110.7 (Ar), 
116.4 (C3`), 118.9 (Ar), 124.5 (Ar), 128.2 (Ar), 135.7 (C2`), 152.9 (Ar), 159.7 
(Ar), 199.2 (CO) ppm. 
 
HR-MS: (ESI+); m/z calc. for C13H11ClO2Na [M-Na]
+ 235.0513, found 235.0520. 
 
FT-IR: (neat); ῦ = 2952 (m), 2884 (w), 1716 (m), 1596 (w), 1459 (w), 1441 (w), 1365 
(w), 1332 (w), 1285 (w), 1183 (m), 1117 (w), 1056 (w), 1033 (s), 983 (m), 919 
(m), 847 (w), 760 (w), 602 (w) cm-1. 
 
8.2.3 4-Chloro-5-methoxy-3-vinyl-2,3-dihydro-1H-inden-1-one 136 
Indenone 84 [M 194.61] 1.00 equiv. 187 µmol 36.0 mg 
[Rh(cod)OH]2 [M 456.19] 0.03 equiv. 5.60 µmol 2.60 mg 
rac. BINAP 107 [M 622.67] 0.10 equiv. 19.0 µmol 11.6 mg 
Trifluoroborate 135 [M 133.95] 2.00 equiv. 373 mmol 50.0 mg 
LiOH∙H2O [M 31.96] 0.50 equiv. 93.3 µmol 3.00 mg 
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Under Ar-atmosphere [Rh(cod)OH]2 (2.60 mg, 5.60 µmol, 0.03 equiv.), trifluoroborate 135 
(50.0 mg, 373 µmol, 2.00 equiv.) and rac. BINAP 113 (11.6 mg, 19.0 µmol, 0.10 equiv.) were 
stirred in degassed 1,4-dioxane/H2O (1.1 mL, 10:1) at rt for 30 min. Indenone 84 (36.0 mg, 
187 µmol, 1.00 equiv.) and LiOH∙H2O (3.00 mg, 93.3 µmol, 0.50 equiv.) were added and the 
reaction mixture was stirred at this temperature for 5 h. It was diluted with H2O (1.5 mL), 
extracted with Et2O (3x1.5 mL), dried over Na2SO4 and all volatile compounds were removed 
in vacuo. After column chromatography (n-pentane/EtOAc 4:1) vinylated indanone 136 
(40.0 mg, 179 µmol, 96%) was obtained as pale-yellow oil. 
 
TLC:   Rf = 0.15 (n-pentane/EtOAc 4:1). 
 
1H-NMR:   300 MHz, CDCl3; δ = 2.56 (dd, J = 2.1, 19.0 Hz, 1 H, 2-HA), 3.00 (dd, J = 8.1, 
19.0 Hz, 1 H, 2-HB), 4.00 (s, 3 H, OMe), 4.13 (t, J = 7.7 Hz, 1 H, 3-H), 
5.12-5.13 (m, 1 H, 2`-HA), 5.15 (dd, J = 3.4, 17.5 Hz, 1 H, 2`-HB), 5.84 (ddd, 
J = 7.7, 9.9, 17.5 Hz, 1 H, 1`-H), 7.02 (d, J = 8.4 Hz, 1 H, 6-H), 7.69 (d, 
J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:   75 MHz, CDCl3; δ = 41.6 (C3), 44.3 (C2), 56.9 (OMe), 111.7 (C6), 112.2 
(C2`), 116.4 (Ar), 123.5 (C7), 131.2 (Ar), 137.5 (C1`), 155.1 (Ar), 160.7 (Ar), 
203.5 (CO) ppm. 
 
HR-MS: (ESI+); m/z calc. for C12H11ClO2H [M-H]
+ 223.0520, found 223.0525. 
 
FT-IR: (neat); ῦ = 3085 (w), 2940 (w), 2844 (w), 1709 (s), 1639 (w), 1596 (s), 1574 
(w), 1480 (m), 1461 (w), 1439 (w), 1330 (m), 1284 (s), 1259 (w), 1189 (w), 
1158 (w), 1128 (m), 1092 (w), 1062 (m), 988 (w), 920 (w), 835 (w), 810 (w), 
694 (w), 604 (w), 522 (w) cm-1. 
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 Allylation of indanone 136 
 
Indanone 136 [M 222.67] 1.00 equiv. 404 µmol 90.0 mg 
KOt-Bu [M 112.21] 1.00 equiv. 404 µmol 45.0 mg 
Allyl bromide [M 120.99, ρ 1.40] 1.50 equiv. 606 µmol 52.4 µL 
 
Under Ar-atmosphere indanone 136 (90.0 mg, 404 µmol, 1.00 equiv.) was dissolved in THF 
(1 mL). KOt-Bu (45.0 mg, 404 µmol 1.00 equiv.) was added and the mixture was stirred at rt 
for 30 min. Freshly distilled allyl bromide (52.4 µL, 606 µmol, 1.50 equiv.) was added and 
the mixture was stirred at rt for 12 h. Sat. aq. NaHCO3 (1 mL) was added, it was extracted 
with Et2O (3x1 mL), dried over Na2SO4, filtrated and concentrated in vacuo. After column 
chromatography (n-pentane/EtOAc 4:1) allylated indanone 137 (57.0 mg, 217 µmol, 54%) 
and doubly allylated indanone 138 (55.0 mg, 173 µmol, 43%) were obtained as yellow oils.  
 
2-Allyl-4-chloro-3-ethylidene-5-methoxy-2,3-dihydro-1H-inden-1-one 137: 
 
TLC:   Rf = 0.33 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 1.98 (d, J = 7.2 Hz, 3 H, 2`-H), 2.53-2.74 (m, 2 H, 
1"-H), 3.33-3.35 (m, 1 H, 2-H), 4.00 (s, 3 H, OMe), 4.89 (d, J = 9.9 Hz, 1 H, 
3"-HA), 5.02 (dd, J = 1.7, 17.1 Hz, 1 H, 3"-HB), 5.60 (tdd, J = 7.2, 9.9, 17.1 Hz, 
1 H, 2"-H), 6.95 (d, J = 8.3 Hz, 1 H, 6-H), 7.31 (ddd, J = 2.0, 7.2, 7.5 Hz, 1 H, 
1`-H), 7.69 (d, J = 8.3 Hz, 1 H, 7-H) ppm. 
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13C-NMR:  75 MHz, CDCl3; δ = 16.1 (C2`), 35.8 (C1"), 49.9 (C2), 57.0 (OMe), 111.5 
(Ar), 117.6 (Ar), 118.1 (C3"), 123.4 (Ar), 127.0 (C1`), 131.5 (Ar), 133.5 (C2"), 
136.0 (Ar), 146.7 (C3), 161.1 (Ar), 203.4 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C15H15ClO2H [M-H]
+ 263.0833, found 263.0840. 
 
FT-IR: (neat); ῦ = 3086 (w), 2941 (w), 1709 (s), 1592 (m), 1478 (m), 1438 (w), 1333 
(w), 1281 (s), 1183 (w), 1132 (w), 1060 (m), 826 (w), 786 (w), 735 (w) cm-1. 
 
2,2-Diallyl-4-chloro-3-ethylidene-5-methoxy-2,3-dihydro-1H-inden-1-one 138: 
 
TLC:   Rf = 0.42 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.07 (d, J = 7.5 Hz, 3 H, 2`-H), 2.65 (d, J = 7.2 Hz, 4 H, 
1"-H), 3.99 (s, 3 H, OMe), 4.79 (dd, J = 1.4, 10.0 Hz, 2 H, 3"-HA), 4.97 (dd, 
J = 1.4, 17.0 Hz, 2 H, 3"-HB), 5.39 (tdd, J = 7.2, 10.0, 17.0 Hz, 2 H, 2"-H), 
6.95 (d, J = 8.4 Hz, 1 H, 6-H), 7.60 (d, J = 7.5 Hz, 1 H, 1`-H), 7.69 
(d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 15.3 (C2`), 41.0 (C1"), 57.7 (OMe), 57.4 (C2), 111.6 
(C6), 117.8 (C3"), 118.0 (Ar), 123.1 (C7), 128.3 (Ar), 131.2 (Ar), 133.0 (C2"), 
137.4 (C1`), 146.7 (C3), 161.3 (Ar), 205.8 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C18H19ClO2H [M-H]
+ 303.1146, found 303.1154. 
 
FT-IR: (neat); ῦ = 3076 (w), 3005 (w), 2976 (w), 2919 (w), 2846 (w), 1706 (s), 1640 
(w), 1590 (s), 1560 (m), 1464 (w), 1438 (m), 1413 (w), 1358 (w), 1325 (m), 
1275 (s), 1253 (w), 1200 (w), 1178 (w), 1126 (m), 1097 (w), 1067 (s), 992 (w), 
963 (w), 915 (m), 822 (m), 783 (w), 756 (m), 679 (w), 628 (w), 601 (m), 533 
(w), 458 (w) cm-1. 
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 Methyl (1R,4R,7R)-7-isopropyl-5-methylbicyclo[2.2.2]octa-2,5-diene-2-carboxy-
late 211 
 
(R)-α-Phellandrene 211 [50wt%; M 136.24] 1.05 equiv. 31.5 mmol 10.2 mL 
Methyl propiolate [M 84.07; ρ 0.95] 1.00 equiv. 30.0 mmol 2.67 mL 
Me2AlCl [1.0 M, n-hexane; M 92.50] 1.00 equiv. 30.0 mmol 30.0 mL 
(R)-(‒)-α-Phellandrene 211 (10.2 mL, 31.5 mmol, 50wt% technical grade, 1.05 equiv.) and 
methyl propiolate (2.67 mL, 30.0 mmol, 1.00 equiv.) were dissolved in CH2Cl2 (30 mL) under 
Ar-atmosphere. At 0 °C Me2AlCl (30.0 mL, 30.0 mmol, 1.0 M in n-hexane, 1.00 equiv.) was 
added dropwise and the mixture was stirred at this temperature for 6 h. H2O (30 mL) was 
added to quench the reaction, it was extracted with Et2O (3x30 mL), the combined org. layers 
were dried over MgSO4, filtrated and all volatile compounds were removed in vacuo. After 
column chromatography (n-pentane/EtOAc 20:1) diene 115 (3.80 g, 17.3 mmol, 55%) was 
obtained as colorless oil.  
 
TLC:   Rf = 0.45 (n-pentane/EtOAc 20:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.81 (d, J = 5.9 Hz, 3 H, i-Pr), 0.80 (dd, J = 2.6, 6.8 Hz, 
1 H, 8-HA), 0.99 (d, J = 5.7 Hz, 3 H, i-Pr), 1.07-1.20 (m, 2 H, 7-H, i-Pr), 1.55 
(ddd, J = 3.0, 8.8, 11.5 Hz, 1 H, 8-HB), 1.81 (d, J = 1.7 Hz, 3 H, 5-Me), 3.38 
(dq, J = 2.5, 6.8 Hz, 1 H, 4-H), 3.72 (s, 3 H, OMe), 4.07 (dt, J = 2.0, 6.1 Hz, 
1 H, 1-H), 5.80 (dt, J = 1.7, 5.9 Hz, 1 H, 6-H), 7.29 (dd, J = 1.9, 6.4 Hz, 1 H, 
3-H) ppm. 
The spectroscopic data of 115 matched that reported in the literature.[81] 
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 5-((1R,4R,7R)-7-Isopropyl-5-methylbicyclo[2.2.2]octa-2,5-dien-2-yl)propan-5-ol 
116 
 
Ester 115 [M 220.31] 1.00 equiv. 4.54 mmol 1.00 g 
MeLi [1.6 M, n-hexane; M 21.98] 2.50 equiv. 11.3 mmol 7.09 mL 
Under Ar-atmosphere ester 115 (1.00 g, 4.54 mmol, 1.00 equiv.) was dissolved in THF 
(25 mL). At 0 °C MeLi (7.09 mL, 11.3 mmol, 1.6 M in hexane, 2.50 equiv.) was added and 
the mixture was stirred at rt for 1 h. H2O (60 mL) was added to quench the reaction, it was 
extracted with Et2O (3x60 mL), the combined org. layers were dried over MgSO4, filtrated 
and all volatile compounds were removed in vacuo. After column chromatography 
(n-pentane/EtOAc 4:1) alcohol 116 (1.03 g, 4.67 mmol, 96%) was obtained as pale-yellow 
oil.  
 
TLC:   Rf = 0.23 (n-pentane/EtOAc 20:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.80 (d, J = 5.8 Hz, 3 H, i-Pr), 0.87 (ddd, J = 2.3, 4.3, 
11.4 Hz, 1 H, 8-HA), 0.96 (d, J = 5.8 Hz, 3 H, i-Pr), 1.04-1.13 (m, 2 H, 7-H, 
i-Pr), 1.32 (s, 3 H, Me), 1.34 (s, 3 H, Me), 1.56 (ddd, J = 3.0, 8.2, 11.4 Hz, 1 H, 
8-HB), 1.80 (d, J = 1.7 Hz, 3 H, 5-Me), 3.18 (dt, J = 2.3, 5.1 Hz, 1 H, 4-H), 
3.61 (dt, J = 1.8, 6.1 Hz, 1 H, 1-H), 5.75 (dt, J = 1.8, 6.1 Hz, 1 H, 6-H), 6.02 
(dd, J = 2.0, 6.1 Hz, 1 H, 3-H) ppm. 
 
The spectroscopic data of 116 matched that reported in the literature.[81] 
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 5-((1R,4R,7R)-7-Isopropyl-5-methylbicyclo[2.2.2]octa-2,5-dien-2-yl)nonan-5-ol 
117 
 
Ester 115 [M 220.31] 1.00 equiv. 1.45 mmol 318 mg 
n-BuLi [1.6 M, n-hexane; M 64.05] 2.50 equiv. 3.61 mmol 2.25 mL 
Under Ar-atmosphere ester 115 (318 mg, 1.45 mmol, 1.00 equiv.) was dissolved in THF 
(5 mL). At 0 °C n-BuLi (2.25 mL, 3.61 mmol, 1.6 M in n-hexane, 2.50 equiv.) was added and 
the mixture was stirred at rt for 1 h. H2O (20 mL) was added to quench the reaction, it was 
extracted with Et2O (3x20 mL), the combined org. layers were dried over MgSO4, filtrated 
and all volatile compounds were removed in vacuo. After column chromatography 
(n-pentane/EtOAc 20:1) alcohol 117 (353 mg, 1.16 mmol, 80%) was obtained as pale-yellow 
oil.  
 
TLC:   Rf = 0.40 (n-pentane/EtOAc 20:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.80 (d, J = 5.8 Hz, 3 H, i-Pr), 0.84-0.91 (m, 7 H, 8-HA, 
n-Bu), 0.94 (d, J = 5.8 Hz, 3 H, i-Pr), 1.05-1.09 (m, 2 H, 7-H, i-Pr), 1.21-1.34 
(m, 8 H, n-Bu), 1.45-1.64 (m, 5 H, n-Bu, 8-HB), 1.79 (d, J = 1.7 Hz, 3 H, 
5-Me), 3.18 (dt, J = 2.2, 5.0 Hz, 1 H, 4-H), 3.43 (dt, J = 1.7, 6.0 Hz, 1 H, 1-H), 
5.70 (dd, J = 1.7, 6.0 Hz, 1 H, 6-H), 5.99 (dd, J = 2.2, 6.1 Hz, 1 H, 3-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 14.2 (n-Bu), 14.3 (n-Bu), 19.1 (5-Me), 21.7 (i-Pr), 22.0 
(i-Pr), 23.3 (n-Bu), 23.3 (n-Bu), 25.7 (n-Bu), 25.9 (n-Bu), 32.9 (C8), 33.9 
(i-Pr), 38.6 (n-Bu), 38.7 (n-Bu), 40.9 (C1), 43.2 (C4), 47.9 (C7), 76.9 (COH), 
124.0 (C6), 126.7 (C3), 145.6 (C2), 153.9 (C5) ppm. 
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HR-MS: (ESI+); m/z calc. for C21H36O [M-H]
+ 304.2718, found 304.2718. 
 
FT-IR: (neat); ῦ = 3471 (w), 3034 (w), 2955 (w), 2931 (s), 2866 (w), 1709 (w), 1464 
(m), 1380 (w), 1323 (w), 1290 (w), 1257 (w), 1206 (w), 1142 (w), 1011 (w), 
884 (w), 861 (w), 816 (m), 789 (w), 733 (w), 687 (w), 637 (w) cm-1. 
 
[α]:   22 (c 0.71, EtOAc). 
 
 (R,E)-4-Chloro-5-methoxy-3-styryl-2,3-dihydroinden-1-one 141 
 
 
Indenone 84 [M 194.61] 1.0 equiv. 5.41 mmol 1.05 g 
[Rh(C2H4)2Cl]2 [M 388.93] 0.02 equiv. 0.11 mmol 42.1 mg 
Diene 116 [M 220.35] 0.10 equiv. 0.54 mmol 119 mg 
Boronic acid 140 [M 298.31] 2.50 equiv. 13.5 mmol 2.00 g 
LiOH∙H2O [M 31.96] 0.50 equiv. 2.70 mmol 113 mg 
 
Under Ar-atmosphere [Rh(C2H4)2Cl]2 (42.1 mg, 0.11 mmol, 0.02 equiv.), styrene boronic 
acid 140 (2.00 g, 13.5 mmol, 2.50 equiv.) and diene ligand 116 (119 mg, 0.54 mmol, 
0.10 equiv.) were stirred in degassed toluene/H2O (33 mL, 10:1) at rt for 30 min. At 0 °C 
indenone 84 (1.05 g, 5.41 mmol, 1.00 equiv.) and LiOH∙H2O (113 mg, 2.70 mmol, 
0.50 equiv.) were added and the reaction mixture was stirred at this temperature for 5 h. It was 
diluted with H2O (100 mL), extracted with Et2O (3x75 mL), dried over Na2SO4, filtrated and 
all volatile compounds were removed in vacuo. After column chromatography 
(n-pentane/EtOAc 4:1) styrylated indanone 141 (1.61 g, 5.39 mmol, 99%, 74%ee) was 
obtained as pale-yellow crystals. Recrystallization from n-pentane/CH2Cl2 (1:1) gave 1.01 g 
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(63%, >99% ee) of 141. 
 
TLC:   Rf = 0.17 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.64 (dd, J = 2.0, 19.0 Hz, 1 H, 2-HA), 3.09 (dd, 
J = 8.2 Hz, 19.0 Hz, 1 H, 2-HB), 3.99 (s, 3 H, OMe), 4.29 (dt, J = 2.0, 8.2 Hz, 
1 H, 3-H), 6.14 (dd, J = 8.2, 15.8 Hz, 1 H, 1`-H), 6.53 (dd, J = 0.8, 15.8 Hz, 
1 H, 2`-H), 7.03 (d, J = 8.4 Hz, 1 H, 6-H), 7.18-7.35 (m, 5 H, Ph), 7.72 
(d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 41.2 (C3), 44.7 (C2), 56.9 (OMe), 112.3 (6-H), 120.9 
(Ar), 123.5 (7-H), 126.4 (Ar), 127.7 (Ar), 128.7 (Ar), 129.3 (C2`), 131.2 (Ar), 
131.9 (C1`), 137.0 (Ar), 155.4 (Ar), 160.7 (Ar), 203.4 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C18H15ClO2Na [M-Na]
+ 299.0833, found 299.0828. 
 
FT-IR: (neat); ῦ = 3025 (w), 2941 (w), 2843 (w), 1709 (s), 1595 (m), 1573 (w), 1479 
(w), 1439 (w), 1328 (m), 1283 (s), 1254 (w), 1186 (w), 1157 (w), 1127 (w), 
1061 (m), 965 (w), 813 (w), 749 (w), 695 (w), 606 (w), 542 (w) cm-1. 
 
m.p.:  138 °C (EtOAc). 
 
HPLC: (Chiralpac IC, n-hexane/EtOAc 9/1, 0.7 mL/min, 254 nm) tR(major) = 
31.5 min, tR(minor) = 34.9 min. 
 
[α]:  82 (c 0.50, CHCl3), for recrystallized compound with ee > 99%). 
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using rac-BINAP 
 
 
with diene 116: 
 
 
after recrystallization: 
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 4-Chloro-5-methoxy-3-(2-phenylethylidene)-2,3-dihydroinden-1-one 147 
 
Indanone 141 [M 298.77] 1.00 equiv. 335 µmol 100 mg 
KHMDS [0.5 M, toluene; M 199.48] 1.00 equiv. 335 µmol 669 µL 
Under Ar-atmosphere indanone 141 (100 mg, 335 µmol, 1.00 equiv.) was dissolved in THF 
(5 mL). At –20 °C KHMDS (669 µL, 335 µmol, 0.5 M in toluene, 1.00 equiv.) was added and 
the mixture was stirred at this temperature for 20 min. Sat. aq. NaHCO3 (5 mL) was added, it 
was extracted with Et2O (3x10 mL), the combined org. layers were dried over Na2SO4, 
filtrated and concentrated in vacuo. After column chromatography (n-pentane/EtOAc 4:1) 
indanone 147 (99.0 mg, 335 µmol, 99%) was obtained as yellow oil. 
 
TLC:   Rf = 0.17 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 3.33-3.34 (m, 2 H, 2-H), 3.61 (d, J = 7.5 Hz, 2 H, 2`-H), 
3.98 (s, 3 H, OMe), 6.95 (d, J = 8.4 Hz, 1 H, 6-H), 7.20-7.35 (m, 5 H, Ph), 7.40 
(td, J = 2.0, 7.5 Hz, 1 H, 1`-H), 7.70 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 37.0 (C2`), 40.7 (C2), 57.0 (OMe), 111.7 (C6), 118.5 
(Ar), 123.3 (Ar), 126.5 (C7), 128.5 (Ar), 128.8 (C1`), 130.2 (Ar), 139.6 (Ar), 
146.5 (C3), 160.9 (Ar), 200.2 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C18H15ClO2Na [M-Na]
+ 299.0833, found 299.0828. 
 
FT-IR: (neat); ῦ = 3060 (w), 3025 (w), 2939 (m), 2843 (w), 1705 (s), 1588 (s), 1561 
(m), 1493 (w), 1464 (s), 1437 (w), 1418 (m), 1391 (w), 1324 (s), 1277 (w), 
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1258 (s), 1163 (w), 1126 (s), 1059 (s), 995 (w), 908 (s), 809 (s), 730 (s), 698 
(s), 642 (m), 604 (m), 584 (w), 549 (w), 500 (w), 439 (w) cm-1. 
 
 Allylation of Indanone 141 
 
Indanone 141 [M 298.77] 1.00 equiv. 837 µmol 250 mg 
KHMDS [0.5 M, toluene; M 199.48] 1.00 equiv. 837 µmol 1.67 mL 
Allyl bromide [M 120.99, ρ 1.40] 1.00 equiv. 837 µmol 72.3 µL 
Under Ar-atmosphere indanone 141 (250 mg, 837 µmol, 1.00 equiv.) was dissolved in THF 
(10 mL). At –20 °C KHMDS (1.67 mL, 837 µmol, 0.5 M in toluene, 1.00 equiv.) was added 
and the mixture was stirred for 2 min. Freshly distilled allyl bromide (72.3 µL, 837 µmol, 
1.00 equiv.) was added and the mixture was stirred at –20 °C for further 2 min. Sat. aq. 
NaHCO3 (5 mL) was added, it was extracted with Et2O (3x10 mL), the combined org. layers 
were dried over Na2SO4, filtrated and all volatile compounds were concentrated in vacuo. 
After column chromatography (n-pentane/EtOAc 4:1) allylated indanone 143 (127 mg, 
375 µmol, 45% cis/trans 1:6.5), doubly allylated indanone 144 (79.0 mg, 208 µmol, 25%) and 
recovered indanone 141 (70 mg, 237 µmol, 28%) were obtained as yellow oils.  
 
(2S,3S)-2-Allyl-4-chloro-5-methoxy-3-((E)-styryl)-2,3-dihydroinden-1-one 143: 
 
TLC:   Rf = 0.32 (n-pentane/EtOAc 4:1). 
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1H-NMR:  300 MHz, CDCl3; δ = 2.32-2.43 (m, 1 H, 1"-HA), 2.61-2.69 (m, 1 H, 1"-HB), 
3.10 (dd, J = 7.4, 7.4 Hz, 1 H, 2-H), 3.92-3.97 (m, 1 H, 3-H), 3.99 (s, 3 H, 
OMe), 5.09 (dd, J = 1.7, 9.9 Hz, 1 H, 3"-HA), 5.17 (dd, J = 1.7, 16.7 Hz, 1 H, 
3"-HB), 5.80 (tdd, J = 6.7, 6.7, 13.4 Hz, 1 H, 2"-H), 6.14 (dd, J = 8.5, 15.8 Hz, 
1 H, 1`-H), 6.51 (d, J = 15.8 Hz, 1 H, 2`-H), 7.04 (d, J = 8.4 Hz, 1 H, 6-H), 
7.21-7.34 (m, 5 H, Ph), 7.71 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 35.9 (C1"), 46.0 (C3), 47.2 (C2), 56.9 (OMe), 112.4 (C6), 
117.8 (C3"), 121.1 (Ar), 123.7 (C7), 126.4 (Ar), 127.6 (Ar), 128.7 (Ar), 129.2 
(C2`), 131.2 (Ar), 132.1 (C2`), 135.1 (C1"), 137.1 (Ar), 154.1 (Ar), 161.0 (Ar), 
205.0 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C21H19ClO2Na [M-Na]
+ 361.0966, found 361.0965. 
 
FT-IR: (neat); ῦ = 3060 (w), 3025 (w), 2940 (w), 2842 (w), 1706 (s), 1640 (w), 1590 
(s), 1564 (w), 1493 (w), 1468 (m), 1437 (w), 1419 (w), 1326 (m), 1279 (s), 
1257 (w), 1184 (w), 1163 (w), 1127 (m), 1061 (s), 995 (w), 966 (w), 919 (w), 
812 (m), 749 (m), 698 (m), 641 (w), 606 (w) cm-1. 
 
Due to the low stability of 143 upon purification (double bond isomerization) no sample pure 
enough for a reliable measurement of optical rotation could be obtained. 
 
(S,E)-2,2-Diallyl-4-chloro-5-methoxy-3-styryl-2,3-dihydro-1H-inden-1-one 144: 
 
TLC:   Rf = 0.41 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.22-2.56 (m, 4 H, 1"-H), 3.99 (s, 3 H, OMe), 4.07 
(d, J = 9.4 Hz, 1 H, 3-H), 5.00-5.09 (m, 1 H, 3"-H), 5.58 (tdd, J = 7.4, 10.0, 
17.5 Hz, 1 H, 2"-H), 5.86 (dddd, J = 6.5, 7.9, 10.0, 17.5 Hz, 1 H, 2"-H), 6.05 
(dd, J = 9.4, 15.8 Hz, 1 H, 1`-H), 6.52 (d, J = 15.8 Hz, 1 H, 1`-H), 7.02 
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(d, J = 8.4 Hz, 1 H, 6-H), 7.21-7.34 (m, 5 H, Ph), 7.71 (d, J = 8.4 Hz, 1 H, 7-H) 
ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 37.3 (C1"A), 42.4 (C1“B), 51.6 (C2), 56.8 (OMe), 57.9 
(C3), 112.2 (C6), 118.5 (C3"A), 118.9 (C3"B), 120.8 (Ar), 123.7 (C7), 126.4 
(Ar), 127.6 (Ar), 128.7 (Ar), 129.1 (C2`), 130.1 (C1`), 133.2 (C2"A), 133.4 
(C2"B), 133.8 (Ar), 137.1 (Ar), 153.2 (Ar), 160.8 (Ar), 206.4 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C24H23ClO2H [M-H]
+ 379.1459, found 379.1470. 
 
FT-IR: (neat); ῦ = 3078 (w), 3024 (w), 2976 (w), 2939 (w), 2843 (w), 1707 (s), 1640 
(w), 1595 (s), 1573 (w), 1479 (m), 1439 (w), 1330 (m), 1280 (s), 1161 (w), 
1129 (w), 1064 (m), 992 (w), 966 (w), 919 (w), 818 (w), 789 (w), 750 (w), 696 
(w), 661 (w), 612 (w), 590 (w) cm-1. 
 
If the enolate mixture of 141 was stirred for 20 min or more at –20 °C the isomerized allylated 
compounds 148 and 149 were isolated as yellow oils.  
 
2-Allyl-4-chloro-5-methoxy-3-(2-phenylethylidene)-2,3-dihydro-1H-inden-1-one 148: 
 
TLC:   Rf = 0.32 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.63 (ddt, J = 1.3, 7.2, 14.0 Hz, 1 H, 1"-HA), 2.70-2.79 
(m, 1 H, 1"-HB), 3.46 (ddd, J = 1.6, 4.6, 6.5 Hz, 1 H, 2-H), 3.70 (d, J = 7.6 Hz, 
2 H, 2`-H), 3.99 (s, 3 H, OMe), 4.91 (ddt, J = 1.0, 1.7, 10.0 Hz, 1 H, 3"-HA), 
5.02 (dq, J = 1.7, 17.3 Hz, 1 H, 3"-HB), 5.63 (tdd, J = 7.2, 10.0, 17.3 Hz, 1 H, 
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2"-H), 6.98 (d, J = 8.4 Hz, 1 H, 6-H), 7.24-7.36 (m, 5 H, Ph), 7.42 (td, J = 1.7, 
7.6 Hz, 1 H, 1`-H), 7.72 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 36.5 (C1"), 47.2 (C2), 50.1 (C2`), 57.0 (OMe), 111.8 
(C6), 118.0 (C3"), 123.4 (C7), 126.4 (Ar), 127.6 (Ar), 128.5 (Ar), 128.7 (C1`), 
128.9 (Ar), 130.3 (Ar), 135.9 (C2"), 139.7 (Ar), 146.6 (C3), 154.1 (Ar), 161.2 
(Ar), 203.0 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C21H19ClO2Na [M-Na]
+ 361.0966, found 361.0965. 
 
FT-IR: (neat); ῦ = 3078 (w), 3025 (w), 2976 (w), 2939 (w), 2842 (w), 1708 (s), 1640 
(w), 1592 (s), 1564 (w), 1468 (m), 1438 (w), 1417 (w), 1328 (m), 1278 (s), 
1256 (w), 1184 (w), 1161 (w), 1128 (m), 1064 (s), 992 (w), 966 (w), 920 (m), 
814 (w), 748 (m), 698 (m), 663 (w), 590 (w), 499 (w), 442 (w) cm-1. 
 
2,2-Diallyl-4-chloro-5-methoxy-3-(2-phenylethylidene)-2,3-dihydro-1H-inden-1-one 149: 
 
TLC:   Rf = 0.41 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.65 (dd, J = 1.2, 7.3 Hz, 4 H, 1"-H), 3.77 (d, J = 7.6 Hz, 
2 H, 2`-H), 3.91 (s, 3 H, OMe), 4.74 (dd, J = 1.8, 10.1 Hz, 2 H, 3"-HA), 4.91 
(dd, J = 1.8, 17.0 Hz, 2 H, 3"-HB), 5.36 (tdd, J = 7.2, 10.1, 17.0 Hz, 2 H, 2"-H), 
6.90 (d, J = 8.4 Hz, 1 H, 6-H), 7.16-7.31 (m, 5 H, Ph), 7.62 (d, J = 7.6 Hz, 1 H, 
1`-H), 7.64 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 35.3 (C2`), 41.4 (C1"), 56.9 (C2), 57.2 (OMe), 111.8 
(C6), 118.0 (C3"), 118.2 (Ar), 123.0 (C7), 126.4 (Ph), 128.4 (Ph), 128.7 (Ph), 
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131.2 (Ar), 131.9 (C2`), 132.6 (Ar), 137.1 (C1`), 139.8 (C2"), 146.3 (Ar), 
161.2 (Ar), 205.3 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C24H23ClO2H [M-H]
+ 379.1459, found 379.1470. 
 
FT-IR: (neat); ῦ = 3076 (w), 3026 (w), 2976 (w), 2938 (w), 2841 (w), 1707 (s), 1640 
(w), 1589 (s), 1561 (m), 1495 (w), 1464 (w), 1438 (m), 1413 (w), 1362 (w), 
1325 (m), 1276 (w), 1253 (s), 1183 (w), 1160 (w), 1125 (m), 1067 (s), 1030 
(w), 992 (w), 964 (w), 917 (m), 851 (w), 823 (m), 781 (w), 743 (m), 698 (m), 
680 (w), 628 (w), 597 (w), 531 (w), 494 (w), 452 (w) cm-1. 
 
8.4.9 (2R,3S)-2-Allyl-4-chloro-5-methoxy-3-((E)-styryl)-2,3-dihydroinden-1-one 153 
 
Indanone 143 [M 338.83] 1.00 equiv. 207 µmol 70.0 mg 
i-Pr2NH [M 101.19; ρ 0.72] 1.10 equiv. 227 µmol 31.9 µL 
n-BuLi [1.6 M, n-hexane; M 64.05] 1.05 equiv. 217 µmol 86.8 µL 
Ethyl salicylate [M 166.18; ρ 1.13] 4.00 equiv. 826 µmol 122 µL 
Under Ar-atmosphere n-BuLi (86.8 µL, 217 µmol, 1.6 M in THF, 1.05 equiv.) was added to a 
solution of i-Pr2NH (31.9 µL, 227 µmol, 1.10 equiv.) in THF (2 mL) at 0 °C and the mixture 
was stirred at 0 °C for 30 min. At –20 °C indanone 143 (70.0 mg, 207 µmol, 1.00 equiv.) was 
added and the mixture was stirred for 2 min. The resulting enolate was added dropwise to a 
solution of ethyl salicylate (122 µL, 826 µmol, 4.00 equiv.) in THF (2 mL) at –78 °C and the 
mixture was stirred at this temperature for 15 min. The reaction mixture was warmed to rt and 
AcOH (50.0 µL, 0.83 mmol, 4.00 equiv.) was added. It was filtrated through a short pad of 
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celite, washed with sat. aq. NaHCO3 (3 mL) and H2O (3x3 mL) and extracted with Et2O 
(3x3 mL). The combined org. layers were dried over Na2SO4, filtrated and concentrated 
in vacuo. After column chromatography (n-pentane/EtOAc 4:1) allylated indanone 
mixture 153/143 (47.0 mg, 141 µmol, 67%, cis/trans 2:1) was obtained as yellow oil.  
 
TLC:   Rf = 0.32 (n-pentane/EtOAc 4:1). 
 
The following signals could be assigned to the cis-configured indanone 153. 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.21-2.30 (m, 1 H, 1"-HA), 2.80 (dtt, J = 1.9, 4.1, 
15.5 Hz, 1 H, 1"-HB), 2.98 (ddd, J = 4.1, 7.5, 10.4 Hz, 1 H, 2-H), 3.93-3.96 (m, 
1 H, 3-H), 3.99 (s, 3 H, OMe), 5.09 (dd, J = 1.7, 9.9 Hz, 1 H, 3"-HA), 5.17 (dd, 
J = 1.7, 17.0 Hz, 1 H, 3"-HB), 5.95 (ddt, J = 6.7, 10.4, 17.0 Hz, 1 H, 2"-H), 
6.14 (dd, J = 8.5, 15.8 Hz, 1 H, 1`-H), 6.42 (d, J = 15.8 Hz, 1 H, 2`-H), 7.02 
(d, J = 8.4 Hz, 1 H, 6-H), 7.19-7.35 (m, 5 H, Ph), 7.74 (d, J = 8.4 Hz, 1 H, 7-H) 
ppm. 
 
 (8R,9S)-3-Chloro-4-methoxy-8,9-dihydrocyclopentainden-8-one 154 
 
Indanone mixture 153/143 [M 338.83] 1.00 equiv. 139 µmol 47.0 mg 
GRUBBS II catalyst [M 848.97] 0.05 equiv. 6.94 µmol 5.80 mg 
Under Ar-atmosphere the allylated indanone mixture 153/143 (47.0 mg, 139 µmol, 
1.00 equiv.) and GRUBBS II catalyst (5.80 mg, 6.94 µmol, 0.05 equiv.) were dissolved in 
CH2Cl2 (8 mL) and stirred at rt for 12 h. The reaction mixture was filtrated through a short 
pad of celite and all volatile compounds were removed under reduced pressure. After column 
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chromatography (n-pentane/EtOAc 4:1) an inseparable mixture of tricyclic compound 154 
and trans-indanone 143 (32.0 mg, 121 µmol, 85%, 2:1) were obtained as yellow oil.  
 
The following analytical data could be assigned to tricycle 154: 
 
TLC:   Rf = 0.32 (n-pentane/EtOAc 4:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 2.72 (ddd, J = 2.8, 6.5, 11.6 Hz, 1 H, 10-HA), 2.82 (ddd, 
J = 2.3, 2.3, 10.5 Hz, 1 H, 10-HB), 3.40 (ddd, J = 3.2, 7.0, 10.5 Hz, 1 H, 9-H), 
3.99 (s, 3 H, OMe), 4.53 (dd, J = 2.3, 6.5 Hz, 1 H, 9-H), 5.68 (dd, J = 2.3, 
5.5 Hz, 1 H, 11-H), 6.06 (dd, J = 2.3, 5.5 Hz, 1 H, 12-H), 6.96 (d, J = 8.4 Hz, 
1 H, 5-H), 7.66 (d, J = 8.4 Hz, 1 H, 6-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 35.5 (C10), 50.3 (C9), 51.7 (C13), 56.9 (OMe), 111.8 
(C5), 124.3 (C6), 126.4 (Ar), 130.0 (Ar), 131.3 (C11), 135.11 (C12), 156.8 
(Ar), 160.5 (Ar), 207.6 (C8) ppm.  
 
HR-MS: (ESI+); m/z calc. for C13H11ClO2Na [M-Na]
+ 257.0339, found 257.0340.  
 
Compound 154 could not be separated from 143 chromatographically, therefore no sample 
pure enough for a reliable measurement of optical rotation or an IR spectrum could be 
obtained. 
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 3,3-Dimethyldioxirane  
 
Acetone [M 58.08] 12.5 equiv. 2.58 mol 192 mL 
NaHCO3 [M 84.01] 3.75 equiv. 775 mmol 65.1 g 
Oxone® [M 307.38] 1.00 equiv. 209 mmol 64.2 g 
Acetone (192 mL, 2.58 mol, 12.5 equiv.) and NaHCO3 (65.1 g, 775 mmol, 3.75 equiv.) were 
dissolved in H2O (254 mL) under vigorous stirring. At 0 °C oxone
® (64.2 g, 209 mmol, 
1.00 equiv.) was added and the mixture was stirred at this temperature for 30 min. It was 
warmed to rt and DMDO (150 mL, 9.00 mmol, 0.06 M in acetone, 4%) was distilled off as 
pale-yellow solution into a precooled (–78 °C) flask at 120 mbar. 
 
1H-NMR: 300 MHz, CDCl3; 1.67 (s, 6 H, Me) ppm. 
 
The spectroscopic data obtained matched that reported in the literature.[152] 
 
 Bis(trimethylsilyl) peroxide 212 
 
Urotropine [M 140.19] 1.00 equiv. 143 mmol 20.0 g 
H2O2 [30%, aq.; M 34.02; ρ 1.11] 1.80 equiv. 257 mmol 26.2 mL 
TMSCl [M 108.64; ρ 0.85] 1.50 equiv. 202 mmol 25.8 mL 
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To finely powdered urotropine (20.0 g, 143 mmol, 1.00 equiv.) aq. H2O2 (26.2 mL, 
256 mmol, 30%, 1.80 equiv.) was added slowly at 0 °C. The mixture was stirred until 
complete dissolution (15 min) and all volatile compounds were removed under reduced 
pressure. The crude H2O2-urotropine complex 211 (23.5 g, 135 mmol, 95%) was dried 
in vacuo and was directly used for the next step. 
Under Ar-atmosphere crude 211 (23.5 g, 135 mmol, 1.00 equiv.) was suspended in CH2Cl2 
(100 mL). At 0 °C TMSCl (25.8 mL, 202 mmol, 1.50 equiv.) was added over a period of 2 h 
and the mixture was stirred at this temperature for 30 min. The reaction mixture was filtrated 
and CH2Cl2 was removed at atmospheric pressure to yield bis(trimethylsilyl) peroxide 212 
(18.0 g, 95.3 mmol, 71%) as colorless liquid. 
 
1H-NMR: 300 MHz, CDCl3; δ = 0.19 (s, 18 H, TMS) ppm. 
 
The spectroscopic data of 212 matched that reported in the literature.[96] 
 
 
 (2S,3R)-2-Allyl-4-chloro-2-hydroxy-5-methoxy-3-((E)-styryl)-2,3-dihydroinden-1-
one 157 
 
Indanone 143 [M 338.83] 1.00 equiv. 177 µmol 60.0 mg 
KHMDS [0.5 M, toluene; 199.48] 1.05 equiv. 186 µmol 370 µL 
DMDO [0.06 M, acetone; M 74.08] 1.40 equiv. 248 µmol 6.16 mL 
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Under Ar-atmosphere allylated indanone 143 (60.0 mg, 177 µmol, 1.00 equiv.) was dissolved 
in THF (6 mL). At –78 °C KHMDS (370 µL, 186 µmol, 0.5 M in toluene, 1.05 equiv.) was 
added, the reaction mixture was stirred for 5 min, freshly prepared DMDO (6.16 mL, 
248 µmol, 0.06 M in acetone, 1.40 equiv.) was added and the stirring was continued for 
further 2 min. Sat. aq. NH4Cl was added to quench the reaction and it was slowly warmed to 
rt. The layers were separated and the aq. layer was extracted with Et2O (3x5 mL), the 
combined org. layers were dried over Na2SO4, filtrated and concentrated in vacuo. After 
column chromatography (n-pentane/EtOAc 2:1) hydroxylated indanone 157 (60.0 mg, 
173 µmol, 95%) was obtained as yellow oil. 
 
TLC:   Rf = 0.33 (n-pentane/EtOAc 2:1). 
 
1H-NMR:  300 MHz, CDCl3; δ = 2.47-2.52 (m, 2 H, 1"-H), 4.00 (s, 3 H, OMe), 4.18 
(d, J = 9.3 Hz, 1 H, 3-H), 5.18 (dd, J = 1.8, 11.5 Hz, 1 H, 3"-HA), 5.22 
(d, J = 3.2 Hz, 1 H, 3"-HB), 5.89-6.03 (m, 1 H, 2"-H), 6.13 (dd, J = 9.3, 
15.8 Hz, 1 H, 1`-H), 6.60 (d, J = 15.8 Hz, 1 H, 2`-H), 7.05 (d, J = 8.4 Hz, 1 H, 
6-H), 7.23-7.39 (m, 5 H, Ph), 7.76 (d, J = 8.4 Hz, 1 H, 7-H) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 39.0 (C1"), 53.9 (C3), 56.8 (OMe), 81.9 (C2), 112.3 (C6), 
120.5 (C3"), 121.1 (C7), 124.6 (Ar), 125.7 (Ar), 126.4 (Ar), 127.7 (Ar), 128.0 
(C2`), 128.6 (Ar), 131.5 (C2`), 134.2 (C1"), 136.9 (Ar), 151.8 (Ar), 161.5 (Ar), 
202.9 (C1) ppm. 
 
HR-MS: (ESI+); m/z calc. for C21H19ClO3Na [M-Na]
+ 377.0915, found 377.0910. 
 
FT-IR: (neat); ῦ = 3470 (w), 3403 (w), 2977 (w), 2925 (w), 2361 (m), 1713 (s), 1596 
(s), 1572 (w), 1479 (w), 1438 (w), 1394 (w), 1332 (m), 1283 (s), 1158 (w), 
1130 (w), 1062 (m), 996 (w), 968 (w), 920 (w), 787 (w), 755 (w), 696 (w), 456 
(w) cm-1. 
 
Due to the low stability of 157 upon purification no sample pure enough for a reliable 
measurement of optical rotation could be obtained. 
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 (1R,9S)-3-Chloro-9-hydroxy-4-methoxy-1,10-dihydrocyclopentainden-8-one 155 
 
Indanone 157 [M 356.85] 1.00 equiv. 168 µmol 60.0 mg 
GRUBBS II catalyst [M 848.97] 0.05 equiv. 8.45 µmol 7.18 mg 
 
Under Ar-atmosphere 157 (60.0 mg, 168 µmol, 1.00 equiv.) and GRUBBS II catalyst (7.18 mg, 
8.45 µmol, 0.05 equiv.) were dissolved in CH2Cl2 (8 mL) and stirred at rt for 12 h. The 
reaction mixture was filtrated through a short pad of celite and all volatile compounds were 
removed under reduced pressure. After column chromatography (n-pentane/EtOAc 2:1) 
tricyclic compound 155 (30.0 mg, 0.12 mmol, 70%) was obtained as colorless crystals.  
TLC:   Rf = 0.27 (n-pentane/EtOAc 2:1). 
 
1H-NMR:  500 MHz, CDCl3; δ = 2.67 (dtd, J = 1.1, 2.2, 18.5 Hz, 1 H, 10-HA), 2.84 (dq, 
J = 2.4, 18.5 Hz, 1 H, 10-HB), 4.00 (s, 3 H, OMe), 4.26 (sbr, 1 H, 1-H), 5.68 
(dq, J = 2.2, 6.0 Hz, 1 H, 11-H), 6.19 (dq, J = 2.4, 6.0 Hz, 1 H, 12-H), 7.00 (d, 
J = 8.4 Hz, 1 H, 5-H), 7.70 (d, J = 8.4 Hz, 1 H, 6-H) ppm.  
 
13C-NMR:  126 MHz, CDCl3; δ = 43.9 (C10), 56.9 (OMe), 58.9 (C1), 86.5 (C9), 112.3 
(C5), 119.8 (Ar), 125.3 (C6), 127.7 (Ar), 128.8 (C11), 129.9 (C12), 153.9 (Ar), 
161.5 (Ar), 204.6 (C8) ppm. 
 
HR-MS: (ESI+); m/z calc. for C13H11ClO3Na [M-Na]
+ 273.0289, found 273.0285. 
 
FT-IR: (neat); ῦ = 3413 (w), 3058 (w), 3024 (w), 2930 (w), 2847 (w), 1710 (s), 1595 
(s), 1571 (w), 1479 (w), 1438 (w), 1330 (m), 1283 (s), 1249 (w), 1164 (w), 
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1131 (m), 1062 (m), 1002 (w), 966 (w), 924 (w), 899 (w), 820 (w), 780 (w), 
754 (w), 695 (w), 642 (w), 598 (w), 544 (w) cm-1. 
 
m.p.:   135 °C (EtOAc).  
 
[α]:   109 (c 0.50, CHCl3). 
 
When the reaction sequence of allylation, α-hydroxylation and ring closing metathesis was 
streamlined with the respective crude product mixtures 228 mg (25%) of tricycle 155 were 
obtained starting from 143 (1.10 g, 3.68 mmol). 
 
 
8.2.4 Reduction of α-hydroxyketone 155 
 
Ketone 155 [M 250.68] 1.00 equiv. 878 µmol 220 mg 
Red-Al [3.5 M, toluene; 92.14] 5.00 equiv. 4.39 mmol 1.25 mL 
Under Ar-atmosphere a solution of tricycle 155 (220 mg, 878 µmol, 1.00 equiv.) in toluene 
(24 mL) was added to precooled Red-Al (1.25 mL, 4.39 mmol, 3.5 M in toluene, 5.00 equiv.) 
at –78 °C. The mixture was slowly warmed to –60 °C and was stirred at this temperature for 
4 h. Sat. aq. ROCHELLE salt (25 mL) was added and the mixture was slowly warmed to rt. The 
layers were separated and the aq. layer was extracted with EtOAc (3x25 mL). The combined 
org. layers were dried over Na2SO4, filtrated and all volatile compounds were removed under 
reduced pressure to yield trans-diol 158 (221 mg, 0.88 mmol, 99%) as colorless crystals 
which were used for the next step without further purification. 
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If the reaction was performed at temperatures above –60 °C up to 25% of cis-diol 159 were 
obtained as colorless oil. 
 
(1R,8S,9S)-3-Chloro-4-methoxy-1,10-dihydrocyclopentaindene-8,9-diol 158 
 
TLC:   Rf = 0.17 (n-pentane/EtOAc 1:1). 
 
1H-NMR:  500 MHz, CD3OD; δ = 2.31 (dt, J = 2.2, 17.7 Hz, 1 H, 10-HA), 2.98 (dq, 
J = 2.2, 17.7 Hz, 1 H, 10-HB), 3.86 (s, 3 H, OMe), 3.92 (d, J = 2.3 Hz, 1 H, 
1-H), 4.98 (s, 1 H, 8-H), 5.72 (ddd, J = 2.2, 2.2, 6.0 Hz, 1 H, 11-H), 6.12 (dtd, 
J = 2.3, 2.6, 6.0 Hz, 1 H, 12-H), 6.98 (d, J = 8.3 Hz, 1 H, 5-H), 7.23 (d, 
J = 8.3 Hz, 1 H, 6-H) ppm. 
13C-NMR:  126 MHz, CD3OD; δ = 41.4 (C10), 56.9 (OMe), 65.5 (C1), 83.2 (C8), 92.6 
(C9), 112.8 (C5), 119.7 (Ar), 125.0 (C6), 130.5 (C11), 131.4 (C12) 137.6 (Ar), 
142.9 (Ar), 156.9 (Ar) ppm.  
 
HR-MS:  (ESI+); m/z calc. for C13H13ClO3Na [M-Na]
+ 275.0445, found 275.0441.  
 
FT-IR:  (neat); ῦ = 3399 (w), 3055 (w), 2923 (m), 2849 (w), 1707 (m), 1597 (m), 1572 
(w), 1478 (m), 1437 (w), 1328 (w), 1283 (s), 1261 (w), 1164 (w), 1132 (w), 
1066 (s), 957 (w), 926 (w), 897 (w), 809 (m), 721 (w), 699 (w), 601 (w) cm-1.  
 
m.p.:   145 °C (decomposition).  
 
[α]:   208 (c 0.56, EtOAc). 
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(1R,8R,9S)-3-Chloro-4-methoxy-1,10-dihydrocyclopentaindene-8,9-diol 159 
 
TLC:   Rf = 0.23 (n-pentane/EtOAc 1:1).  
 
1H-NMR:  500 MHz, CD3OD; δ = 2.56 (d, J = 2.2 Hz, 1 H, 10-HA), 2.57 (d, J = 2.2 Hz, 
1 H, 10-HB), 3.85 (s, 3 H, OMe), 4.07 (d, J = 2.1 Hz, 1 H, 1-H), 4.77 (s, 1 H, 
8-H), 5.69 (dq, J = 2.2, 6.0 Hz, 1 H, 11-H), 5.96 (dq, J = 2.1, 6.0 Hz, 1 H, 
12-H), 6.95 (d, J = 8.2 Hz, 1 H, 5-H), 7.24 (dd, J = 0.9, 8.2 Hz, 1 H, 6-H) ppm. 
13C-NMR:  126 MHz, CD3OD; δ = 43.9 (C10), 55.5 (OMe), 61.4 (C1), 79.1 (C8), 88.5 
(C9), 111.2 (Ar), 118.4 (Ar), 123.9 (Ar), 129.0 (C11), 129.3 (C12), 136.5 (Ar), 
141.8 (Ar), 155.6 (Ar) ppm. 
 
HR-MS: (ESI+); m/z calc. for C13H13ClO3Na [M-Na]
+ 275.0445, found 275.0441.  
 
FT-IR: (neat); ῦ = 3357 (w), 3056 (w), 3006 (w), 2931 (w), 2841 (w), 2508 (w), 1721 
(w), 1607 (w), 1574 (w), 1477 (m), 1436 (w), 1319 (w), 1260 (s), 1189 (w), 
1164 (w), 1136 (w), 1067 (s), 1037 (w), 1009 (w), 952 (w), 897 (m), 810 (m), 
771 (m), 747 (w), 720 (w), 677 (w), 654 (w), 602 (w) cm-1.  
 
The cis-diol 159 was obtained from a racemic sample of tricyclic compound 161, therefore no 
measurement of optical rotation was performed. 
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 (1R,8S,9S)-3-Chloro-9-hydroxy-4-methoxy-1,8,9,10-tetrahydrocyclopentainden-8-
yl 4-nitrobenzoate 163 
 
trans-Diol 158 [M 252.69] 1.00 equiv. 47.5 µmol 12.0 mg 
DMAP [M 122.17] 1.50 equiv. 71.2 µmol 8.70 mg 
para-Nitro benzoyl chloride [M 185.56] 1.20 equiv. 57.0 µmol 10.6 mg 
Under Ar-atmosphere diol 158 (12.0 mg, 47.5 µmol, 1.00 equiv.) was dissolved in CH2Cl2 
(0.5 mL). At 0 °C DMAP (8.70 mg, 71.2 µmol, 1.50 equiv.) and para-nitro benzoyl chloride 
(10.6 mg, 57.0 µmol, 1.20 equiv.) were added and the mixture was stirred at this temperature 
for 1 h. The reaction was quenched by the addition of H2O (2 mL), extracted with Et2O 
(3x2 mL), dried over Na2SO4, filtrated and concentrated in vacuo. After column 
chromatography (n-pentane/EtOAc 4:1) ester 163 (12.0 mg, 29.9 µmol, 63%) was obtained as 
colorless oil. 
 
TLC:   Rf = 0.18 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  300 MHz, C6D6; δ = 2.22 (ddt, J = 2.2, 2.2, 17.5 Hz, 1 H, 10-HA), 2.74 (ddt, 
J = 2.2, 2.2, 17.5 Hz, 1 H, 10-HB), 3.23 (s, 3 H, OMe), 4.22 (sbr, 1 H, 1-H), 
5.51 (ddt, J = 2.2, 2.2, 6.0 Hz, 1 H, 11-H), 6.18 (d, J = 0.9 Hz, 1 H, 8-H), 6.31 
(dtd, J = 2.2, 2.2, 6.0 Hz, 1 H, 12-H), 6.40 (d, J = 8.3 Hz, 1 H, 5-H), 7.03 (dd, 
J = 0.9, 8.3 Hz, 1 H, 6-H) ppm. 
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13C-NMR:  75 MHz, C6D6; δ = 42.4 (C10), 55.9 (OMe), 63.3 (C1), 87.4 (C8), 91.1 (C9), 
111.8 (C5), 119.8 (Ar), 123.6 (Ph), 124.3 (C6), 129.8 (C11), 130.0 (C12), 
130.7 (Ph), 131.5 (Ph), 134.7 (Ph), 143.0 (Ar), 150.9 (Ar), 157.0 (Ar), 165.9 
(CO) ppm. 
 
HR-MS:  (ESI+); m/z calc. for C20H16ClNO6Na [M-Na]
+ 424.0558, found 424.0569. 
 
FT-IR:  (neat); ῦ = 3246 (s), 2943 (s), 2836 (s), 1601 (s), 1576 (m), 1496 (m), 1461 (s), 
1423 (m), 1362 (m), 1305 (s), 1286 (s), 1241 (m), 1187 (w), 1147 (s), 1053 
(m), 1023 (m), 993 (m), 922 (s), 871 (s), 785 (s), 618 (m), 573 (s), 549 (m), 
522 (s) cm-1.  
 
[α]:   121 (c 0.63, EtOAc). 
 
 
 (1R,8S,9S)-3-Chloro-4,8,9-trimethoxy-1,8,9,10-tetrahydrocyclopentaindene 162 
 
trans-Diol 158 [M 252.69] 1.00 equiv. 772 µmol 195 mg 
KHMDS [0.5 M, toluene; 199.48] 2.20 equiv. 1.70 mmol 3.39 mL 
MeI [M 141.94; ρ 2.28] 4.00 equiv. 3.08 mmol 192 µL 
Under Ar-atmosphere diol 158 (195 mg, 772 µmol, 1.00 equiv.) was dissolved in THF 
(15 mL). At 0 °C KHMDS (3.39 mL, 1.70 mmol, 0.5 M in toluene, 2.20 equiv.) and MeI 
(192 µL, 3.08 mmol, 4.00 equiv.) were added and the mixture was stirred at this temperature 
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for 15 min. The reaction was quenched by the addition of H2O (15 mL), extracted with Et2O 
(3x20 mL), dried over Na2SO4, filtrated and concentrated in vacuo. After column 
chromatography (n-pentane/EtOAc 4:1) methylated compound 162 (150 mg, 534 µmol, 67%) 
was obtained as colorless oil. 
 
TLC:   Rf = 0.50 (n-pentane/EtOAc 4:1). 
 
1H-NMR:  500 MHz, CD3OD; δ = 2.50 (ddt, J = 1.2, 2.5, 18.5 Hz, 1 H, 10-HA), 2.87 (ddt, 
J = 2.0, 2.8, 18.5 Hz, 1 H, 10-HB), 3.28 (s, 3 H, OMe), 3.54 (s, 3 H, OMe), 3.84 
(s, 3 H, OMe), 4.09 (d, J = 2.1 Hz, 1 H, 1-H), 4.75 (s, 1 H, 8-H), 5.76 (ddt, 
J = 2.0, 2.5, 6.0 Hz, 1 H, 11-H), 6.19 (dtd, J = 2.1, 2.8, 6.0 Hz, 1 H, 12-H), 
6.95 (d, J = 8.3 Hz, 1 H, 5-H), 7.17 (d, J = 8.3 Hz, 1 H, 6-H) ppm.  
 
13C-NMR:  126 MHz, CD3OD; δ = 36.2 (C10), 51.8 (C1), 56.8 (OMe), 58.8 (OMe), 58.9 
(OMe), 90.2 (C8), 98.6 (C9), 112.8 (C5), 119.4 (Ar), 125.3 (C6), 130.5 (C12), 
131.7 (C11), 135.0 (Ar), 142.0 (Ar), 157.0 (Ar) ppm. 
HR-MS: (ESI+); m/z calc. for C15H17ClO3Na [M-Na]
+ 303.0758, found 303.0758. 
 
FT-IR:  (neat); ῦ = 3051 (w), 2935 (m), 2830 (w), 1607 (w), 1576 (w), 1480 (m), 1440 
(w), 1354 (w), 1324 (w), 1304 (w), 1274 (m), 1248 (w), 1195 (w), 1166 (w), 
1140 (w), 1091 (w), 1069 (s), 1016 (w), 984 (w), 952 (w), 910 (w), 874 (w), 
814 (w), 782 (w), 736 (w), 697 (w), 671 (w), 628 (w), 596 (w) cm-1. 
 
[α]:   117 (c 0.57, EtOAc). 
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 (8S,9S,12S)-11-Bromo-3-chloro-4,8,9-trimethoxy-8,9,10,11-tetrahydrocyclo-
pentaindene 165 
 
Olefin 162 [M 280.75] 1.00 equiv. 74.8 µmol 21.0 mg 
Bromine [0.26 M, CH2Cl2; M 159.81] 1.10 equiv. 82.5 µmol 317 µL 
KHMDS [0.5 M, toluene; 199.48] 3.80 equiv. 279 µmol 559 µL 
Under Ar-atmosphere olefin 162 (21.0 mg, 74.8 µmol, 1.00 equiv.) was dissolved in CH2Cl2 
(1 mL). At 0 °C Br2 (317 µL, 82.5 µmol, 0.26 M in CH2Cl2, 1.10 equiv.) was added and the 
mixture was stirred at this temperature for 30 min. Phosphate puffer solution (1.5 mL, pH = 7) 
was added and the excess of Br2 quenched by addition of 20% aq. Na2S2O3 (3 mL). The 
reaction mixture was extracted with CH2Cl2 (3x5 mL) and dried over Na2SO4. It was filtrated 
and all volatile compounds were removed in vacuo. Since the resulting dibromide 164 
decomposed upon purification the crude product was directly used for the next step. 
The crude dibromide 164 was dissolved in THF (0.5 mL) under Ar-atmosphere. At –78 °C 
KHMDS (559 µL, 279 µmol, 0.5 M in toluene, 3.80 equiv.) was added and the mixture was 
stirred at this temperature for 1 h. Sat. aq. NH4Cl (2 mL) was added, it was extracted with 
Et2O (3x5 mL), the combined org. layers were dried over Na2SO4, filtrated and concentrated 
under reduced pressure. After column chromatography (n-pentane/EtOAc 4:1) allyl 
bromide 165 (8.00 mg, 22.2 µmol, 30%) was obtained as colorless oil. 
 
TLC:   Rf = 0.23 (n-pentane/EtOAc 4:1).  
 
1H-NMR:  300 MHz, acetone-d6; δ = 2.66 (dd, J = 6.3, 14.4 Hz, 1 H, 10-HA), 2.84 (dd, 
J = 6.3, 14.4 Hz, 1 H, 10-HB), 3.14 (s, 3 H, OMe), 3.37 (s, 3 H, OMe), 3.94 
(s, 3 H, OMe), 4.25 (s, 1 H, 8-H), 5.69 (dt, J = 1.6, 6.3 Hz, 1 H, 11-H), 6.48 
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(d, J = 1.6 Hz, 1 H, 12-H), 7.09 (d, J = 8.3 Hz, 1 H, 5-H), 7.47 (d, J = 8.3 Hz, 
1 H, 6-H) ppm. 
 
13C-NMR:  75 MHz, acetone-d6: δ = 40.3 (C10), 51.5 (C11), 56.7 (OMe), 57.0 (OMe), 
57.0 (OMe), 57.8 (OMe), 83.2 (C8), 99.8 (C9), 113.5 (C5), 127.5 (C6), 130.0 
(C12), 134.9 (Ar), 141.8 (Ar), 147.9 (Ar), 157.0 (Ar) ppm.  
 
HR-MS: (ESI+); m/z calc. for C15H16ClO3 [M-H]
+ 279.0793, found 279.0782.  
 
FT-IR: (neat); ῦ = 3286 (m), 2925 (m), 2853 (w), 1604 (w), 1477 (m), 1432 (w), 1308 
(w), 1282 (m), 1189 (w), 1165 (w), 1141 (w), 1101 (w), 1066 (s), 1037 (w), 
975 (w), 891 (w), 817 (m), 789 (w), 721 (w), 697 (w), 669 (w) cm-1.  
 
The bromination/elimination sequence of 165 was performed using a racemic sample, 
therefore no measurement of optical rotation was done. 
 
 
 (1S,8S,9S,11S,12R)-3-Chloro-4,8,9-trimethoxy-1,8,9,10,11,12hexahydroben-
zo[1,8]pentaleno[11,12]oxirene 171 
 
Olefin 162 [M 280.75] 1.00 equiv. 594 µmol 150 mg 
DMDO [0.06 M, acetone; M 74.08] 1.80 equiv. 1.06 mmol 17.8 mL 
Under Ar-atmosphere olefin 162 (150 mg, 594 µmol, 1.00 equiv.) was dissolved in CH2Cl2 
(20 mL). At 0 °C freshly distilled DMDO (17.8 mL, 1.06 mmol, 0.06 M in acetone, 
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1.80 equiv.) was added and the mixture was stirred at rt for 2 h. All volatile compounds were 
removed in vacuo. After column chromatography (n-pentane/EtOAc 4:1) epoxide 171 
(126 mg, 428 µmol, 72%) was obtained as colorless oil. 
 
TLC:   Rf = 0.29 (n-pentane/EtOAc 4:1).  
 
1H-NMR:  300 MHz, C6D6; δ = 2.10 (d, J = 15.9 Hz, 1 H, 10-HA), 2.44 (dd, J = 2.4, 
15.9 Hz, 1 H, 10-HB), 2.95 (dd, J = 2.4, 2.4 Hz, 1 H, 11-H), 3.20 (s, 3 H, 
OMe), 3.22 (s, 3 H, OMe), 3.34 (s, 3 H, OMe), 3.93 (sbr, 1 H, 1-H), 4.02 
(d, J = 2.4 Hz, 1 H, 12-H), 4.69 (d, J = 1.0 Hz, 1 H, 8-H), 6.37 (d, J = 8.3 Hz, 
1 H, 5-H), 7.14 (dd, J = 1.0, 8.3 Hz, 1 H, 6-H) ppm.  
 
13C-NMR:  75 MHz, C6D6; δ = 31.4 (C10), 51.6 (OMe), 52.5 (C1), 55.6 (C12), 57.6 
(OMe), 57.8 (C11), 58.8 (OMe), 90.1 (C9), 97.7 (C8), 112.1 (C5), 124.2 (C6), 
127.8 (Ar), 135.0 (Ar), 137.8 (Ar), 156.8 (Ar) ppm.  
 
HR-MS: (ESI+); m/z calc. for C15H17ClO4Na [M-Na]
+ 319.0708, found 319.0707.  
 
FT-IR: (neat); ῦ = 2939 (m), 2833 (w), 1715 (w), 1605 (w), 1576 (w), 1480 (m), 1439 
(w), 1400 (w), 1355 (w), 1327 (w), 1307 (w), 1279 (m), 1251 (w), 1197 (w), 
1168 (w), 1139 (w), 1099 (w), 1068 (s), 982 (w), 951 (w), 912 (w), 873 (w), 
843 (m), 816 (w), 787 (w), 723 (w), 691 (w), 600 (w), 568 (w) cm-1.  
 
[α]:   24 (c 0.62, EtOAc). 
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 (1S,8S,9S,12R)-3-Chloro-4,8,9-trimethoxy-1,8,9,12-tetrahydrocyclopentainden-
12-ol 174 
 
Epoxide 171 [M 296.75] 1.00 equiv. 118 µmol 35.0 mg 
Diphenyl diselenide [M 312.13] 4.50 equiv. 531 µmol 165 mg 
NaBH4 [M 37.83] 8.80 equiv. 1.04 mmol 39.3 mg 
NaHCO3 [M 84.00] 6.00 equiv. 708 µmol 59.4 mg 
H2O2 [30wt%, aq.; M 34.02] 30.0 equiv. 3.53 mmol 361 µL 
Under Ar-atmosphere diphenyl diselenide (165 mg, 531 µmol, 4.50 equiv.) was dissolved in 
degassed EtOH (8 mL). At 0 °C NaBH4 (39.3 mg, 1.04 mmol, 8.80 equiv.) was added. After 
15 min the solution was added to epoxide 171 (35.0 mg, 118 µmol, 1.00 equiv.) and the 
mixture was stirred at 80 °C for 2 h. The reaction mixture was cooled to rt, THF (15 mL), 
NaHCO3 (59.4 mg, 708 µmol, 6.00 equiv.) and aq. H2O2 (361 µL, 3.53 mmol, 30%, 
30.00 equiv.) were added and the heating was continued for 25 min. Sat. aq. NH4Cl was 
added to quench the reaction, it was extracted with Et2O (3x15 mL), dried over Na2SO4, 
filtrated and all volatile compounds were removed in vacuo to yield allylic alcohol 174 
(25.0 mg, 84.2 µmol, 71%) as colorless oil after column chromatography 
(n-pentane/EtOAc 2:1). 
TLC:   Rf = 0.27 (n-pentane/EtOAc 2:1).  
 
1H-NMR:  300 MHz, C6D6; δ = 1.75 (sbr, 1 H, OH), 3.25 (s, 3 H, OMe), 3.27 (s, 3 H, 
OMe), 3.50 (s, 3 H, OMe), 3.53 (s, 1 H, 1-H), 4.66 (sbr, 1 H, 12-H), 4.94 (d, 
J = 1.1 Hz, 1 H, 8-H), 5.77 (dd, J = 2.4, 5.7 Hz, 1 H, 11-H), 5.84 (d, J = 5.7 Hz, 
1 H, 10-H), 6.36 (d, J = 8.3 Hz, 1 H, 5-H), 7.11 (dd, J = 1.1, 8.3 Hz, 1 H, 6-H) 
ppm. 
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13C-NMR:  75 MHz, C6D6; δ = 52.1 (OMe), 55.9 (C1), 58.7 (OMe), 59.0 (OMe), 80.8 
(C12), 91.9 (C8), 102.0 (C9), 112.2 (C5), 119.9 (Ar), 124.7 (C6), 132.8 (C10), 
135.2 (Ar), 137.4 (C11), 141.2 (Ar), 156.1 (Ar) ppm.  
 
HR-MS: (ESI+); m/z calc. for C15H17ClO4Na [M-Na]
+ 319.0708, found 319.0709.  
 
FT-IR: (neat); ῦ = 3433 (sbr), 2938 (w), 2830 (w), 2128 (w), 1716 (w), 1606 (w), 1577 
(m), 1481 (w), 1439 (w), 1357 (m), 1321 (s), 1277 (s), 1239 (m), 1193 (m), 
1171 (m), 1149 (m), 1089 (s), 1066 (s), 1036 (m), 1016 (m), 988 (w), 969 (w), 
949 (w), 907 (w), 808 (s), 788 (m), 754 (m), 714 (w), 602 (m), 540 (w), 513 
(w) cm-1.  
 
[α]:   129 (c 0.49, EtOAc). 
 
If the reaction sequence of reduction, methylation, epoxidation and GRIECO elimination was 
streamlined with the respective crude products 21.0 mg (32%) of allyl alcohol 174 could be 
obtained starting from tricyclic compound 155 (55.0 mg, 224 µmol). 
 
 (8S,9S)-3-Chloro-4,8,9-trimethoxy-8,9-dihydrocyclopentaindene 79 
 
 
Allyl alcohol 174 [M 296.75] 1.00 equiv. 43.8 µmol  13.0 mg 
PhNTf2 [357.25] 1.50 equiv. 65.7 µmol 23.5 mg 
KHMDS [0.5 M, toluene; 199.48] 2.50 equiv. 110 µmol 219 µL 
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Under Ar-atmosphere allylic alcohol 174 (13.0 mg, 43.8 µmol, 1.00 equiv.) was dissolved in 
THF (1 mL). At –78 °C KHMDS (219 µL, 110 µmol, 0.5 M in toluene, 2.50 equiv.) and 
PhNTf2 (23.5 mg, 65.7 µmol, 1.50 equiv.) were added. After stirring at this temperature for 
20 min the solution was quenched by the addition of H2O (2 mL), extracted with Et2O 
(3x3 mL), dried over Na2SO4 and filtrated. All volatiles were removed in vacuo to yield 
cyclopentadiene 79 (10.0 mg, 35.9 µmol, 82%) as colorless oil after column chromatography 
(n-pentane/EtOAc 4:1). 
 
TLC:   Rf = 0.50 (n-pentane/EtOAc 2:1).  
 
1H-NMR:  500 MHz, C6D6; δ = 3.00 (s, 3 H, OMe), 3.06 (s, 3 H, OMe), 3.22 (s, 3 H, 
OMe), 4.77 (s, 1 H, 8-H), 6.22 (d, J = 8.1 Hz, 1 H, 5-H), 6.27 (dd, J = 0.7, 
5.4 Hz, 1 H, 10-H), 6.29 (dd, J = 1.9, 5.4 Hz, 1 H, 11-H), 6.59 (d, J = 1.9 Hz, 
1 H, 12-H), 7.02 (d, J = 8.1 Hz, 1 H, 6-H) ppm.  
 
13C-NMR:  126 MHz, C6D6; δ = 51.3 (OMe), 55.4 (OMe), 55.9 (OMe), 85.8 (C8), 100.7 
(C9), 110.2 (C5), 118.4 (Ar), 126.1 (C6), 126.9 (C12), 135.2 (C10), 136.1 (Ar), 
138.1 (C11), 144.0 (Ar), 151.0 (C13), 156.5 (Ar) ppm.  
 
HR-MS:  (ESI+); m/z calc. for C15H15ClO3Na [M-Na]
+ 301.0602, found 301.0603.  
FT-IR:  (neat); ῦ = 3070 (w), 2933 (w), 2896 (w), 2824 (w), 1603 (w), 1563 (w), 1467 
(m), 1437 (w), 1337 (w), 1277 (m), 1195 (w), 1172 (w), 1091 (s), 1055 (w), 
1006 (w), 980 (w), 936 (w), 864 (w), 810 (w), 761 (w), 717 (w), 601 (w) cm-1.  
 
[α]:   126 (c 0.75, EtOAc). 
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8.3 Synthetic Procedures for Preparation of Oxathiazinane 192 
 
8.3.1 4-Allyl-2-chloro-6-methoxyphenol 175 
 
Eugenol (80) [M 164.20] 1.00 equiv. 50.0 mmol 7.65 mL 
CuCl2∙ 2 H2O [M 170.48] 0.13 equiv 6.25 mmol 1.08 g 
LiCl [M 42.39] 2.30 equiv. 112 mmol 4.25 g 
Under O2-atmosphere eugenol (80) (7.65 mL, 50.0 mmol, 1.00 equiv.) was dissolved in 
AcOH (125 mL), CuCl2∙2 H2O (1.08 g, 6.25 mmol, 0.13 equiv.) and LiCl (4.25 g, 112 mmol, 
2.30 equiv.) were added and the mixture was stirred at 80 °C for 6 h. Sat. aq. NaHCO3 
(100 mL) was added, the reaction mixture was extracted with Et2O (3x150 mL), the combined 
org. layers were dried over Na2SO4, filtrated and concentrated in vacuo. After column 
chromatography (n-pentane/EtOAc 8:1) 6-chloroeugenol 175 (8.43 g, 42.4 mmol, 85%) was 
isolated as pale-yellow oil.  
 
TLC:   Rf = 0.23 (n-pentane/EtOAc 8:1).  
1H-NMR:  300 MHz, CDCl3; δ = 3.29 (ddt, J = 0.7, 1.4, 6.7 Hz, 2 H, 1-H), 3.86 (s, 3 H, 
OMe), 5.04-5.07 (m, 1 H, 3-HA), 5.09-5.12 (m, 1 H, 3-HB), 5.78 (s, 1 H, 
ArOH), 5.91 (ddt, J = 6.7, 9.6, 17.5 Hz, 1 H, 2-H), 6.59 (s, 1 H, Ar), 6.77 
(s, 1 H, Ar) ppm. 
 
  The analytical data were in accordance with that reported in the literature.[112] 
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 (4-Allyl-2-chloro-6-methoxyphenoxy)(tert-butyl)dimethylsilane 176 
 
6-Chloroeugenol 175 [M 198.65] 1.00 equiv. 24.6 mmol 4.88 g 
TBSCl [M 150.72] 1.20 equiv. 29.5 mmol 4.44 g 
DMAP [M 122.17] 0.50 equiv. 12.3 mmol 1.50 g 
NEt3 [M 101.19; ρ 0.73] 1.30 equiv. 31.9 mmol 4.43 mL 
Under Ar-atmosphere 6-chloroeugenol 175 (4.88 g, 24.6 mmol, 1.00 equiv.) was dissolved in 
CH2Cl2 (100 mL). At 0 °C DMAP (1.50 g, 12.3 mmol, 0.50 equiv.), NEt3 (4.26 mL, 
31.9 mmol, 1.30 equiv.) and TBSCl (4.42 g, 29.5 mmol, 1.20 equiv.) were added and the 
mixture was stirred at rt for 4 h. The reaction mixture was diluted with CH2Cl2 (100 mL), 
washed with H2O (50 mL) and brine (50 mL) and was dried over Na2SO4. All volatiles were 
removed in vacuo. After column chromatography (n-pentane/EtOAc 40:1) TBS-protected 
chloroeugenol 176 (7.43 g, 23.7 mmol, 97%) was obtained as colorless oil.  
 
TLC:   Rf = 0.65 (n-pentane/EtOAc 40:1). 
 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.19 (s, 6 H, TBS), 1.04 (s, 9 H, TBS), 3.29 
(d, J = 6.7 Hz, 2 H, 1-H), 3.78 (s, 3 H, OMe), 5.04-5.13 (m, 2 H, 3-H), 5.93 
(ddt, J = 6.7, 9.6, 17.4 Hz, 1 H, 2-H), 6.57 (s, 1 H, Ar), 6.79 (s, 1 H, Ar) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = –4.0 (TBS), 19.0 (TBS), 26.1 (TBS), 39.8 (C1), 55.5 
(OMe), 110.7 (Ar), 116.4 (C3), 122.0 (Ar), 133.4 (Ar), 137.1 (C2), 151.5 (Ar) 
ppm. 
 
HR-MS:  (ESI+): m/z calc. for C16H25ClO2Na [M-Na]+ 564.1244, found 564.1249. 
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FT-IR: (neat): ῦ = 2937 (w), 1598 (w), 1572 (m), 1490 (s), 1461 (w), 1415 (m), 1273 
(m), 1235 (m), 1181 (w), 1140 (m), 1051 (s), 1001 (s), 968 (w), 913 (m), 837 
(m), 778 (m), 686 (m), 598 (w), 3078 (w), 3002 (w), 2830 (w), 1639 (w) cm-1. 
 
 3-(4-((tert-Butyldimethylsilyl)oxy)-3-chloro-5-methoxyphenyl)propanol 177 
 
TBS-protected 6-chloroeugenol 176 [M 312.91] 1.00 equiv. 23.7 mmol 7.43 g 
BH3•SMe [M 75.96; ρ 0.80] 1.00 equiv. 23.7 mmol 2.25 mL 
NaOH [15wt% aq.; M 40.00] 1.50 equiv. 35.6 mmol 8.20 mL 
H2O2 [30wt% aq.; M 34.02; ρ 1.11] 2.00 equiv. 47.4 mmol 4.90 mL 
Under Ar-atmosphere olefin 176 (7.43 g, 23.7 mmol, 1.00 equiv.) was dissolved in THF 
(120 mL). At 0 °C BH3∙SMe2 (2.25 mL, 23.7 mmol, 1.00 equiv.) was added, the mixture was 
stirred at this temperature for 10 min and at rt for 1 h. Aq. NaOH (8.20 mL, 35.6 mmol, 
15wt%, 1.50 equiv.) and aq. H2O2 (4.90 mL, 47.4 mmol, 30%, 2.00 equiv.) were added at 
0 °C and the reaction mixture was stirred for 2 h at rt. The reaction was quenched with brine 
(100 mL), extracted with Et2O (3x50 mL), dried over MgSO4 and concentrated in vacuo. 
After column chromatography (n-pentane/EtOAc 1:1) alcohol 177 (5.82 g, 17.6 mmol, 74%) 
was obtained as colorless oil. 
 
TLC:  Rf = 0.65 (EtOAc).
 
 
1H-NMR:  300 MHz, CDCl3; δ = 0.18 (s, 6 H, TBS), 1.03 (s, 9 H, TBS), 1.71 (s, 1 H, 
OH), 1.84 (dt, J = 6.4, 13.5 Hz, 2 H, 2-H), 2.60 (dd, J = 6.8, 8.6 Hz, 2 H, 3-H), 
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3.65 (t, J = 6.4 Hz, 2 H, 1-H), 3.77 (s, 3 H, OMe), 6.58 (d, J = 2.0 Hz, 1 H, Ar), 
6.77 (d, J = 2.0 Hz, 1 H, Ar) ppm. 
 
13C-NMR: 75 MHz, CDCl3; δ = –4.0 (TBS), 19.1 (TBS), 26.1 (TBS), 31.8 (C2), 34.2 
(C3), 55.5 (OMe), 62.2 (C1), 110.6 (Ar), 121.7 (Ar), 125.7 (Ar), 135.1 (Ar), 
139.9 (Ar), 151.5 (Ar) ppm. 
 
HR-MS:  (ESI+): m/z calc. for C16H28ClO3Si [M-H]
+ 331.1491, found 331.1502. 
 
FT-IR: (neat): ῦ = 3337 (w), 2931 (m), 2885 (w), 2857 (w), 1571 (w), 1495 (s), 1466 
(w), 1415 (w), 1391 (w), 1361 (w), 1321 (w), 1249 (s), 1187 (w), 1149 (m), 
1055 (s), 1010 (w), 906 (s), 837 (s), 804 (w), 782 (m), 738 (w), 695 (w), 660 
(w), 600 (w) cm-1. 
 
 3-(4-((tert-Butyldimethylsilyl)oxy)-3-chloro-5-methoxyphenyl)propyl sulfamate 
178 
 
Chlorosulfonyl isocyante 214 [M 141.53; ρ 1.63] 1.50 equiv. 26.4 mmol 0.99 mL 
Formic acid [M 46.04; ρ 1.22] 1.50 equiv. 26.4 mmol 2.29 mL 
Alcohol 177 [M 330.92] 1.00 equiv. 17.6 mmol 5.82 g 
Pyridine [M 79.10; ρ 0.98] 1.50 equiv. 26.4 mmol 2.13 mL 
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Under Ar-atmosphere formic acid (0.99 mL, 26.4 mmol, 1.50 equiv.) was added dropwise to 
neat chlorosulfonyl isocyanate (214) (2.29 mL, 26.4 mmol, 1.50 equiv.) at 0 °C. After 5 min 
of vigorous stirring, CH2Cl2 (15 mL) was added and the mixture was stirred at 0 °C for 1 h 
and at rt for 8 h. At 0 °C alcohol 177 (5.82 g, 17.6 mmol, 1.00 equiv.) and pyridine (2.13 mL, 
26.4 mmol, 1.50 equiv.) in CH2Cl2 (15 mL) were added dropwise. The reaction mixture was 
slowly warmed to rt and was stirred for 12 h. The mixture was diluted with EtOAc (60 mL), 
quenched with H2O (60 mL) and the layers were separated. The aq. layer was extracted with 
EtOAc (2x30 mL) and the combined org. layers were washed with brine (2x20 mL), dried 
over MgSO4 and concentrated under reduced pressure. After column chromatography 
(n-pentane/EtOAc 2:1) sulfamate 178 (5.80 g, 14.2 mmol, 80%) was isolated as colorless 
solid.  
 
TLC:   Rf = 0.48 (n-pentane/EtOAc 1:1).
 
 
1H-NMR: 300 MHz, CDCl3; δ = 0.18 (s, 6 H, TBS), 1.02 (s, 9 H, TBS), 2.01 (ddt, J = 4.9, 
7.3, 8.4 Hz, 2 H, 2-H), 2.63 (dd, J = 6.7, 8.4 Hz, 2 H, 3-H), 3.78 (s, 3 H, OMe), 
4.18 (t, J = 6.2 Hz, 2 H, 1-H), 6.58 (s, 1 H, Ar), 6.76 (s, 1 H, Ar) ppm. 
13C-NMR: 75 MHz, CDCl3; δ = –4.0 (TBS), 19.0 (TBS), 26.0 (TBS), 30.4 (C2), 31.1 
(C3), 55.5 (OMe), 70.4 (C1), 110.8 (Ar), 121.6 (Ar), 125.7 (Ar), 133.7 (Ar), 
 140.1 (Ar), 151.5 (Ar) ppm. 
 
HR-MS:  (ESI+): m/z calc. for C16H28ClNO5SSiNa [M-Na]+ 432.1038, found 432.1049.  
 
FT-IR: (neat): ῦ = 3282 (w), 2931 (m), 2895 (w), 2857 (w), 1570 (w), 1495 (s), 1466 
(w), 1416 (w), 1360 (m), 1324 (w), 1272 (w), 1249 (s), 1179 (s), 1149 (w), 
1054 (m), 1010 (w), 905 (m), 836 (m), 804 (w), 781 (s), 740 (w), 694 (w), 662 
(w), 593 (w), 662 (w) cm-1. 
 
m.p.:   46 °C (EtOAc). 
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 Iodosobenzene  
 
PhI(OAc)2 [M 322.10] 1.00 equiv. 20.0 mmol 6.44 g 
NaOH [3.0 M, aq.; M 40.00] 4.50 equiv. 90.0 mmol 40.0 mL 
Aq. NaOH (30.0 mL, 90.0 mmol, 3.0 M, 4.50 equiv.) was added to PhI(OAc)2 (6.44 g, 
20.0 mmol, 1.00 equiv.) under vigorous stirring over a period of 5 min and was afterwards 
stirred for 1 h at rt. H2O (40 mL) was added and the crude product was filtrated. The filter 
cake was washed with H2O (2x20 mL) and CHCl3 (15 mL) and dried in vacuo to give 
iodosobenzene (4.10 g, 18.6 mmol, 93%) as colorless solid.   
 
C6H5IO (22.01) calc.  C 32.76 H 2.29 
   found C 32.81 H 2.27  
 
 (S)-4-Methyl-N-(2-oxopiperidin-3-yl)benzenesulfonamide 191 
 
L-(+)-Ornithine hydrochloride 190 [M 168.62] 1.00 equiv. 25.0 mmol 4.21 g 
AcCl [M 78.50; ρ 1.10] 2.50 equiv. 62.5 mmol 4.46 mL 
NEt3 [M 101.19; ρ 0.73] 3.00 equiv. 75.0 mmol 10.4 mL 
TsCl [M 190.64] 1.20 equiv. 30.0 mmol 5.72 g 
Pyridine [M 79.10; ρ 0.98] 2.00 equiv. 50.0 mmol 4.04 mL 
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At 0 °C acetyl chloride (4.46 mL, 62.5 mmol, 2.50 equiv.) was added slowly to a solution of 
L-(+)-ornithine hydrochloride (190) (4.21 g, 25.0 mmol, 1.00 equiv.) in MeOH (100 mL). 
After 10 min the mixture was refluxed for 12 h. The reaction mixture was concentrated 
in vacuo and dried under high vacuum for 4 h. The colorless solid was dissolved in MeOH 
(100 mL), NEt3 (10.4 mL, 75.0 mmol, 3.00 equiv.) was added and the solution was refluxed 
for 2 h. All volatile compounds were removed under reduced pressure and the crude product 
was dried under high vacuum for further 3 h. The resulting solid was suspended in CH2Cl2 
(100 mL) and pyridine (4.04 mL, 50.0 mmol, 2.00 equiv.) was added. At 0 °C TsCl (5.72 g, 
30.0 mmol, 1.20 equiv.) was added, the mixture was slowly warmed to rt and stirred for 8 h. 
The crude product was concentrated under reduced pressure, dissolved in warm EtOAc 
(100 mL) and washed with sat. aq. NH4Cl (100 mL). The organic layer was dried over 
NaSO4, filtrated and concentrated in vacuo. After recrystallization from EtOAc lactam 191 
(1.67 g, 6.22 mmol, 25%) was obtained as colorless solid. 
 
TLC:   Rf = 0.48 (n-pentane/EtOAc 1:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 1.72-1.98 (m, 3 H, 4-HA, 5-H), 2.42 (s, 3 H, Me), 
2.46-2.53 (m, 1 H, 4-HB), 3.27-3.32 (m, 2 H, 6-H), 3.44-3.51 (m, 1 H, 3-H), 
5.67 (sbr, 1 H, TsNH), 5.82 (sbr, 1 H, NH), 7.31 (d, J = 8.0 Hz, 2 H, Ts), 7.78 
(d, J = 8.0 Hz, 2 H, Ts) ppm. 
 
  The analytical data were in accordance with that reported in the literature.[35] 
 
 Rh2(S-nap)4 185 
Rh2(OAc)4 [M 441.99] 1.00 equiv. 0.11 mmol 49.3 mg 
Lactam 191 [M 268.33] 8.00 equiv. 0.89 mmol 239 mg 
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Under Ar-atmosphere lactam 191 (239 mg, 0.89 mmol, 8.00 equiv.) and Rh2(OAc)4 (49.3 mg, 
0.11 mmol, 1.00 equiv.) were suspended in chlorobenzene (20 mL). The solvent was distilled 
off and replaced four times. The crude product was directly purified via column 
chromatography (CH2Cl2/MeCN 4:1). The resulting Rh2(S-nap)4 was dissolved in acetone 
(5 mL), concentrated under reduced pressure and dried in vacuo at 80 °C for 12 h to give 
catalyst 185 (73.0 mg, 57.1 µmol, 52%) as blue-green solid. 
 
TLC:   Rf = 0.19 (CH2Cl2/MeCN 4:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 1.22-1.61 (m, 14 H, 4-HA, 5-H), 1.84-1.91 (m, 2 H, 
4-HB), 2.39 (s, 6 H, Me), 2.43 (s, 6 H, Me), 2.93-3.34 (m, 12 H, 6-H, 3-H), 5.79 
(d, J = 2.7 Hz, 2 H, TsNH), 5.86 (d, J = 3.0 Hz, 2 H, TsNH), 7.32 (d, 
J = 7.8 Hz, 4 H, Ts), 7.40 (d, J = 7.8 Hz, 4 H, Ts), 7.68 (d, J = 8.4 Hz, 4 H, Ts), 
7.76 (d, J = 8.4 Hz, 4 H, Ts) ppm. 
 
  The analytical data were in accordance with that reported in the literature.[35] 
  (R)-4-(4-((tert-Butyldimethylsilyl)oxy)-3-chloro-5-methoxyphenyl)-1,2,3-oxathia-
zinane 2,2-dioxide 192 
 
Sulfamate 178 [M 409.11] 1.00 equiv. 235 µmol 96.3 mg 
Rh2(S-nap)4 [M 1279.14] 0.02 equiv. 4.70 µmol 6.00 mg 
Iodosobenzene [M 220.01] 1.30 equiv. 306 µmol 67.2 mg 
MgO [M 40.32] 2.00 equiv 470 µmol 19.0 mg 
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Under Ar-atmosphere sulfamate 178 (96.3 mg, 235 µmol, 1.00 equiv.), MgO (19.0 mg, 
470 µmol, 2.00 equiv.) and Rh2(S-nap)4 (6.00 mg, 4.70 µmol, 0.02 equiv.) were dissolved in 
CH2Cl2 (1 mL). Iodosobenzene (67.2 mg, 306 µmol, 1.30 equiv.) was added and the mixture 
was stirred at rt for 2 h. CH2Cl2 (3 mL) was added and the reaction mixture was filtrated 
through a pad of Celite. The crude product was concentrated in vacuo. After column 
chromatography (n-pentane/EtOAc 4:1) oxathiazinane 192 (35.0 mg, 85.8 µmol, 37%, 
83%ee) was isolated as colorless solid. 
 
TLC:   Rf = 0.33 (n-pentane/EtOAc 4:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 0.19 (s, 6 H, TBS), 1.02 (s, 9 H, TBS), 1.99 (ddd, 
J = 2.3, 4.2, 14.3 Hz, 1 H, 5-HA), 2.22 (dtd, J = 5.0, 12.4, 14.3 Hz, 1 H, 5-HB), 
3.82 (s, 3 H, OMe), 4.39 (d, J = 9.6 Hz, 1 H, NH), 4.64 (ddd, J = 1.7, 5.0, 
11.7 Hz, 1 H, 6-HA), 4.75 (ddd, J = 2.5, 9.0, 12.4 Hz, 1 H, 4-H), 4.85 (dd, 
J = 2.3, 11.7 Hz, 1 H, 6-HB), 6.78 (d, J = 2.2 Hz, 1 H, Ar), 6.91 (d, J = 2.2 Hz, 
1 H, Ar) ppm. 
 
13C-NMR: 75 MHz, CDCl3; δ = –3.9 (TBS), 19.0 (TBS), 26.0 (TBS), 30.1 (C5), 55.7 
(OMe), 58.6 (C4), 71.9 (C6), 108.6 (Ar), 119.7 (Ar), 126.2 (Ar), 131.1 (Ar), 
142.4 (Ar), 152.1 (Ar) ppm. 
 
HR-MS: (ESI+): m/z calc. for C24H32ClNO7SSiNa [M-Na]+ 564.1249, found 564.1248.  
 
FT-IR: (neat): ῦ = 3262 (w), 2931 (w), 2896 (w), 2857 (w), 1573 (w), 1500 (m), 1467 
(w), 1420 (w), 1360 (w), 1333 (w), 1306 (w), 1251 (m), 1188 (s), 1155 (w), 
1055 (m), 1022 (w), 988 (w), 909 (w), 884 (w), 870 (w), 840 (m), 782 (s), 742 
(w), 714 (w), 742 (w), 714 (w), 681 (w), 600 (w), 579 (w) cm-1. 
 
m.p.:   169 °C (EtOAc). 
 
HPLC:  (Chiralpac IC, n-hexane/EtOAc 9/1, 0.7 mL/min, 254 nm) tR(major) = 
31.1 min, tR(minor) = 21.9 min.  
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[α]D23   –7.3 (c 0.5, EtOAc, for a sample with 82%ee). 
 
Using Rh2(esp)2 
 
 
The peaks around 26.5 and 38.5 min belong to minor impurities of the non-chlorinated oxathiazinane  
Using Rh2(S-nap)4 under optimized conditions 
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 Benzyl (S)-4-(4-((tert-butyldimethylsilyl)oxy)-3-chloro-5-methoxyphenyl)-1,2,3-
oxathiazinane-3-carboxylate 2,2-dioxide 193 
 
Oxathiazinane 192 [M 407.98] 1.00 equiv. 90.0 µmol 36.7 mg 
KOt-Bu [M 112.21] 1.50 equiv. 135 µmol 15.1 mg 
CbzCl [M 170.60; ρ 1.20] 2.50 equiv. 225 µmol 32.0 µL 
 
Under Ar-atmosphere oxathiazinane 192 (36.7 mg, 90.0 µmol, 1.00 equiv.) was dissolved in 
THF (1.5 mL). KOt-Bu (15.1 mg, 135 µmol, 1.50 equiv.) was added and the mixture was 
stirred at rt for 1.5 h. Benzyl chloroformate (32.0 µL, 225 µmol. 2.50 equiv.) was added and 
the mixture was stirred at rt for 16 h. H2O (3 mL) was added to quench the reaction, it was 
extracted with EtOAc (3x2 mL), washed with brine (2 mL), dried over MgSO4 and filtrated. 
All volatiles were removed under reduced pressure. After column chromatography 
(n-pentane/CH2Cl2 1:1) Cbz-N-protected oxathiazinane 194 (45.0 mg, 83.0 µmol, 92%) was 
isolated as colorless oil.  
 
TLC:  Rf = 0.10 (n-pentane/CH2Cl2 1:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 0.19 (s, 6 H, TBS), 1.03 (s, 9 H, TBS), 2.40 (dddd, 
J = 2.3, 3.5, 6.2, 14.7 Hz, 1 H, 5-HA), 2.90 (dddd, J = 4.9, 7.4, 10.8, 14.7 Hz, 
1 H, 5-HB), 3.71 (s, 3 H, OMe), 4.46 (td, J = 6.2, 10.8 Hz, 1 H, 6-HA), 4.70 
(ddd, J = 2.3, 7.4, 10.8 Hz, 1 H, 6-HB), 5.32 (s, 2 H, Cbz), 5.64 (t, J = 5.6 Hz, 
1 H, 4-H), 6.78 (d, J = 2.2 Hz, 1 H, Ar), 6.91 (dd, J = 0.7, 2.2 Hz, 1 H, Ar), 
7.31-7.38 (m, 5 H, Ph) ppm. 
Experimental Procedures 
144 
 
 
13C-NMR: 75 MHz, CDCl3; δ = –3.9 (TBS), 19.0 (TBS), 26.0 (TBS), 28.5 (C5), 55.5 
(OMe), 60.4 (ArCN), 69.8 (C4), 70.1 (C6), 107.8 (Ar), 119.1 (Ar), 126.3 (Ar), 
128.0 (Ph), 128.7 (Ph), 128.8 (Ph), 130. 9 (Ar), 134.8 (Ph), 151.8 (Ar), 152.2 
(NCO2) ppm. 
 
HR-MS: (ESI+): m/z calc. for C24H32ClNO7SSiNa [M-Na]+ 564.1249, found 564.1248. 
 
FT-IR: (neat): ῦ = 3246 (s), 2943 (s), 2836 (m), 1601 (m), 1576 (s), 1496 (s), 1461 (s), 
1423 (s), 1362 (m), 1305 (m), 1286 (m), 1241 (s), 1187 (s), 1147 (s), 1053 (m), 
1023 (m), 993 (s), 922 (s), 871 (w), 785 (w), 618 (w), 573 (w), 549 (w), 522 
(w) cm-1. 
 
Oxathiazinane 193 was synthesized using racemic oxathiazinane 192, therefore no 
measurement of optical rotation was performed. 
 
 
8.3.2 5-Allyl-1-chloro-2,3-dimethoxybenzene 195 
 
6-Chloroeugenol 175 [M 198.65] 1.00 equiv. 5.28 mmol 1.05 g 
NaH [60wt%, mineral oil; M 24.00] 1.20 equiv. 6.34 mmol 290 mg 
MeI [M 141.94; ρ 2.28] 4.00 equiv. 21.1 mmol 1.50 mL 
Under Ar-atmosphere 6-chloroeugenol 175 (1.05 g, 5.28 mmol, 1.00 equiv.) was dissolved in 
DMF (100 mL). At 0 °C NaH (290 mg, 6.34 mmol, 1.20 equiv.) was added. After 15 min MeI 
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(1.50 mL, 21.1 mmol, 4.00 equiv.) was added and the mixture was stirred at rt for 16 h. The 
reaction was quenched with H2O (150 mL) and extracted with cyclohexane (3x40 mL), dried 
over Na2SO4, filtrated and concentrated in vacuo. After column chromatography 
(n-pentane/EtOAc 8:1) 5-allyl chloro-2,3-dimethoxybenzene 195 (1.12 g, 5.26 mmol, 99%) 
was isolated as colorless oil.  
 
TLC:  Rf = 0.55 (n-pentane/EtOAc 8:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 3.31 (dd, J = 1.4, 6.8 Hz, 2 H, 1-H), 3.84 (s, 3 H, OMe), 
3.86 (s, 3 H, OMe), 5.07-5.14 (m, 2 H, 3-H), 5.92 (ddt, J = 6.8, 9.6, 17.4 Hz, 
1 H, 2-H), 6.63 (d, J = 1.9 Hz, 1 H, Ar), 6.81 (d, J = 1.9 Hz, 1 H, Ar) ppm. 
 
13C-NMR:   75 MHz, CDCl3; δ = 39.9 (C1), 56.2 (OMe), 60.8 (OMe), 111.6 (Ar), 116.6 
(C3), 121.9 (Ar), 128.2 (Ar), 136.7 (C2), 143.9 (Ar), 153.8 (Ar) ppm.  
 
HR-MS: (ESI+): m/z calc. for C11H13ClO2Na [M-Na]+ 235.0496, found 235.0497. 
 
FT-IR: (neat): ῦ = 3078 (w), 3001 (w), 2934 (w), 2832 (w), 1681 (w), 1639 (w), 1598 
(w), 1572 (m), 1490 (s), 1459 (w), 1415 (m), 1273 (m), 1235 (m), 1182 (w), 
1140 (m), 1051 (s), 1001 (m), 968 (w), 913 (m), 837 (m), 777 (w), 745 (w), 
686 (w), 598 (w), 548 (w) cm-1. 
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 3-(3-Chloro-4,5-dimethoxyphenyl) propanol 196 
 
Olefin 195 [M 212.67] 1.00 equiv. 5.27 mmol 1.12 g 
9-BBN [0.5 M, THF; M 122.02] 1.05 equiv. 5.53 mmol 11.1 mL 
NaOH [15wt% aq.; M 40.00] 1.50 equiv. 7.90 mmol 1.80 mL 
H2O2 [30wt% aq.; M 34.02; ρ 1.11] 2.00 equiv. 10.5 mmol 1.08 mL 
Under Ar-atmosphere 5-allyl-1-chloro-2,3-dimethoxybenzene 195 (1.12 g, 5.27 mmol, 
1.00 equiv.) was dissolved in THF (20 mL). At 0 °C 9-BBN (11.1 mL, 5.53 mmol, 0.5 M in 
THF, 1.05 equiv.) was added and the mixture was stirred at 0 °C for 10 min and at rt for 1 h. 
15% aq. NaOH (1.80 mL, 7.90 mmol, 1.50 equiv.) and aq. H2O2 (1.08 mL, 10.5 mmol, 30%, 
2.00 equiv.) were added at 0 °C and the reaction mixture was stirred at rt for 2 h. The reaction 
was quenched with brine (40 mL), extracted with Et2O (3x20 mL), dried over MgSO4, 
filtrated and concentrated in vacuo. After column chromatography (n-pentane/EtOAc 1:1) 
alcohol 196 (1.05 g, 4.56 mmol, 87%) was obtained as colorless oil.  
 
TLC:  Rf = 0.30 (EtOAc).
 
 
1H-NMR: 300 MHz, CDCl3; δ = 1.82-1.91 (m, 2 H, 2-H), 2.65 (dd, J = 6.7, 8.7 Hz, 2 H, 
3-H), 3.67 (t, J = 6.4 Hz, 2 H, 1-H), 3.85 (s, 3 H, OMe), 3.86 (s, 3 H, OMe), 
6.58 (d, J = 2.0 Hz, 1 H, Ar), 6.77 (d, J = 2.0 Hz, 1 H, Ar) ppm. 
13C-NMR: 75 MHz, CDCl3; δ = 31.0 (C2), 34.1 (C3), 56.3 (OMe), 60.8 (OMe), 62.2 (C1), 
111.5 (Ar), 121.7 (Ar), 128.2 (Ar), 138.6 (Ar), 143.8 (Ar), 153.8 (Ar) ppm. 
 
HR-MS: (ESI+): m/z calc. for C11H15ClO3Na [M-Na]+ 253.0602, found 253.0603. 
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FT-IR: (neat): ῦ = 3387 (w), 3054 (w), 2939 (w), 2877 (w), 1599 (w), 1572 (m), 1491 
(m), 1457 (w), 1414 (m), 1307 (w), 1270 (m), 1234 (m), 1183 (w), 1141 (m), 
1049 (s), 1001 (m), 963 (w), 916 (w), 852 (m), 774 (w), 733 (s), 702 (w), 655 
(w), 610 (w), 573 (w), 512 (w), 472 (w) cm-1. 
 
 3-(3-Chloro-4,5-dimethoxyphenyl) propyl sulfamate 197 
 
Chlorosulfonyl isocyante 214 [M 141.53; ρ 1.63] 2.50 equiv. 19.8 mmol 1.72 mL 
Formic acid [M 46.04; ρ 1.22] 2.50 equiv. 19.8 mmol 0.75 mL 
Alcohol 205 [M 230.69] 1.00 equiv. 7.90 mmol 1.82 g 
Pyridine [M 79.10; ρ 0.98] 2.50 equiv. 19.8 mmol 1.59 mL 
 
Under Ar-atmosphere formic acid (0.75 mL, 19.8 mmol, 2.50 equiv.) was added dropwise to 
neat chlorosulfonyl isocyanate 214 (1.72 mL, 19.8 mmol, 2.50 equiv.) at 0 °C. After 5 min of 
vigorous stirring, CH2Cl2 (8 mL) was added and the mixture was stirred at 0 °C for 1 h and at 
rt for 8 h. At 0 °C alcohol 196 (1.82 g, 7.90 mmol, 1.00 equiv.) and pyridine (1.59 mL, 
19.8 mmol, 2.50 equiv.) in CH2Cl2 (10 mL) were added dropwise. The reaction mixture was 
slowly warmed to rt and was stirred for 12 h. The mixture was diluted with EtOAc (100 mL), 
quenched with H2O (100 mL) and the layers were separated. The aq. layer was extracted with 
EtOAc (3x50 mL) and the combined org. layers were washed with brine (2x20 mL), dried 
over MgSO4 and concentrated under reduced pressure. After column chromatography 
(n-pentane/EtOAc 2:1) sulfamate 197 (1.65 g, 5.40 mmol, 70%) was isolated as colorless oil.  
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TLC:   Rf = 0.33 (n-pentane/EtOAc 2:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 2.00-2.09 (m, 2 H, 2-H), 2.68 (t, J = 7.5 Hz, 2 H, 3-H), 
3.85 (s, 3 H, OMe), 3.86 (s, 3 H, OMe), 4.21 (t, J = 6.2 Hz, 2 H, 1-H), 4.74 (sbr, 
1 H, NH), 6.65 (d, J = 1.8 Hz, 1 H, Ar), 6.80 (d, J = 1.8 Hz, 1 H, Ar) ppm. 
 
13C-NMR: 75 MHz, CDCl3; δ = 30.4 (C2), 31.4 (C3), 56.3 (OMe), 60.8 (OMe), 70.4 (C1), 
111.7 (Ar), 121.7 (Ar), 128.3 (Ar), 137.2 (Ar), 144.1 (Ar), 154.0 (Ar) ppm. 
 
HR-MS: (ESI+): m/z calc. for C11H16ClNO5SNa [M-Na]+ 332.0330, found 332.0333.  
 
FT-IR: (neat): ῦ = 3361 (w), 3270 (w), 3106 (w), 2940 (w), 1599 (w), 1572 (m), 1492 
(m), 1459 (w), 1416 (w), 1360 (s), 1309 (w), 1277 (w), 1234 (w), 1176 (s), 
1141 (m), 1083 (w), 1048 (m), 996 (w), 927 (s), 818 (m), 777 (w), 734 (w), 
657 (w), 590 (w), 552 (s) cm-1. 
 
m.p.:   66 °C (EtOAc). 
 
 1-Butoxy-2-iodobenzene 215 
 
ortho-Iodophenol 199 [M 220.01] 1.00 equiv. 741 µmol 163 mg 
K2CO3 [M 138.20] 5.00 equiv. 3.70 mmol 512 mg 
n-BuBr [M 137.02; ρ 1.27] 1.50 equiv. 1.11 mmol 120 µL 
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Under Ar-atmosphere 2-iodophenol (199) (163 mg, 741 µmol, 1.00 equiv.) was dissolved in 
DMF (4 mL), K2CO3 (512 mg, 3.70 mmol, 5.00 equiv.) was added and the mixture was 
stirred at rt for 10 min. n-BuBr (120 µL, 1.11 mmol, 1.50 equiv.) was added and the reaction 
mixture was heated to 50 °C for 3 h. H2O (3 mL) was added to quench the reaction, it was 
extracted with CH2Cl2 (3x5 mL), the combined org. layer were dried over Na2CO3, filtrated 
and all volatile compounds were removed in vacuo. After column chromatography 
(n-pentane/EtOAc 20:1) ether 215 (189 mg, 685 µmol, 93%) was isolated as colorless oil.  
 
TLC:   Rf = 0.80 (n-pentane/EtOAc 2:1).
 
 
1H-NMR: 300 MHz, CDCl3; δ = 1.00 (t, J = 7.5 Hz, 3 H, Me), 1.56 (dq, J = 7.5, 14.5 Hz, 
2 H, n-Bu), 1.83 (tt, J = 6.3, 8.4 Hz, 2 H, n-Bu), 4.02 (t, J = 6.3 Hz, 2 H, 
On-Bu), 6.69 (td, J = 1.4, 7.5 Hz, 1 H, Ar), 6.80 (dd, J = 1.4, 8.2 Hz, 1 H, Ar), 
7.28 (ddd, J = 1.6, 7.5, 8.2 Hz, 1 H, Ar), 7.76 (dd, J = 1.6, 7.5 Hz, Ar) ppm. 
 
 The analytical data were in accordance with that reported in the literature.[144] 
 
 
 1-Butoxy-2-iodosobenzene 200 
 
n-Butoxy-2-iodbenzene 215 [M 276.12] 1.00 equiv. 684 µmol 189 mg 
DMDO [0.06 M, acetone; M 74.08] 3.50 equiv. 2.40 mmol 39.9 mL 
Under Ar-atmosphere ether 215 (189 mg, 684 µmol, 1.00 equiv.) was dissolved in CH2Cl2 
(4 mL). At 0 °C DMDO (39.4 mL, 2.40 mmol, 0.06 M in acetone, 3.50 equiv.) was added and 
the mixture was stirred at rt for 12 h. It was filtrated, Et2O (15 mL) was added to the filtrate 
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and it was filtrated again. The precipitates were combined, washed with Et2O (2x10 mL) and 
dried under reduced pressure to give 200 (157 mg, 409 µmol, 75%) as colorless solid.   
 
1H-NMR: 300 MHz, CDCl3; δ = 0.99 (t, J = 7.3 Hz, 3 H, Me), 1.50 (dq, J = 7.3, 14.5 Hz, 
2 H, n-Bu), 1.84 (tt, J = 6.6, 14.5 Hz, 2 H, n-Bu), 4.17 (t, J = 6.6 Hz, 2 H, 
On-Bu), 7.04 (dd, J = 1.0, 8.2 Hz, 1 H, Ar), 7.24-7.30 (m, 1 H, Ar), 7.59 (ddd, 
J = 1.6, 7.4, 8.6 Hz, 1 H, Ar), 7.98 (dd, J = 1.6, 7.9 Hz, Ar) ppm. 
 
 The analytical data were in accordance with that reported in the literature.[143] 
 
 
 (R)-4-(3-chloro-4,5-dimethoxyphenyl)-1,2,3-oxathiazinane 2,2-dioxide 198 
 
Sulfamate 197 [M 309.76] 1.00 equiv. 646 µmol 200 mg 
Rh2(S-nap)4 [M 1279.14] 0.02 equiv. 12.9 µmol 16.5 mg 
Iodosobenzene [M 220.01] 1.10 equiv. 710 µmol 156 mg 
MgO [M 40.32] 2.00 equiv 1.29 mmol 52.1 mg 
Under Ar-atmosphere sulfamate 197 (200 mg, 646 µmol, 1.00 equiv.), MgO (52.1 mg, 
1.29 mmol, 2.00 equiv.) and Rh2(S-nap)4 (16.5 mg, 12.9 µmol, 0.02 equiv.) were dissolved in 
CH2Cl2 (5 mL). Iodosybenzene (156 mg, 710 µmol, 1.10 equiv.) was added and the mixture 
was stirred at rt for 3 h. CH2Cl2 (10 mL) was added and the reaction mixture was filtered 
through a pad of Celite. The crude product was concentrated in vacuo. After column 
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chromatography (n-pentane/EtOAc 2:1) oxathiazinane 198 (119 mg, 387 µmol, 60%, 88% ee) 
was isolated as colorless solid.  
 
TLC:      Rf = 0.28 (n-pentane/EtOAc 2:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 2.02 (ddd, J = 2.3, 2.5, 14.4 Hz, 1 H, 5-HA), 2.22 (ddt, 
J = 5.0, 12.5, 14.4 Hz, 1 H, 5-HB), 3.86 (s, 3 H, OMe), 3.88 (s, 3 H, OMe), 4.40 
(d, J = 9.3 Hz, 1 H, NH), 4.66 (ddd, J = 1.7, 5.0, 11.7 Hz, 1 H, 6-HA), 4.78 
(ddd, J = 2.5, 9.3, 12.5 Hz, 1 H, 4-H), 4.85 (dd, J = 2.3, 11.7 Hz, 1 H, 6-HB), 
6.82 (d, J = 2.0 Hz, 1 H, Ar), 6.93 (d, J = 2.0 Hz, 1 H, Ar) ppm. 
 
13C-NMR:  75 MHz, CDCl3; δ = 29.9 (C5), 56.4 (OMe), 58.3 (C4), 60.9 (OMe), 71.8 (C6), 
109.5 (Ar), 119.6 (Ar), 128.8 (Ar), 134.6 (Ar), 145.7 (Ar), 154.3 (Ar) ppm. 
 
HR-MS:  (ESI+): m/z calc. for C11H14ClNO5SNa [M-Na]+ 330.0173, found 330.0171.  
 
FT-IR: (neat): ῦ = 3246 (w), 2943 (w), 2836 (w), 1601 (w), 1576 (w), 1496 (w), 1461 
(w), 1423 (m), 1362 (m), 1305 (w), 1286 (w), 1241 (w), 1187 (s), 1147 (w), 
1053 (m), 1023 (w), 993 (m), 922 (w), 871 (w), 785 (m), 618 (w), 573 (w), 549 
(w), 522 (w) cm-1.  
 
HPLC:  (Chiralpac IC, n-hexane/EtOAc 3/2, 0.7 mL/min, 277 nm) tR(major) = 
27.1 min, tR(minor) = 18.3 min.  
 
[α]D23     –6.4 (c 0.6, EtOAc, for a sample with 88% ee). 
 
m.p.:   66 °C (EtOAc). 
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Using Rh2(esp)2 
 
 
Using Rh2(S-nap)4 under optimized conditions 
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 Benzyl 4-(3-chloro-4,5-dimethoxyphenyl)-1,2,3-oxathiazinane-3-carboxylate 2,2-
dioxide 201 
 
Oxathiazinane 198 [M 407.98] 1.00 equiv. 4.87 mmol 1.50 g 
KOt-Bu [M 112.21] 1.50 equiv. 7.31 mmol 820 mg 
CbzCl [M 170.60; ρ 1.20] 2.50 equiv. 12.2 mmol 1.73 mL 
Under Ar-atmosphere oxathiazinane 198 (1.50 g, 4.87 mmol, 1.00 equiv.) was dissolved in 
THF (120 mL). KOt-Bu (820 mg, 7.31 mmol, 1.50 equiv.) was added and the mixture was 
stirred at rt for 1.5 h. Benzyl chloroformate (1.73 mL, 12.2 mmol. 2.50 equiv.) was added and 
the mixture was stirred at rt for 12 h. H2O (100 mL) was added to quench the reaction and it 
was extracted with EtOAc (3x30 mL), washed with brine (20 mL), dried over MgSO4, 
filtrated and all volatile compounds were removed under reduced pressure. After column 
chromatography (n-pentane/CH2Cl2 2:1) Cbz-N-protected oxathiazinane 201 (1.75 g, 
3.96 mmol, 82%) was isolated as colorless oil.  
 
TLC:  Rf = 0.17 (n-pentane/CH2Cl2 2:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 2.33 (dddd, J = 2.3, 3.5, 6.2, 14.7 Hz, 1 H, 5-HA), 2.82 
(dddd, J = 5.0, 7.3, 10.9, 14.7 Hz, 1 H, 5-HB), 3.70 (s, 3 H, OMe), 3.77 (s, 3 H, 
OMe), 4.38 (td, J = 6.2, 10.9 Hz, 1 H, 6-HA), 4.61 (ddd, J = 2.3, 7.3, 9.9 Hz, 
1 H, 6-HB), 5.24 (s, 2 H, Cbz), 5.56 (t, J = 4.2 Hz, 1 H, 4-H), 6.76 
(d, J = 2.2 Hz, 1 H, Ar), 6.85 (d, J = 2.2 Hz, 1 H, Ar) ppm. 
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13C-NMR: 75 MHz, CDCl3; δ = 28.2 (C5), 56.2 (OMe), 60.3 (C4), 60.8 (OMe), 69.9 
(Cbz), 70.1 (C6), 108.6 (Ar), 118.9 (Ar), 128.0 (Ph), 128.7 (Ph), 128.8 (Ph), 
128.9 (Ar), 134.4 (Ar), 134.7 (Ph), 145.0 (Ar), 152.1 (Ar), 154.2 (NCO2) ppm. 
 
HR-MS: (ESI+): m/z calc. for C19H20ClNO7SNa [M-Na]+ 464.0541, found 464.0542. 
 
FT-IR: (neat): ῦ = 2942 (w), 2834 (2), 1734 (s), 1600 (w), 1573 (w), 1494 (m), 1457 
(m), 1383 (s), 1274 (s), 1241 (m), 1177 (s), 1142 (m), 1095 (w), 1045 (m), 998 
(s), 971 (s), 933 (m), 884 (w), 855 (w), 786 (m), 760 (m), 743 (m), 697 (m), 
666 (m), 596 (m), 570 (m), 477 (w) cm-1. 
 
m.p.:   109 °C (EtOAc). 
 
Oxathiazinane 201 was synthesized using racemic oxathiazinane 198, therefore no 
measurement of optical rotation was performed. 
 
 
 
 
 
 
 
 
 
 
Experimental Procedures 
155 
 
 3-(((Benzyloxy)carbonyl)amino)-3-(3-chloro-4,5-dimethoxyphenyl)propanoic acid 
203 
 
Oxathiazinane 201 [M 441.88] 1.00 equiv. 679 µmol 300 mg 
TEMPO [M 156.25] 0.09 equiv. 58.4 µmol 9.10 mg 
Na2HPO4•12 H2O [M 358.14] 1.40 equiv. 950 µmol 340 mg 
NaOCl [M 74.44; 12wt%] 0.02 equiv. 13.6 µmol 6.90 µL 
NaClO2 [M 90.44] 2.00 equiv. 1.36 mmol 123 mg 
Na2SO3 [M 126.04] 2.40 equiv. 1.63 mmol 205 mg 
Cbz-protected oxathiazinane 201 (300 mg, 679 µmol, 1.00 equiv.) was dissolved in 
MeCN/H2O (6 mL, 4:3) and the mixture was stirred at 70 °C for 16 h. The mixture was 
cooled to 35 °C and Na2HPO4∙12 H2O (340 mg, 950 µmol, 1.40 equiv.) was added to reach 
pH~4. TEMPO (9.10 mg, 58.4 µmol, 0.09 equiv.) was added, aq. NaOCl (6.90 µL, 
13.6 µmol, 12wt%, 0.02 equiv.) and NaClO2 (123 mg, 1.36 mmol, 2.00 equiv.) were added in 
7 portions over 3 h and the mixture was stirred at this temperature for 3 d. Aq. NaOH (2.0 M) 
was added to reach pH~8, aq. Na2SO3 (205 mg, 1.63 mmol, 2.40 equiv.) was added and 
stirring was continued at rt for 30 min. The reaction mixture was washed with EtOAc 
(10 mL), the pH was adjusted to ~3 by addition of HCl (1.0 M) and the layers were separated. 
The aq. layer was extracted with EtOAc (3x15 mL), the combined org. layers were washed 
with H2O (2x10 mL) and brine (15 mL), dried over MgSO4, filtrated and concentrated 
in vacuo to yield amino acid 203 (179 mg, 471 µmol, 70%) as colorless solid. 
 
TLC:  Rf = 0.29 (CH2Cl2/EtOAc:AcOH 100:20:1). 
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1H-NMR: 300 MHz, DMSO-d6; δ = 2.65 (d, J = 8.2 Hz, 2 H, 2-H), 3.72 (s, 3 H, OMe), 
3.81 (s, 3 H, OMe), 4.90 (q, J = 7.7 Hz, 1 H, 3-H), 5.00 (sbr, 2 H, Cbz), 6.96 (d, 
J = 2.0 Hz, 1 H, Ar), 7.02 (d, J = 2.0 Hz, 1 H, Ar), 7.26-7.38 (m, 5 H, Ph), 
12.29 (sbr, 1 H, CO2H) ppm.
 
 
13C-NMR: 75 MHz, DMSO-d6; δ = 41.1 (C2), 51.3 (C3), 56.0 (OMe), 60.1 (OMe), 65.3 
(Cbz), 110.2 (Ar), 118.2 (Ar), 126.5 (Ar), 127.6 (Ph), 127.7 (Ph), 128.3 (Ph), 
137.0 (Ar), 139.8 (Ph), 143.5 (Ar), 153.3 (Ar), 155.3 (NCO2), 171.4 (CO2H) 
ppm. 
 
HR-MS: (ESI+): m/z calc. for C19H20ClNO6Na [M-Na]+ 416.0871, found 416.0883. 
 
FT-IR: (neat); ῦ = 3322 (w), 2940 (w), 2833 (w), 2483 (w), 2072 (w), 1692 (s), 1599 
(m), 1574 (m), 1531 (s), 1492 (s), 1453 (s), 1414 (m), 1341 (s), 1271 (s), 1233 
(s), 1180 (m), 1139 (m), 1044 (s), 997 (m), 909 (w), 848 (m), 774 (m), 738 (m), 
696 (m), 666 (m), 581 (m), 466 (w) cm-1. 
 
m.p.:   177-178 °C (EtOAc, decomposition). 
 
Amino acid 203 was synthesized using racemic oxathiazinane 201, therefore no measurement 
of optical rotation was performed. 
 
If only the ring opening was performed without oxidation amino alcohol 202 was obtained. 
 
Benzyl (1-(3-chloro-4,5-dimethoxyphenyl)-3-hydroxypropyl)carbamate 202 
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TLC:  Rf = 0.16 (CH2Cl2/EtOAc 5:1). 
 
1H-NMR: 300 MHz, MeOD-d4; δ = 3.60 (ddq, J = 6.0, 11.0, 16.8 Hz, 2 H, 2-H), 3.82 (s, 
6 H, OMe), 3.88 (s, 2 H, 3-H), 4.76 (t, J = 7.4 Hz, 1 H, 1-H), 5.10 (sbr, 2 H, 
Cbz), 6.96-6.98 (m, 2 H, Ar), 7.33-7.36 (m, 5 H, Ph) ppm. 
 
13C-NMR: 75 MHz, MeOD-d4; δ = 40.2 (C2), 53.3 (C1), 56.6 (OMe), 59.5 (C3), 60.9 
(OMe), 67.5 (Cbz), 110.8 (Ar), 120.5 (Ar), 128.6 (Ar), 128.7 (Ph), 129.0 (Ph), 
129.4 (Ph), 138.4 (Ar), 141.8 (Ph), 145.4 (Ar), 155.2 (Ar), 158.2 (NCO2) ppm. 
 
HR-MS: (ESI+): m/z calc. for C19H22ClNO5Na [M-Na]+ 402.1079, found 402.1089. 
 
FT-IR: (neat); ῦ = 3328 (w), 2940 (w), 2881 (w), 1691 (s), 1574 (w), 1517 (w), 1493 
(m), 1455 (w), 1420 (w), 1342 (w), 1237 (m), 1136 (w), 1049 (s), 1000 (w), 
899 (w), 853 (w), 740 (w), 698 (m), 654 (w), 584 (w), 457 (w), 421 (w) cm-1. 
 
Amino alcohol 202 was synthesized using racemic oxathiazinane 201, therefore no 
measurement of optical rotation was performed. 
 
 (R)-1-(4-(3-Chloro-4,5-dimethoxyphenyl)-2,2-dioxido-1,2,3-oxathiazinan-3-yl)-
ethan-1-one 204 
 
Oxathiazinane 198 [M 407.98] 1.00 equiv. 260 µmol 80.0 mg 
KOt-Bu [M 112.21] 1.50 equiv. 390 µmol 43.8 mg 
AcCl [M 78.40; ρ 1.10] 2.50 equiv. 650 µmol 46.2 µL 
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Under Ar-atmosphere oxathiazinane 198 (80.0 mg, 260 µmol, 1.00 equiv.) was dissolved in 
THF (5 mL). KOtBu (43.8 mg, 390 µmol, 1.50 equiv.) was added and the mixture was stirred 
at rt for 1.5 h. Acetyl chloride (46.2 µL, 650 µmol, 2.50 equiv.) was added and the mixture 
was stirred at rt for 12 h. H2O (10 mL) was added to quench the reaction, it was extracted 
with EtOAc (3x10 mL), washed with brine (10 mL), dried over MgSO4 and all volatile 
compounds were removed under reduced pressure. After column chromatography 
(n-pentane/EtOAc 2:1) N-acetylated oxathiazinane 204 (76.0 mg, 217 µmol, 84%) was 
isolated as colorless oil.  
 
TLC:   Rf = 0.20 (n-pentane/CH2Cl2 2:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 2.47 (dddd, J = 2.3, 3.5, 6.2, 14.7 Hz, 1 H, 5-HA), 2.59 
(s, 3 H, Me), 2.87 (dddd, J = 4.6, 7.4, 10.8, 14.7 Hz, 1 H, 5-HB), 3.85 (s, 3 H, 
OMe), 3.86 (s, 3 H, OMe), 4.51 (td, J = 6.2, 10.8 Hz, 1 H, 6-HA), 4.73 (ddd, 
J = 2.3, 7.4, 10.8 Hz, 1 H, 6-HB), 5.89 (t, J = 4.6 Hz, 1 H, 4-H). 6.80 (d, 
J = 2.1 Hz, 1 H, Ar), 6.94 (dd, J = 0.8, 2.1 Hz, 1 H, Ar) ppm. 
 
13C-NMR: 75 MHz, CDCl3; δ = 24.8 (Me), 28.2 (C5), 56.3 (OMe), 57.7 (C4), 60.8 (OMe), 
70.9 (C6), 108.9 (Ar), 119.3 (Ar), 128.9 (Ar), 134.3 (Ar), 145.2 (Ar), 154.2 
(Ar), 168.6 (CO) ppm. 
 
FT-IR: (neat): ῦ = 2942 (w), 2837 (w), 1705 (s), 1601 (w), 1574 (w), 1495 (w), 1462 
(w), 1417 (w), 1372 (s), 1262 (s), 1177 (s), 1144 (w), 1113 (w), 1047 (m), 988 
(s), 958 (w), 924 (m), 888 (w), 790 (s), 731 (m), 683 (w), 646 (w), 583 (s), 543 
(w), 506 (w), 479 (w), 434 (w) cm-1. 
 
HR-MS: (ESI+): m/z calc. for C13H16ClNO6SNa [M-Na]+ 372.0279, found 372.0290. 
 
m.p.:   102 °C (EtOAc). 
 
[α]D23   20 (c 0.55, EtOAc). 
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 (R)-3-acetamido-3-(3-chloro-4,5-dimethoxyphenyl)propanoic acid 206 
 
Oxathiazinane 204 [M 349.78] 1.00 equiv. 198 µmol 69.3 mg 
TEMPO [M 156.25] 0.09 equiv. 17.0 µmol 2.60 mg 
Na2HPO4•12 H2O [M 358.14] 1.40 equiv. 277 µmol 38.3 mg 
NaOCl [M 74.44; 12wt%] 0.02 equiv. 4.00 µmol 2.01 µL 
NaClO2 [M 90.44] 2.00 equiv. 396 µmol 35.8 mg 
Na2SO3 [M 126.04] 2.40 equiv. 475 µmol 59.7 mg 
Acetylated oxathiazinane 204 (69.3 mg, 198 µmol, 1.00 equiv.) was dissolved in MeCN/H2O 
(1.2 mL, 4:3) and the mixture was stirred at 50 °C for 4 h. The mixture was cooled to 35 °C 
and Na2HPO4∙12 H2O (38.3 mg, 277 µmol, 1.40 equiv.) was added to reach pH~4. TEMPO 
(2.60 mg, 17.0 µmol, 0.09 equiv.) was added, aq. NaOCl (2.01 µL, 4.00 µmol, 12wt%, 
0.02 equiv.) and NaClO2 (35.8 mg, 396 µmol, 2.00 equiv.) were added in 7 portions over 3 h 
and the mixture was stirred at this temperature for 24 h. Aq. NaOH (2.0 M) was added to 
reach pH~8, aq. Na2SO3 (59.7 mg, 475 µmol, 2.40 equiv.) was added and stirring was 
continued at rt for 30 min. The reaction mixture was washed with EtOAc (10 mL), the pH 
was adjusted to ~3 by addition of HCl (1.0 M) and the layers were separated. The aq. layer 
was extracted with EtOAc (3x15 mL), the combined org. layers were washed with H2O 
(2x10 mL) and brine (15 mL), dried over MgSO4, filtrated and concentrated in vacuo to yield 
amino acid 206 (50.1 mg, 166 µmol, 83%) as colorless solid. 
 
TLC:  Rf = 0.29 (CH2Cl2/MeOH/AcOH 100:20:1). 
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1H-NMR: 300 MHz, DMSO-d6; δ = 1.82 (s, 3 H, Me), 2.65 (d, J = 7.4 Hz, 2 H, 2-H), 3.71 
(s, 3 H, OMe), 3.82 (s, 3 H, OMe), 5.11 (q, J = 7.6 Hz, 1 H, 3-H), 6.93 (d, 
J = 2.0 Hz, 1 H, Ar), 6.99 (d, J = 2.0 Hz, 1 H, Ar), 8.34 (d, J = 8.4 Hz, 1 H, 
NH), 12.17 (sbr, 1 H, CO2H) ppm. 
 
300 MHz, MeOD-d4; δ = 2.00 (s, 3 H, Me), 2.81 (dd, J = 4.6, 7.4 Hz, 2 H, 
2-H), 3.83 (s, 3 H, OMe), 3.92 (s, 3 H, OMe), 5.30 (t, J = 7.4 Hz, 1 H, 3-H), 
7.02 (sbr, 1 H, Ar) ppm.
 
 
13C-NMR: 75 MHz, MeOD-d4; δ = 22.6 (Me), 41.4 (C2), 51.2 (C3), 56.7 (OMe), 60.9 
(OMe), 111.3 (Ar), 120.7 (Ar), 129.0 (Ar), 139.9 (Ar), 145.8 (Ar), 155.2 (Ar), 
171.4 (NAc), 173.8 (CO2H) ppm. 
 
HR-MS: (ESI+): m/z calc. for C13H16ClNO5Na [M-Na]+ 324.0609, found 324.0617. 
 
FT-IR: (neat); ῦ = 2939 (s), 2836 (w), 2470 (w), 1718 (m), 1620 (s), 1575 (w), 1491 
(w), 1461 (w), 1418 (s), 1278 (s), 1236 (w), 1181 (w), 1143 (m), 1049 (s), 1000 
(s), 911 (w), 851 (m), 778 (w), 669 (w), 628 (w), 492 (w) cm-1. 
 
m.p.:   174 °C (EtOAc). 
 
[α]D23   26 (c 0.6, EtOAc). 
 
If only the ring opening was performed without oxidation amino alcohol 205 was obtained as 
pale-yellow oil. 
 
N-(1-(3-Chloro-4,5-dimethoxyphenyl)-3-hydroxypropyl)acetamide 205 
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TLC:  Rf = 0.59 (CH2Cl2/MeOH/AcOH 100:20:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 1.82 (ddt, J = 3.5, 10.0, 13.4 Hz, 2 H, 2-H), 2.05 (s, 3 H, 
Me), 3.60-3.76 (m, 2 H, 3-H), 3.85 (s, 3 H, OMe), 3.87 (s, 3 H, OMe), 5.13 (td, 
J = 3.9, 9.1 Hz, 1 H, 1-H), 6.04 (sbr, 1 H, NH), 6.75 (d, J = 2.1 Hz, 1 H, Ar), 
6.91 (d, J = 2.1 Hz, 1 H, Ar) ppm. 
 
13C-NMR: 75 MHz, CDCl3; δ = 23.4 (Me), 38.4 (C2), 50.8 (C3), 56.4 (OMe), 59.0 (OMe), 
60.8 (C1), 110.3 (Ar), 119.5 (Ar), 119.6 (Ar), 138.4 (Ar), 144.9 (Ar), 154.1 
(Ar), 170.9 (CO) ppm. 
 
HR-MS: (ESI+): m/z calc. for C13H18ClNO4Na [M-Na]+ 310.0817, found 310.0824. 
 
FT-IR: (neat); ῦ = 3246 (s), 2943 (s), 2836 (s), 1601 (s), 1576 (m), 1496 (m), 1461 
(m), 1423 (m), 1362 (m), 1305 (s), 1286 (m), 1241 (m), 1187 (m), 1147 (m), 
1053 (m), 1023 (s), 993 (m), 922 (s), 871 (m), 785 (s), 618 (m), 573 (m), 549 
(m), 522 (s) cm-1. 
 
Amino alcohol 205 was synthesized using racemic oxathiazinane 204, therefore no 
measurement of optical rotation was performed. 
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 (R)-3-acetamido-3-(3-chloro-4,5-bis((triethylsilyl)oxy)phenyl)propanoic acid 59 
 
Amino acid 206 [M 301.72] 1.00 equiv. 67.0 µmol 20.2 mg 
AlBr3 [M 266.69] 8.00 equiv. 536 µmol 143 mg 
EtSH [M 62.14; ρ 0.84] 70.00 equiv. 4.69 mmol 347 µL 
TESCl [M 150.72; ρ 0.90] 7.50 equiv. 503 µmol 84.3 µL 
NEt3 [M 101.19; ρ 0.73] 8.00 equiv. 536 µmol 74.7 µL 
DMAP [M 122.17] 0.15 equiv. 10.0 µmol 1.20 mg 
Under Ar-atmosphere amino acid 206 (20.2 mg, 67.0 µmol, 1.00 equiv.) was suspended in 
CH2Cl2 (0.3 mL) and added to a solution of AlBr3 (143 mg, 536 µmol, 8.00 equiv.) in EtSH 
(347 µL, 4.69 mmol, 70.00 equiv.) at 0 °C. The mixture was warmed to rt and stirred for 24 h 
at this temperature. It was quenched by the addition of 1.0 M HCl (0.3 mL) and diluted with 
EtOAc (0.5 mL). NaCl was added to saturate the aq. layer and it was extracted with EtOAc 
(5x10 mL). The combined org. layers were dried over Na2SO4, filtrated and all volatile 
compounds were removed in vacuo to yield crude amino acid 81 (18.0 mg), which was 
directly used for the next step without further purification. 
Under Ar-atmosphere crude amino acid 81, NEt3 (74.7 µL, 536 µmol, 8.00 equiv.) and 
DMAP (1.20 mg, 10.0 µmol, 0.15 equiv.) were dissolved in DMF (0.4 mL). At 0 °C TESCl 
(84.3 µL, 503 µmol, 7.50 equiv.) was added and the mixture was stirred at rt for 8 h. Sat. aq. 
NH4Cl was added to quench the reaction, it was extracted with Et2O (3x7 mL), the combined 
layers were washed with brine (5 mL), dried over Na2SO4 and all volatile compounds were 
removed in vacuo. After column chromatography (CH2Cl2/MeOH/AcOH 100:2:1) 
TES-protected amino acid 59 (23.0 mg, 45.8 µmol, 68%) was isolated as colorless oil.  
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TLC:  Rf = 0.11 (CH2Cl2/MeOH:AcOH 100:2:1). 
 
1H-NMR: 300 MHz, CDCl3; δ = 0.72-0.80 (m, 12 H, TES), 0.96 (td, J = 6.0, 7.8 Hz, 1 H, 
TES), 2.03 (s, 3 H, Me), 2.80 (dd, J = 5.8, 16.1 Hz, 1 H, 2-HA), 2.91 (dd, 
J = 5.8, 16.1 Hz, 1 H, 2-HB), 5.30 (dt, J = 5.8, 8.5 Hz, 1 H, 3-H), 6.48 (d, 
J = 8.5 Hz, 1 H, NH), 6.67 (d, J = 2.3 Hz, 1 H, Ar), 6.86 (d, J = 2.3 Hz, 1 H, 
Ar) ppm. 
The carboxylic acid proton could not be detected. 
 
13C-NMR: 75 MHz, CDCl3; δ = 5.2 (TES), 5.6 (TES), 6.7 (TES), 6.8 (TES), 23.4 (Me), 
39.5 (C2), 48.8 (C3), 116.6 (Ar), 120.0 (Ar), 126.8 (Ar), 133.4 (Ar), 143.6 
(Ar), 148.4 (Ar), 170.1 (NAc), 174.8 (CO2H) ppm. 
 
HR-MS: (ESI+): m/z calc. for C23H40ClNO5Si2H [M-H]+ 502.2212, found 502.2206. 
 
FT-IR: (neat); ῦ = 3246 (s), 2943 (m), 2836 (s), 1601 (s), 1576 (s), 1496 (s), 1461 (m), 
1423 (m), 1362 (m), 1305 (s), 1286 (m), 1241 (m), 1187 (s), 1147 (s), 1053 
(m), 1023 (m), 993 (m), 922 (s), 871 (s), 785 (w), 618 (s), 573 (s), 549 (s), 522 
(w) cm-1. 
 
[α]D23  38 (c 1.0, CHCl3). 
 
The analytical data were in accordance with that reported in the literature.[14c] 
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8.4 Crystal structures 
8.4.1 Crystal Structure of Indanone (R)-141: 
 
Habitus, colour  nugget, colourless 
Crystal size 0.23 x 0.19 x 0.16 mm3 
Crystal system  Orthorhombic 
Space group  P212121 Z = 4 
Unit cell dimensions a = 7.4545(3) Å α= 90°. 
 b = 8.5743(3) Å β= 90°. 
 c = 22.5355(9) Å γ = 90°. 
Volume 1440.40(10) Å3 
Cell determination  9898 peaks with Theta 2.9 to 27.5°. 
Empirical formula  C18 H15 Cl O2 
Moiety formula  C18 H15 Cl O2 
Formula weight  298.75 
Density (calculated) 1.378 Mg/m3 
Absorption coefficient 0.266 mm-1 
F(000) 624 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.542 to 27.510°. 
Index ranges -9<=h<=9, -11<=k<=11, -26<=l<=29 
Data collection software  APEX3 (Bruker AXS Inc., 2015)[1] 
Cell refinement software  SAINT V8.37A (Bruker AXS Inc., 2015)[2] 
Data reduction software  SAINT V8.37A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 25314 
Independent reflections 3308 [R(int) = 0.0203] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  3253[I > 2σ(I)]  
Reflections used for refinement  3308 
Absorption correction Semi-empirical from equivalents[3] 
Max. and min. transmission 0.96 and 0.93 
Flack parameter (absolute struct.)   0.019(8)[4] 
Largest diff. peak and hole 0.224 and -0.264 e.Å-3 
Solution  Dual space algorithm 
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Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[5] 
 SHELXL-2014/7 (Sheldrick, 2014)[6] 
 DIAMOND (Crystal Impact)[7] 
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[8]  
Data / restraints / parameters 3308 / 0 / 191 
Goodness-of-fit on F2 1.080 
R index (all data) wR2 = 0.0632 
R index conventional  [I>2sigma(I)] R1 = 0.0233 
 
 
8.4.2 Crystal Structure of Indanone 155: 
 
Habitus, colour  block, colorless 
Crystal size 0.12 x 0.07 x 0.05 mm3 
Crystal system  Triclinic 
Space group  P-1 Z = 4 
Unit cell dimensions a = 9.1838(2) Å α= 95.877(2)°. 
 b = 9.3213(2) Å β= 103.180(2)°. 
 c = 14.8602(4) Å γ = 109.791(2)°. 
Volume 1142.83(5) Å3 
Cell determination  15313 peaks with Theta 3.1 to 69.7°. 
Empirical formula  C13 H11 Cl O3 
Moiety formula  C13 H11 Cl O3 
Formula weight  250.67 
Density (calculated) 1.457 Mg/m3 
Absorption coefficient 2.915 mm-1 
F(000) 520 
 
Data collection:  
 
Diffractometer type  STOE STADIVARI 
Wavelength  1.54184 Å 
Temperature  100(2) K 
Theta range for data collection 3.115 to 69.513°. 
Index ranges -11<=h<=9, -11<=k<=10, -8<=l<=17 
Data collection software  X-Area Pilatus3_SV 1.31.127.0 (STOE, 2016)[1] 
Cell refinement software  X-Area Recipe 1.33.0.0 (STOE, 2015)[2] 
Data reduction software  X-Area Integrate 1.71.0.0 (STOE, 2016)[3]  
 X-Area LANA 1.68.2.0 (STOE, 2016)[4] 
 
Appendix – Crystal structures 
166 
 
Solution and refinement: 
 
Reflections collected 17645 
Independent reflections 4198 [R(int) = 0.0331] 
Completeness to theta = 67.684° 99.0 %  
Observed reflections  3366[I > 2σ(I)]  
Reflections used for refinement  4198 
Absorption correction Semi-empirical from equivalents[4] 
Max. and min. transmission 0.9695 and 0.2938 
Largest diff. peak and hole 0.533 and -0.290 e.Å-3 
Solution  dual space algorithm 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH calculated, constr. ref., OH located, isotr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[5] 
 SHELXL-2016/6 (Sheldrick, 2016)[6] 
 DIAMOND (Crystal Impact)[7] 
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[8]  
Data / restraints / parameters 4198 / 0 / 317 
Goodness-of-fit on F2 1.015 
R index (all data) wR2 = 0.1185 
R index conventional  [I>2sigma(I)] R1 = 0.0426 
 
 
8.4.3 Crystal Structure of Oxathiazinane 192: 
 
 
Habitus, colour  block, colourless 
Crystal size 0.60 x 0.19 x 0.17 mm3 
Crystal system  Monoclinic 
Space group  P21 Z = 2 
Unit cell dimensions a = 6.6235(3) Å α= 90°. 
 b = 7.7531(3) Å β= 92.834(2)°. 
 c = 19.9152(8) Å γ = 90°. 
Volume 1021.45(7) Å3 
Cell determination  9953 peaks with Theta 3.1 to 27.5°. 
Empirical formula  C16 H26 Cl N O5 S Si 
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Moiety formula  C16 H26 Cl N O5 S Si 
Formula weight  407.98 
Density (calculated) 1.326 Mg/m3 
Absorption coefficient 0.37 mm-1 
F(000) 432 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.820 to 27.528°. 
Index ranges -8<=h<=8, -10<=k<=9, -25<=l<=25 
Data collection software  BRUKER APEX2 2014.9-0 [1] 
Cell refinement software  BRUKER SAINT [2] 
Data reduction software  SAINT V8.34A (Bruker AXS Inc., 2013) [2] 
 
Solution and refinement: 
 
Reflections collected 39159 
Independent reflections 4545 [R(int) = 0.0344] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  4397[I>2sigma(I) ]  
Reflections used for refinement  4545 
Absorption correction Semi-empirical from equivalents [3] 
Max. and min. transmission 0.7456 and 0.7033 
Flack parameter (absolute struct.)   0.031(15) 
Largest diff. peak and hole 0.262 and -0.464 e.Å-3 
Solution  Direct methods [4,4] 
Refinement  Full-matrix least-squares on F2 
[4]
 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014) [4,5] 
 SHELXL-2014/7 (Sheldrick, 2014) [4,6] 
 DIAMOND (Crystal Impact) [7] 
Data / restraints / parameters 4545 / 1 / 236 
Goodness-of-fit on F2 1.083 
R index (all data) wR2 = 0.0777 
R index conventional  [I>2sigma(I)] R1 = 0.0277 
 
8.4.4 Crystal Structure of Oxathiazinane 198: 
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Habitus, colour  plate, colourless 
Crystal size 0.27 x 0.14 x 0.05 mm3 
Crystal system  Orthorhombic 
Space group  P212121 Z = 4 
Unit cell dimensions a = 7.3554(3) Å α= 90°. 
 b = 8.3592(3) Å β= 90°. 
 c = 21.2995(8) Å γ = 90°. 
Volume 1309.61(9) Å3 
Cell determination  18121 peaks with Theta 4.2 to 75.6°. 
Empirical formula  C11 H14 Cl N O5 S 
Moiety formula  C11 H14 Cl N O5 S 
Formula weight  307.74 
Density (calculated) 1.561 Mg/m3 
Absorption coefficient 4.246 mm-1 
F(000) 640 
 
Data collection:  
 
Diffractometer type  STOE STADIVARI 
Wavelength  1.54186 Å 
Temperature  100(2) K 
Theta range for data collection 4.151 to 74.787°. 
Index ranges -9<=h<=7, -8<=k<=10, -26<=l<=26 
Data collection software  X-Area Pilatus3_SV 1.31.127.0 (STOE, 2016)[1] 
Cell refinement software  X-Area Recipe 1.33.0.0 (STOE, 2015)[2] 
Data reduction software  X-Area Integrate 1.71.0.0 (STOE, 2016)[3]  
 X-Area LANA 1.68.2.0 (STOE, 2016)[4] 
 
Solution and refinement: 
 
Reflections collected 12779 
Independent reflections 2647 [R(int) = 0.0449] 
Completeness to theta = 67.686° 99.8 %  
Observed reflections  2491[I > 2σ(I)]  
Reflections used for refinement  2647 
Absorption correction Semi-empirical from equivalents[4] 
Max. and min. transmission 0.8571 and 0.2602 
Flack parameter (absolute struct.)   -0.006(9)[5] 
Largest diff. peak and hole 0.358 and -0.327 e.Å-3 
Solution  intrinsic phasing[6] 
Refinement  Full-matrix least-squares on F
2[7]
 
Treatment of hydrogen atoms  CH calculated, constr., NH located, isotr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[6] 
 SHELXL-2018/1 (Sheldrick, 2018)[7] 
 DIAMOND (Crystal Impact)[8] 
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[9]  
Data / restraints / parameters 2647 / 0 / 178 
Goodness-of-fit on F2 1.041 
R index (all data) wR2 = 0.0863 
R index conventional  [I>2sigma(I)] R1 = 0.0328 
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